Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition by Svolos, V. et al.
Accepted Manuscript
Treatment of Active Crohn’s Disease With an Ordinary Food-based Diet That
Replicates Exclusive Enteral Nutrition
V. Svolos, R. Hansen, B. Nichols, C. Quince, U.Z. Ijaz, R.T. Papadopoulou, C.A.
Edwards, D. Watson, A. Alghamdi, A. Brejnrod, C. Ansalone, H. Duncan, L.
Gervais, R. Tayler, J. Salmond, D. Bolognini, R. Klopfleisch, D.R. Gaya, S. Milling,




To appear in: Gastroenterology
Accepted Date: 7 December 2018
Please cite this article as: Svolos V, Hansen R, Nichols B, Quince C, Ijaz U, Papadopoulou R,
Edwards C, Watson D, Alghamdi A, Brejnrod A, Ansalone C, Duncan H, Gervais L, Tayler R, Salmond
J, Bolognini D, Klopfleisch R, Gaya D, Milling S, Russell R, Gerasimidis K, Treatment of Active
Crohn’s Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition,
Gastroenterology (2019), doi: https://doi.org/10.1053/j.gastro.2018.12.002.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all














































Treatment of Active Crohn’s Disease With an Ordinary Food-based Diet That Replicates Exclusive 
Enteral Nutrition 
V Svolos1, R Hansen2, B Nichols1, C Quince3, UZ Ijaz4, RT Papadopoulou1, CA Edwards1, D 
Watson5, A Alghamdi5, A Brejnrod6, C Ansalone7, H Duncan2, L Gervais2, R Tayler2, J Salmond8, D 
Bolognini9, R Klopfleisch10, DR Gaya11, S Milling7, RK Russell2, K Gerasimidis1* 
1Human Nutrition, School of Medicine, Dentistry & Nursing, College of Medical, Veterinary and Life Sciences, 
University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom 
2Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, 
United Kingdom 
3Warwick Medical School, University of Warwick, Warwick, United Kingdom 
4School of Engineering, University of Glasgow, Glasgow, United Kingdom 
5Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United 
Kingdom 
6Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark 
7Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, 
University of Glasgow, Glasgow, United Kingdom 
8Queen Elizabeth University Hospital, Glasgow, United Kingdom 
9Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, 
Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom 
10Institute of Veterinary Pathology, Freie Universitaet, Berlin, Germany 
11Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom 
*Corresponding author 
Konstantinos Gerasimidis 
Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life 
Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, G31 2ER, Glasgow. Tel: 















Conflict of interest statement 
R Hansen has received speaker's fees, conference support or consultancy fees from Nutricia, Dr Falk, 
MSD Immunology and 4D Pharma. CA Edwards chairs an expert working group for The 
International Life Sciences Institute, Europe, on Early Bacterial Colonization and Potential 
Implications in Later Life. S Milling received speaker’s fees from Janssen and participated in medical 
board meetings with Pfizer. RK Russell has received speaker’s fees, travel support, and participated 
in medical board meetings with Abbvie, Janssen, Shire, Celltrion, NAPP and Nestle. K Gerasimidis 
reports personal fees from Nutricia, research grants and personal fees from Nestle, personal fees from 
Dr Falk, research grants from Mead Johnson Nutrition. The rest of the authors have no conflicts of 
interest to disclose. 
Author contributions 
V Svolos developed the study design, ethical application, funding award, carried out and co-ordinated 
most of the research activities and laboratory analysis, carried out part of the statistical analysis and 
produced the first draft for publication. R Hansen contributed to the study design, ethical application, 
and funding award, led the clinical aspects of the open-label clinical study, identified and followed up 
patients, edited critically the first draft for publication, supported the researcher’s clinical engagement 
and co-supervised the researcher. B Nichols performed the bioinformatics and part of the statistical 
analysis. C Quince contributed to the study design, funding award, performed part of the 
bioinformatics and statistical analysis and supervised the research associate in bioinformatics. UZ 
Ijaz contributed to the study design, advised on bioinformatics and statistical analysis, supervised the 
research associate in bioinformatics and co-supervised the researcher. RT Papadopoulou carried out 
part of the laboratory analysis. CA Edwards contributed to the study design and funding award. D 
Watson supervised the laboratory analysis of metabolomics and advised on interpretation of data. A 
Alghamdi carried out the laboratory analysis of metabolomics. A Brejnrod carried out part of the 
bioinformatics analysis of the sequencing and metabolomics datasets. C Ansalone trained the main 
researcher on animal experiments, carried out part of the laboratory analysis. H Duncan helped with 
the dietary aspects and analysis of human experiments. L Gervais identified and followed up patients 
for the open-label clinical study. R Tayler identified and followed up patients for the open-label 
clinical study. J Salmond performed the histological scoring of tissue specimens. D Bolognini 
contributed to the laboratory analysis of genomics. R Klopfleisch performed the histological scoring 
of tissue specimens. DR Gaya contributed to the study design, ethical application and funding award. 
S Milling supervised and carried out part of the animal experiments, trained and co-supervised the 
main researcher. RK Russell contributed to the study design, funding award, ethical application, 
identified and followed up patients, edited critically the first draft for publication and co-supervised 















study design, ethical application, funding award, edited critically the first draft for publication, trained 
the researcher for the field and laboratory analysis, co-supervised the main researcher and co-
ordinated the study. All authors reviewed the final version of the manuscript and agreed to its content 
prior submission. 
Grant support 
V Svolos was funded by a PhD studentship from the Glasgow Children Hospital Charity, R 
Papadopoulou and H Duncan were funded by the Catherine McEwan Foundation and B Nichols was 
funded from an industrial partnership between the University of Glasgow and Nestle Health Science®, 
UZ Ijaz is funded by NERC Independent Research Fellowship (NE/L011956/1), R Hansen is funded 
by a Career Researcher Fellowship by NHS Research Scotland. The proprietary feeds used in this 
study were a donation from Nestle Health Science®. Animal experiments were funded by a grant from 
the Medical Research Council to S Milling (MR/N023625/1) and the running costs of the open label 
trial from Cure Crohn’s Colitis (C3) charity in Scotland. None of the study sponsors had a role in 
study design, data collection, analysis and interpretation or any aspects during the write up and 
publication of this work. 
Acknowledgments 
The authors would like to thank Dr Andy Barclay, Dr Diana Flynn, Ms Vikki Garrick, Ms Lee Curtis, 
Ms Elaine Buchanan and Ms Tracey Cardigan for their invaluable support during the open label 
clinical trial. The authors would like to acknowledge the support of the clinical IBD team at the Royal 
















Background & Aims: Exclusive enteral nutrition (EEN) is the only established dietary treatment for 
Crohn’s disease (CD), but its acceptability is limited. There is a need for novel dietary treatments for 
CD. 
Methods: We evaluated the effects of an individualized, food-based diet (CD-TREAT), with similar 
composition to EEN, on the gut microbiome, inflammation and clinical response in a rat model, 
healthy adults, and children with relapsing CD. Twenty-five healthy adults randomly received EEN or 
CD-TREAT for 7 days, followed by a 14-day washout period, followed by the alternate diet. Fecal 
microbiome and metabolome were assessed before and after each diet. HLA-B7 and HLA-B27 
transgenic rats with gut inflammation received EEN, CD-TREAT, or standard chow for 4 weeks. 
Fecal, luminal and tissue microbiome, fecal metabolites and gut inflammation were assessed. Five 
children received CD-TREAT with clinical activity and fecal calprotectin evaluated after 8-week 
treatment. 
Results: Among healthy adults, CD-TREAT was easier to comply with and more acceptable than 
EEN. CD-TREAT induced similar effects to EEN (EEN vs CD-TREAT) on fecal microbiome 
composition, metabolome, mean total sulfide (increase 133.0±80.5 vs 54.3±47.0 nmol/g), pH 
(increase 1.3±0.5 vs 0.9±0.6), the short-chain fatty acids (µmol/g) acetate (decrease 27.4±22.6 vs 
21.6±20.4), propionate (decrease 5.7±7.8 vs 5.2±7.9), and  butyrate (decrease 7.0±7.4 vs 10.2±8.5). In 
the rat model, CD-TREAT and EEN produced similar changes in bacterial load (decrease 0.3±0.3 
log10 16S rRNA gene copies/g), short-chain fatty acids, microbiome, and ileitis severity (mean 
histopathology score reductions 1.25 for EEN (P=.015) and 1.0 for CD-TREAT (P=.044) vs chow). 
Among the children receiving CD-TREAT, 4 (80%) had a clinical response and 3 (60%) entered 
remission, with significant concurrent reductions in fecal calprotectin (mean decrease 918±555 
mg/kg, (P=.002)). 
Conclusion: CD-TREAT replicates EEN changes in the microbiome, reduces gut inflammation, is 
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Crohn’s disease (CD) is associated with high morbidity and increased health expenditure. The current 
paradigm of CD pathogenesis suggests an interaction between environmental factors and the gut 
microbiome in people with genetic susceptibility to the illness1. 
 Steroids have been the mainstay therapy in CD, particularly in adults. While effective, 
prolonged use of steroids is associated with significant side effects and higher mortality than anti-TNF 
agents2. Given the cost and side-effects inherent in biological therapy, there is a need to develop 
novel, safe and efficacious therapies. 
 Diet is important in the etiology of CD, particularly in countries where the rising disease 
incidence has paralleled changes in eating habits and food industrialization. Certain nutrients and food 
additives have been associated with CD risk. Consequently, recent studies advocate the inclusion or 
exclusion of these food components in CD management3. 
Exclusive enteral nutrition (EEN) remains the only established dietary treatment in paediatric 
CD, particularly in Europe. EEN induces clinical remission in approximately 80% of patients and 
promotes gut healing3-5. The mechanism of action of EEN is not yet fully understood, but work from 
our group and others, proposes that modulation of the gut microbiome drives its therapeutic 
properties6-8. These effects reversed when patients resumed their habitual diet and gut inflammation 
correspondingly increased7.  
 While successful, EEN is a very restrictive diet with limited acceptability and prolonged use, 
particularly in adults. It is therefore of critical importance that we use our understanding of CD 
pathogenesis and the mechanism of EEN action to develop new effective dietary therapies that are 
more acceptable and tolerable. This unmet need is further supported by health professionals and 
patient groups when asked jointly about priorities for CD research9. 
 In view of the clinical efficacy of EEN, its simple nutritional composition, and a mechanism 















similar to EEN by developing an ordinary food diet, based on the composition of EEN and mimicking 
its effect on the gut microbiome. If this was achievable, such a diet would be likely to induce 
remission in CD. Based on this concept, we devised the Crohn’s Disease Treatment-with-EATing diet 
(CD-TREAT) and explored microbial changes after both CD-TREAT and EEN with a randomized 
controlled trial (RCT) in healthy subjects. We followed this RCT with experiments in animal models 
to explore the anti-inflammatory effect of CD-TREAT and its effect on the gut microbiome in a 
disease state. Finally, we tested the efficacy of CD-TREAT to induce clinical remission and 















Materials and methods 
CD-TREAT diet 
The CD-TREAT diet is a prescriptive and personalized diet. It recreates EEN by the exclusion of 
certain dietary components (e.g. gluten, lactose, alcohol) and matching of others (macronutrients, 
vitamins, minerals and fiber) as closely as possible, using ordinary food. We based the composition of 
CD-TREAT on Modulen® IBD (Nestle, Vevey, Switzerland), the most popular formula used in 
Europe, and on which we have based our mechanistic studies6, 7. Maltodextrin, an artificial glucose 
polymer and the commonest form of carbohydrate in EEN feeds, but not present in natural foods, was 
substituted by food high in starch and low in fiber. As approximately 10% of food starch resists 
digestion (i.e. resistant starch) and so reaches the colon10, this is likely to influence the gut 
microbiome in a different way than EEN. Hence, we purposely decreased the carbohydrate in CD-
TREAT, particularly complex carbohydrates, in favor of protein. Both carbohydrate and protein 
intake remained within the composition range of other EEN feeds with published records of efficacy 
in active CD (e.g. Fresubin® Protein, Peptamen® AF). The micronutrients from EEN were achieved 
with a multivitamin tablet. CD-TREAT provides the daily energy requirements and considers food 
preferences. A CD-TREAT day menu is presented in Supplementary Table S1. 
RCT in healthy volunteers 
Study design 
Healthy adults (>18 y) were recruited from the community. At study enrolment, subjects who suffered 
from any acute or chronic illness (i.e. illness requiring regular visits to health services) were excluded. 
Participants had stable weight (± 2 kg) in the past month, no history of gut surgery and had not used 
antibiotics or steroids the last three months.  
 Participants were randomly allocated to EEN and CD-TREAT for seven days each, with a 14-
day washout period in between to restore the gut microbiome to its baseline state and avoid 















  Modulen® IBD was used for the EEN trial, as described previously11. During CD-TREAT, 
participants were provided with a food list from which to choose their preferred items. An 
individualized dietary plan was then developed by the research dietitians providing their daily energy 
requirements. This plan was developed employing the food group exchange methodology12 and 
Windiets® 2010. Energy requirements were calculated using the participant’s estimated basic 
metabolic rate and self-reported physical activity level13. EEN and CD-TREAT meals were supplied 
to the participants free of charge along with written preparation instructions.  
 Prior to initiation of the first experimental diet, participants recorded their habitual diet using 
7-day estimated weight food diaries. This diet was replicated during the last week of the washout, 
before their second intervention. Weight changes were monitored. 
Dietary intake and acceptability of interventions 
Appetite, gastrointestinal symptoms and adherence to the experimental diets were assessed by self-
reported questionnaire (Supplementary Files S1 and S2). Leftovers of EEN formula were returned as 
additional estimates of treatment adherence. Adherence to CD-TREAT was further assessed by 
recording intake daily using estimated weight food diaries. 
Fecal sample collection  
Fresh fecal samples were collected before and after each experimental diet, providing a total of four 
samples per participant (Supplementary File S2). The shape and texture of the samples was assessed 
using the Bristol Stool Form Scale14. Fecal water, pH and ammonia were measured6. 
Fecal microbiome 
Fecal genomic DNA was extracted using the chaotropic method6. Quantification of total bacteria (16S 
rRNA gene copy number/g stool) was carried out with quantitative PCR using TaqMan™ chemistry6. 
The V4 region of the 16S rRNA gene was amplified and sequencing was performed (MiSeq, Illumina, 















Fecal bacterial metabolites 
Free and total fecal sulfide was measured with a solid-state ion selective electrode (HI4115; Hanna, 
Bedfordshire, United Kingdom). Short-chain fatty acids (SCFA) and branched chain fatty acids 
(BCFA) were quantified by Gas Chromatography6. 
Fecal metabolome 
Untargeted fecal metabolites were measured using Liquid Chromatography-Mass Spectrometry (LC-
MS) (Supplementary File S2) in chloroform/methanol/water (1:3:1) extracts. Metabolite profiling was 
performed using a ZICpHILIC column coupled to an Orbitrap Exactive instrument. 
Animal experiments 
Study design 
The animal experiment explored the effect of CD-TREAT, compared with EEN and regular chow, on 
gut inflammation and microbiome in a disease state. We used adult (36-40 weeks) heterozygous 
HLA-B27 (B27) and HLA-B7 (B7) transgenic rats of a Piebald-Virol-Glaxo background. B27 rats 
express the human major histocompatibility complex class I HLA-B27 gene and the associated human 
β2-microglobulin gene, and develop inflammation throughout their gastrointestinal tract, including the 
ileum15. They do not present gut inflammation in a germ-free environment16 and severity of ileitis is 
decreased by antibiotic treatment17. This model has been used extensively in IBD research, including 
interventions with EEN18. The B27 gut microbiome has a similar phenotype, to that seen in CD, 
including an increase in Proteobacteria and a decrease in Firmicutes species19. The HLA-B27 
genotype has been associated independently with CD, and ankylosing spondylitis patients often have 
sub-clinical gut inflammation20. B7 rats do not present gut inflammation and were used as controls.  
 The B27 animals were fed ad-libitum EEN, CD-TREAT, or standard chow (Special Diets 
Services BK001E) for four weeks (B27-EEN, B27-CD-TREAT and B27-CONTROL respectively). 
To confirm gut inflammation in the B27 animals, a healthy group of B7 rats fed on standard chow was 
included (B7-CONTROL). Similarly, B7 rats on EEN were included to address the net effect of EEN 















not included since the effect of CD-TREAT against EEN on the healthy gut microbiome was 
addressed in the human RCT (Figure 1B). CD-TREAT food items were cooked, homogenized, and 
stored at -20oC. Rats were maintained in individual cages and under specific pathogen-free conditions. 
Weight was monitored. 
Fecal samples, luminal contents and tissue harvesting 
Fecal samples were collected at baseline and weekly, until sacrifice after 28 days. Gut luminal 
contents and ileal, cecal and colonic tissue were stored at -70°C.  The weight of cecal luminal content 
and fecal water were measured. 
Gut histopathology and cytokine expression in ileum 
Colonic and ileal specimens were fixed in 10% formalin until the tissue was paraffin-embedded, 
stained with hematoxylin and eosin and evaluated by two pathologists (RK and JS) in a blinded 
manner (Supplementary File S2). 
Total RNA was isolated from ileal tissues, stored immediately in RNAlater, using the AllPrep 
DNA/RNA Mini kit (Qiagen, Manchester, UK). Reverse transcription was performed using the 
QuantiTect Reverse Transcription kit (Qiagen). Relative expression of genes encoding for TNF-α, ΙL-
6, IL-10, IL-1b, CXCL-1 was measured with quantitative PCR using TaqMan™ chemistry, 
housekeeping genes as endogenous controls and the comparative Ct method (Supplementary File S2). 
Gut microbiome 
DNA from fecal, cecal and colonic luminal contents was extracted as described above. DNA from 
cecal and colonic tissue was extracted using the AllPrep DNA/RNA Mini Kit. 16S rRNA gene 
sequencing in all samples and the concentration of total bacteria and SCFA in fecal samples and cecal 
luminal contents were measured as described above. The total quantity (µmols) of each SCFA and 
















Open label trial in patients with active CD 
Study design 
Previously diagnosed children (6-15 y) with relapsing CD (weighted Pediatric Crohn’s Disease 
Activity Index-wPCDAI≥12.521), were recruited from the Royal Hospital for Children, Glasgow. 
Exclusion criteria included: antibiotics use within one month; change in type or dose of CD therapy 
within three or one month respectively; enrolment in other studies; disease severity sufficient to 
warrant hospitalization; and food allergies incompatible with CD-TREAT. 
 Participants were treated exclusively with CD-TREAT diet for eight weeks. All food was 
provided. In contrast to the healthy volunteer RCT, meals requiring cooking were prepared by a sub-
contracted catering company and were delivered to the participants (Supplementary Figure S1). 
Participants recorded their dietary intake daily (Supplementary File S3). 
 Clinical reviews were scheduled at weeks two (telephone), four and eight (visits). No 
alterations to CD-related medications were allowed. If disease activity deteriorated at any point or 
there was no improvement at four weeks, patients discontinued CD-TREAT. Those patients who 
clinically responded but did not enter clinical remission at eight weeks were offered the option to stay 
on CD-TREAT for a further four weeks (Figure 1C). 
Primary and secondary outcomes 
The outcomes of the trial were selected based on the recommendations of the European Crohn’s and 
Colitis Organization22. The primary outcome was clinical response (wPCDAI fall≥17.5) or clinical 
remission (wPCDAI<12.5) at eight weeks. Secondary outcomes included changes in fecal calprotectin 
(FC) (CALP0170 kit, Calpro™, Norway), serum albumin and C-reactive protein (CRP)6. 
 
Bioinformatics 
Operational taxonomic unit (OTU) assignments were generated using a modified version of the 















File S2). For fecal metabolome, we used probabilistic quotient normalization (PQN)23 for univariate 




A confirmed microbial signal explaining EEN therapeutic effect does not exist. Hence, to power the 
human RCT, we chose a microbial signal which changed significantly during EEN in children with 
CD, was associated with disease improvement, and showed the largest size effect with the narrowest 
standard deviation6. Recruiting 25 healthy adults would give an 80% power to detect a mean fecal 
butyrate decrease of 19 µmol/g (SD: 32), after either of the dietary interventions. The power 
calculation was revised after completion of the first 10 participants (Supplementary File S2). Animal 
experiments were performed on two independent occasions including four rats per group. 
Data Analysis 
For group comparisons we used the general linear model, with Box-Cox transformation and Fisher 
pairwise test. For microbiome, α (Shannon and Chao1) and β-diversity (Bray-Curtis dissimilarity and 
weighted Unifrac distance) were performed (vegan package) in R. Discriminant taxa were identified 
using t-tests on logarithmic proportional abundances. For the metabolome data, PCA and 
PERMANOVA analyses were carried out on Manhattan distance matrices. Differentially abundant 
metabolites were identified using a modification of the univariate function in R's muma package, 
adapted for paired data. All correlations were tested with the Pearson test but for the metabolome 
analysis, the Spearman rank correlation test was used instead to compensate for the disproportionate 
influence of outliers. The significance level for the human RCT and pilot trial in patients was defined 
as P<.05. Benjamini-Hochberg corrections for multiple testing were applied, relaxing the criteria to 
















The RCT in healthy volunteers was approved by the University of Glasgow Ethics Committee 
(Reference: 200130161) and the trial in patients by the West of Scotland Research Ethics Committee 
(Reference: 17/WS/0119). Participants and/or carers provided written consent. The animal 
experiments were conducted under licenses by the UK Home Office.  
 
Results 
RCT in healthy volunteers 
Participant characteristics 
Twenty-eight volunteers were recruited. Three dropped out leaving 25 subjects who completed the 
trial (mean, SD, BMI: 22.4, 2.7 kg/m2; age: 24.5, 3.1 years; females: n=13, 52%). Thirteen and 12 
were randomly allocated to start with EEN and CD-TREAT, respectively. No significant changes in 
body weight were observed (Supplementary Table S2). 
Dietary intake and acceptability of interventions 
Differences between the prescribed and actual intake were minimal during both dietary interventions, 
indicating high compliance (Table 1). Nutrient intake during CD-TREAT was more similar to that of 
EEN than the participants’ habitual diet. During EEN and CD-TREAT, the participants consumed 
more total and saturated fat and less fiber and carbohydrates compared with their habitual diet. Protein 
intake was higher than the habitual diet during CD-TREAT.  
CD-TRE T was easier to follow and more satiating than EEN. Gastrointestinal symptoms 
were uncommon for both diets. Ratings for abdominal pain and diarrhea were however higher (both 















Fecal sample characteristics  
Both dietary interventions decreased Bristol Stool Chart ratings (both P<.001) and fecal output mass 
(EEN: P=.031, CD-TREAT: P=.017). Fecal water content decreased only after EEN (P=.003) 
(Supplementary Table S2). 
Fecal microbiome 
The concentration of total fecal bacteria significantly decreased after both diets (Supplementary Table 
S2). Ninety-six samples from 24 participants were analyzed after removing four samples with <5,000 
reads. The number of unique OTU across all samples was 1,176, annotated to 224 genera. No 
significant changes, from baseline, were observed for the Chao1 index (both P=.143), a measure of 
microbiome richness, or the Shannon α-diversity (EEN: P=.387, CD-TREAT: P=.359) (Figure 2A,B). 
Microbiome structure clustered according to study time point (R2=0.13, P<.001) (Figure 2C). 
Compared with the baseline, EEN (R2=0.14, P<.001) and CD-TREAT (R2=0.05, P<.001) shifted β-
diversity to the same direction explaining 14% and 5% of the variation in microbiome structure, 
respectively. Weighted UniFrac distances analysis produced similar results (Supplementary Figure 
S2). 
After filtering out OTU with abundance <0.01%, 329 OTU remained, aggregated to 118 
genera. A moderate-to-strong correlation between the changes after EEN and CD-TREAT was 
observed for OTU (r=0.67, P<.001) (Figure 2D) and for genera (r=0.65, P<.001) (Supplementary 
Figure S3). 
The relative abundance of 58 (49.3%) and 38 (32.3%) genera changed significantly after EEN 
and CD-TREAT respectively. Twenty-eight of these genera changed in the same direction between 
both dietary interventions (Table 2). Therefore, 48.3% of the EEN effect was replicated by CD-
TREAT and 73.7% of the CD-TREAT effect was observed in EEN. Thirty genera changed 
significantly only during EEN and 10 only during CD-TREAT (Supplementary Tables S4-S6).  
Similar findings were observed from OTU assignments. In total, 109 OTU (33.1%) for EEN 















abundance of 47 OTU was similarly altered after both EEN and CD-TREAT, indicating that 43.1% of 
the EEN-induced OTU changes were replicated by CD-TREAT, and 73.4% of CD-TREAT-induced 
OTU changes were observed in EEN too. The OTU which changed significantly during only EEN or 
CD-TREAT were 62 and 17 respectively (Supplementary Tables S7-S9). No OTU or genera 
demonstrated a significant change of opposite direction when comparing EEN and CD-TREAT. 
Fecal bacterial metabolites 
Fecal pH increased to alkaline levels, with a mean increase of 1.3 units during EEN (P<.001) and 0.9 
units during CD-TREAT (P<.001). Similarly, the fecal concentration of total sulfide increased after 
both dietary interventions (EEN: 213%, CD-TREAT: 109%; both P<.001); free sulfide decreased 
only after EEN. The mean concentrations of acetate, propionate and butyrate significantly decreased 
after both EEN and CD-TREAT, with a similar effect size observed between the two diets. BCFA 
increased only after EEN and valerate decreased only after CD-TREAT (Supplementary Table S2). 
Fecal metabolome 
The number of annotated metabolites across all 100 samples was 886. The metabolome significantly 
changed towards the same direction after both EEN (R2=0.21, P<.001) and CD-TREAT (R2=0.13, 
P<.001), with 21% of the variation in the metabolome profile explained by the four study time points 
(P<.001) (Figure 2E). The log2-fold baseline changes of metabolite abundance were correlated 
between EEN and CD-TREAT (Spearman Rho=0.38, P<.001) (Figure 2F). 
Of the 886 annotated metabolites, 675 (76.2%) and 573 (64.7%) changed significantly after 
EEN and CD-TREAT, respectively (Supplementary Table S10). Two-hundred ninety-four metabolites 
changed in the same direction after both dietary interventions. Therefore, 43.6% of the EEN effect 
was replicated by CD-TREAT and 51.3% of the CD-TREAT effect was observed in EEN. The 
majority of these metabolites were associated to metabolism of lipids (n=90, 30.6%), proteins  (n=47, 
16.0%), carbohydrates (n=8, 2.7%), nucleotides (n=5, 1.7%), cofactors/vitamins (n=7, 2.4%), 
biosynthesis of polyketides and non-ribosomal peptides (n=4, 1.4%), and secondary metabolites (n=9, 















value for EEN change are presented in Table 2. Metabolites which changed significantly in only one 
of the diets are presented in Supplementary File S4. Sixty-eight (7.7%) had changes of opposite 
direction for the two diets. 
For all analysis performed there were no significant differences in the microbiome of the two 
pre-treatment diets (i.e. Pre-EEN and Pre-CD-TREAT); indicating that the washout period and 
replication of pre-intervention diet reverted microbiome to the same baseline characteristics 
(Metabolome: R2=0.01, P=.391; Microbiome: R2=0.01, P=.187; Figure 2C,E). 
Animal experiments 
Animal characteristics 
Twelve B27 and eight B7 rats were included. Each group included two males and two females with 
no group differences in weight (mean, SD, 285.4, 80.3g). Only animals on the experimental diets, 
including B27-EEN, B27-CD-TREAT and B7-EEN, gained weight (Supplementary Table S11).   
 B27-CONTROL had higher colonic and ileal inflammation and fecal water content than the 
B7-CONTROL (Figure 3, Supplementary Figure S4, Supplementary Tables S11,S12). B27-
CONTROL microbiome was characterized by compositional and functional dysbiosis, including 
reduced fecal, cecal bacterial diversity and butyrate production (Figure 4; Supplementary Tables 
S11,S13-S17, Supplementary Figure S5). 
Gut histopathology and cytokine expression in ileum 
The histopathology scores were highly correlated between the two assessors (Spearman Rho; Ileum: 
0.76, P<.001; Colon: 0.84, P<.001). Individual components of the histopathology scoring are 
presented in Supplementary Table S12 and representative sections in Figure 3B, Supplementary 
Figure S4 and Supplementary File S5. EEN and CD-TREAT ameliorated ileitis compared with the 
B27-CONTROL animals (Figure 3, P=.015, P=.044). No such effect was observed for colonic 















 Expression of genes encoding for TNF-α, IL-6, IL-10, and CΧCL-1 in the ileum did not differ 
significantly between the B7-CONTROL and B27-CONTROL groups despite the higher average 
values observed in the latter group. When we looked at the effect of the experimental diets, the B27-
CD-TREAT group had lower mean expression of IL-6 than the B27-CONTROL group (P=.036) and 
whilst CXCL-1 was also lower, this did not reach significance (P=.089). Regardless of intervention, 
fecal water content did not change in the B27 rats. A significant increase was observed in the B7-EEN 
group (Supplementary Tables S11-S12).  
Gut luminal content characteristics 
Both experimental diets reduced the weight of the cecal luminal contents in the B27 animals (EEN: 
P<.001; CD-TREAT: P=.017 compared with B27-CONTROL). This effect was also observed in the 
colon of the B27-EEN (P=.040) and in the cecum and colon of the B7-EEN group (Supplementary 
Table S13). 
Gut microbiome 
B27-EEN and B27-CD-TREAT had a higher concentration of total bacteria in cecal luminal contents 
and in fecal samples than the B27-CONTROL group (Supplementary Table S13). Rat microbiome 
was characterized in 100 fecal; 20 cecal and 17 colonic luminal contents and 19 cecal and 10 colonic 
tissue samples after removing samples with low reads (<5,000). There were 1,072 unique OTU and 
218 unique genera. 
 Both experimental diets shifted the B27 fecal and cecal luminal microbiome structures in the 
same direction. Microbiome signatures were significantly different to the B27-CONTROL group, 
both in fecal samples (EEN: R2=0.45; CD-TREAT: R2=0.43; both P=.034) and cecal luminal contents 
(EEN: R2=0.47; CD-TREAT: R2=0.54; both P=.029) (Figure 4C,D). The effect of EEN and CD-
TREAT on the B27 fecal microbiome was already evident from the first week of intervention (EEN: 
R2=0.57; CD-TREAT: R2=0.58; both P=.030). A similar effect was observed for the B7-EEN when 
compared with the B7-CONTROL group (fecal: R2=0.43, P=.034; cecal: R2=0.54, P=.029). NMDS 















Supplementary Figure S5. Analysis using weighted UniFrac distances produced similar results 
(Supplementary Figures S6-S7). 
Following the 4-week intervention, the B27-CD-TREAT had higher Shannon α-diversity 
index in feces (P=.020) and cecal luminal contents (P=.006) than the B27-CONTROL group. A 
similar pattern of effect was observed for the B27-EEN group, but did not reach significance (Figure 
4A,B). 
After filtering out OTU with abundance <0.01%, 92 genera remained at baseline, 109 at seven 
and 105 at 28 days of intervention in fecal samples and 104 genera were assigned to cecal luminal 
contents. In order to assess the effect of the experimental diets on B27 microbiome, we compared the 
genus relative abundance of fecal samples and cecal luminal contents for the B27-EEN and B27-CD-
TREAT against the B27-CONTROL group. Out of the 105 genera tested in cecal luminal contents, 
the relative abundance of 27 (25.7%), for the B27-EEN, and of 25 (23.8%) for the B27-CD-TREAT 
groups significantly differed compared to the B27-CONTROL group. The relative abundance of 13 
genera responded similarly for EEN and CD-TREAT, indicating that 48% of the EEN-induced 
changes were replicated by CD-TREAT and 52% of the CD-TREAT-induced changes were observed 
in EEN. Twenty-six genera changed in the opposite direction between CD-TREAT and EEN 
(Supplementary Tables S18-S20). Similar effects were observed in fecal samples (Supplementary 
Tables S21-S26) and for OTU assignments (Supplementary Tables S27-S35), although the small 
sample size precluded robust statistical analysis. 
Gut bacterial metabolites 
B27-EEN and B27-CD-TREAT had higher cecal concentration of valerate, iso-butyrate and iso-
valerate (all P<.001) compared to the B27-CONTROL group. Additionally, B27-CD-TREAT group 
had more butyrate (P=.004) and propionate (P=.021) in the cecum whereas, B27-EEN had lower 
acetate (P<.001) and propionate (P=.003). The total amount of SCFA in the entire cecum, a more 
reliable proxy of net production, in the B27 groups, EEN reduced acetate, propionate and butyrate (all 















TREAT increased iso-butyrate (P<.001) and iso-valerate (P=.001) and tended to decrease (P=.096) 
total cecal amount of acetate. In the B7 groups, the effect of EEN on cecal concentration and total 
SCFA production was similar to that of the B27 (Supplementary Table S13). 
In support of these data, sequential data from weekly fecal sample collection showed that 
EEN and CD-TREAT significantly decreased the concentrations of acetate and propionate and 
increased those of iso-butyrate and iso-valerate in B27 groups.  Similar effects were observed for the 
B7-EEN group (Supplementary Table S11). 
Open label trial in patients with active CD 
Five children with mild-to-moderate active luminal disease (wPCDAI range: 22.5-42.5) were enrolled 
between October 2017 to April 2018 and followed up until June 2018. All had been treated previously 
with EEN. Three patients were on monotherapy with thiopurine, one was on combination therapy 
with thiopurine and anti-TNF and one on no background treatment (Supplementary Table S36). 
Compliance to CD-TREAT was high (Table 1). Four (80%) children completed eight weeks of 
treatment and one child discontinued CD-TREAT after nine days due to symptom exacerbation. 
 After four weeks on CD-TREAT, 60% (3/5) clinically responded (wPCDAI change>17.5) 
and 40% (2/5) were in clinical remission (wPCDAI<12.5). At the end of eight weeks treatment, 80% 
(4/5) clinically responded and 60% (3/5) entered clinical remission. In the four children who 
completed eight weeks on CD-TREAT, the wPCDAI decreased from a baseline mean (SD) of 32.5 
(7.5) to 11.3 (9.2) and 7.5 (7.4) at four (P=.012) and eight (P=.005) weeks, respectively (Figure 5A, 
Supplementary Table S37). One patient had raised CRP and low albumin at CD-TREAT initiation; 
both inflammatory markers normalized by treatment completion. All four patients who completed 
eight weeks on CD-TREAT had raised FC (range 307 to 2,602 mg/kg) at treatment initiation (Figure 
5B, Supplementary Table S36). By week four and eight on CD-TREAT, the baseline concentration of 
FC significantly decreased by 53% and 55% respectively [mean (SD); Baseline: 1,960 (1,104), 4 















mg/kg) levels (Figure 5B). Interestingly, FC decreased also in the patient who discontinued CD-
















This series of studies aimed to develop an ordinary food-based therapy for active CD, using EEN as 
exemplar of effective nutritional therapy. EEN is likely to work by exclusion or inclusion of dietary 
components which modify an inflammatory microbiome8. The specific dietary components and how 
these interact with the gut microbiome are not yet fully elucidated. In the absence of detailed 
knowledge, we developed CD-TREAT, a personalized and tolerable diet with comparable 
composition to EEN. We anticipated that CD-TREAT would induce similar broad-spectrum 
alterations in the gut microbiome, while providing similar efficacy in treating gut inflammation and 
improving clinical activity. 
Our RCT in healthy volunteers confirmed the a priori hypothesis that CD-TREAT would 
induce similar effects on the human microbiome, as EEN. Applying multifaceted, targeted and 
untargeted multi-omics methodology, we interrogated changes in microbiome profiling and metabolic 
signatures before and after the two diets. The microbiome composition, fecal pH, SCFA, total sulfide, 
fecal bacterial load and fecal metabolome significantly changed in the same direction for both diets 
with many parallel changes in specific metabolites and species. Some of the effects seen in the current 
study have been previously associated with gut dysbiosis or an “unhealthy” microbiome, but 
paradoxically  associated with disease activity improvement and amelioration of colonic inflammation 
in children with active CD on EEN6, 7. This paradox remains one of the fundamental, yet unresolved, 
questions regarding the mechanism of EEN action and what this in turn indicates about the 
pathophysiology of CD25. It is possible that EEN depletes nutrients necessary for bacterial growth, 
such as fiber, or creates a luminal microenvironment where the functionality of inflammatory 
microbes is suppressed or altered; blunting activation of the gut-associated immune system in CD 
patients. This theoretical mechanism of EEN action is also supported by the clinical effectiveness of 
antibiotics26 and the relative ineffectiveness of probiotics, prebiotics and fiber interventions, aiming to 















 Several of the effects observed in the healthy volunteers RCT were replicated in our animal 
model of gut inflammation which features a microbial dysbiosis similar to human CD19. 
Encouragingly, the changes in metabolites and microbiome composition in fecal samples, cecal 
luminal contents and mucosa-associated microbiome were similar between the two experimental diets 
and significantly different to the B27-CONTROL group. 
The effects of the two experimental diets on secondary outcomes, such as abundance of 
species and metabolites, were very similar, but not always the same. This was anticipated as CD-
TREAT is a far more diverse diet than EEN, the number of microbial signals assessed at one time was 
large and inter and intra-individual variation in microbiome characteristics was considerable; 
something we also observed even after the end of intervention solely with EEN (Figure 2C). 
Importantly, unlike EEN, CD-TREAT is not an identical diet in all individuals. This means inter-
individual food differences can be significant within the CD-TREAT group and so the potent effect of 
ingredients in this food (e.g. phenolics, type of amino acids and fiber) on the microbiome will 
naturally differ too. In truth, one advantage of the natural variability inherent in CD-TREAT is the 
possibility of identifying food-based signals in larger studies of efficacy. Transgressions from 
prescribed CD-TREAT are less likely to explain microbial differences as prescribed and reported 
intake did not differ. It is also possible that a longer intervention may have mitigated the deviation in 
microbiome effects between the two diets. Indeed, this was observed in the animal experiments where 
β-diversity was more similar after 28 days than after 7 days intervention (Figure 4C). 
It is however, noteworthy that several changes in the taxon abundance of certain species and 
metabolites were similar to those described before in CD children on EEN6, 7. Specifically, the 
abundance of genera belonging to Actinobacteria, Bacteroidetes and Firmicutes, such as 
Bifidobacterium, Alistipes, Dialister, Faecalibacterium, Pseudobutyrivibrio and Ruminococcus, fecal 
pH, metabolites such as SCFA, sulfide and adenine substructures, which significantly changed in CD 
children following EEN6-8, 24, also changed in the current RCT. Likewise, differences in fecal amino 
acid and lipid concentrations and metabolism have been described between CD patients and healthy 















and EEN. Whilst important microbial messages emerge from these studies, the main purpose of this 
study was to demonstrate comparability of microbial changes and, by proxy, putative microbial 
mechanism of action and not to look specifically at the mechanism of CD-TREAT or EEN action. 
Such a study is important but would be better specifically addressed by exploring CD-TREAT against 
EEN in patients with active CD. 
The attenuation of ileitis histopathology scores and the lower expression of IL-6 and CXCL-1 
in our B27-CD-TREAT rat model also indicate that CD-TREAT can deliver therapeutic benefit in a 
disease state strongly associated with microbial dysbiosis, much like EEN in CD. In particular, the 
effect of EEN on ileal inflammation in our animals aligns with evidence of its efficacy in ileal 
mucosal healing in pediatric CD4.  
 As pre-clinical findings require replication within clinical trials we next tested CD-TREAT in 
children with active CD. CD-TREAT produced the same clinical efficacy signal and the same 
decrease in FC as in newly diagnosed children with CD on EEN4, 5. Adherence to CD-TREAT was 
high, suggesting it was relatively easy to follow, although meals were cooked and provided free to 
explore the efficacy signal under maximum treatment adherence conditions. In this small number of 
patients, it is not possible to test whether clinical efficacy is associated with an EEN-like modification 
of microbiome. 
We are unable to directly relate our findings with those from clinical research of other 
exclusion diets3. Although such previous studies have shown encouraging efficacy signals in 
uncontrolled trials in patients with active CD, they lack mechanistic evidence which would allow a 
direct comparison with the data presented here. We argue however, that these diets work by reducing 
exposure to free sugars, dietary fat or food additives and emulsifiers or by promoting gut 
‘normobiosis’. Indeed, several EEN feeds used in the management of active CD, are also rich in fat, 
sucrose, contain maltodextrins, carrageenan and lack fiber, and as discussed above, EEN-induced 
dysbiosis is paradoxically associated with mucosal healing6. It is possible that the clinical efficacy 















 EEN acceptability and long-term use, particularly in adult patients, may be limited by taste 
fatigue and poor palatability. In this study, CD-TREAT ranked as more palatable, easier to follow, 
more satiating, causing fewer gastrointestinal side-effects than EEN. These observations are in 
agreement with the opinions of families of CD children, previously treated with EEN, who reported 
that a solid food-based alternative would be preferable29. We did not observe differences in 
satisfaction, fullness and desire to eat ratings, nor in gastrointestinal symptoms such as abdominal 
discomfort, passing wind and constipation between the two diets. This is likely to be because the diets 
were isocaloric, had very similar composition, including low fiber content, and perhaps most 
importantly, the duration of intervention was not long enough to observe a significant effect. 
 The strengths of the study are the well-designed experiments in humans, where provision of 
the CD-TREAT was freely available to the participants to maximize adherence; the replication of our 
findings in animals with gut inflammation and microbiome dysbiosis similar to human CD; the 
extension of these experiments to demonstrate an early pilot signal of efficacy in our target clinical 
population; and the comprehensive multi-omics methodology applied. 
 However, the healthy human microbiome analysis was solely performed on fecal samples and 
so may not reflect the mucosal microbiome. Undertaking repeat colonoscopy assessments in healthy 
volunteers would be ethically unacceptable. However, the microbial signals of the two experimental 
diets on the fecal, cecal luminal contents and tissue specimens were similar in the animal experiments. 
The duration of the intervention lasted for seven days in the human RCT and for four weeks in the 
animal experiment, which is shorter than the 6-8 weeks of EEN that CD patients typically receive. 
However, the immediate response of the fecal rat microbiome within the first week of treatment, with 
fewer changes observed thereafter, suggests the observation was long enough, at least for the main 
study outcomes. We also believe that the effect of animal overfeeding and weight gain on the gut 
microbiome was insignificant as comparable microbial signals were observed in the healthy 
volunteers RCT and previously in CD children gaining weight during EEN6, 7. To ensure the most 
conservative approach to animal experiments, and for animal welfare, we kept the group sizes modest; 















inter-animal variation, such as the effects on specific taxon abundance. This may have also been the 
issue in the expression of some ileal tissue cytokines where despite apparent mean differences 
between groups, the small number of animals and substantial inter-animal variation, as observed 
previously19 reduced statistical power. For a preliminary study developing and supporting our core 
hypothesis however, the rat model, as reported, provided sufficient support to subsequently 
interrogate CD-TREAT in our pilot trial in patients with active CD. 
It is also possible that for some of the outcome measures for which we infer equivalence 
between the EEN and CD-TREAT interventions we may have needed a larger sample size. Such 
outcome measures may include the absence of differences in the expression of cytokines in the ileum 
of the animal experiments and some of the microbiome characteristics in the RCT in healthy 
volunteers. However, the primary objective of these preclinical studies was to explore the effects of 
each of the experimental diets against the control diet, with the equivalence between the experimental 
diets studied as a secondary, yet important, objective. Likewise, the efficacy signals of CD-TREAT in 
children with CD need replication in larger studies and against EEN. 
Conclusion 
We have produced robust proof-of-concept data to support a novel dietary treatment trialed in healthy 
volunteers, subsequently in rats with gut inflammation and microbiome dysbiosis similar to human 
CD and in a pilot trial in children with active CD. With the evidence produced within this scientific 
body of work, the efficacy of CD-TREAT on human CD clinical outcomes now needs to be 
ascertained within large, well-controlled clinical trials and with inclusion of mechanistic studies to 
explore microbial signals of response. If successful, CD-TREAT has the potential to be used 
interchangeably with EEN, particularly in adults where EEN uptake is low, and raises the prospect of 















Figure and Table Legends 
Figure 1. (A) RCT in healthy volunteers, (B) Animal experiments, (C) Open-label trial in patients 
with active CD.  
Figure 2. Effect of experimental diets on the gut microbiome of healthy volunteers (n=24) (A) 
Exponential of Shannon index (eH), (B) Chao1 index, (C) non-metric multidimensional scaling 
(NMDS) using Bray-Curtis distances of operational taxonomic unit (OTU) community structure, (D) 
correlation of OTU abundance changes, (E) principal component analysis of annotated metabolites, 
(F) correlation of annotated metabolite changes.  
Figure 3. (A) Rat ileal histopathology scores, (B) representative sections of all (n=20) animal groups    
(P-values for Fisher pairwise comparisons following general linear model). 
Figure 4. Chao1 and exponential of Shannon index (eH) of (A) rat fecal microbiome during 
experimental diets, (B) rat cecal luminal content microbiome. Non-metric multidimensional scaling 
(NMDS) using Bray-Curtis distances of operational taxonomic unit (OTU) community structure of 
(C) rat fecal microbiome during experimental diets, (D) rat cecal luminal content microbiome in all 
(n= 20) animals. 
Figure 5. (A) wPCDAI, (B) fecal calprotectin in CD children at study enrolment, four and eight weeks 
on CD-TREAT (P-values for Fisher pairwise comparisons following general linear model). 
Table 1. Dietary intake in the RCT in healthy volunteers (n=25) and open label trial in children with 
active CD (n=5). 
Table 2. Mean difference in relative abundance (log10) of genera and fold change (log2) in 
metabolites which similarly (P<.05) changed after EEN and CD-TREAT (genera analysis: n=96 
samples from 24 healthy humans; metabolite analysis: n=100 samples from 25 healthy volunteers; P-
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Energy (kcal) 2093, 497 2234, 428 2407, 344a** 2183, 363 2261, 282   2298, 222 2451, 519 
Energy (%TEE) 96.8, 21.44 103.4, 16.7 111.9, 14.8a** 100.4, 3.3 104.9, 9.1   98.7, 12.6 103.1, 8.0 
Fat (%) 33.9, 4.6 40.3, 0.8a¥ 42.6, 3.3a¥,b¥ 41.4, 0.0a¥ 43.9, 0.9a¥,b¥   39.8, 3.9 41.4, 2.5 
Saturated fat (%) 12.2, 2.7 22.8, 0.5a¥,c* 21.4, 2.1a¥,b¥ 23.4, 0.0a¥ 21.2, 0.6a¥,b¥   22.7, 2.8 23.0, 1.9 
Protein (%) 13.6, 1.9 14.2, 0.2 19.0, 1.8a¥,b¥ 14.4, 0.0a* 18.3, 0.7a¥,b¥   17.5, 2.4 18.2, 0.8 
Carbohydrates (%) 49.9, 4.4 45.4, 1.0a¥,c** 38.2, 3.2a¥,b¥ 43.2, 0.0a¥ 37.9, 0.4a¥,b¥   41.1, 3.4 39.0, 3.1 
Fiber (g/ 1000kcal) 7.8, 2.2 0.0, 0.0a¥ 4.7, 1.0a¥,b¥ 0.0, 0.0a¥ 4.2, 0.3a¥,b¥   4.5, 0.4 5.1, 0.8 
Gluten free No Yes Yes Yes Yes   Yes Yes 
Lactose free No Yes Yes Yes Yes   Yes Yes 
Alcohol free No Yes Yes Yes Yes   Yes Yes 
Data are displayed with means and standard deviations; a significant different to “Habitual diet”; b significant different to “EEN”; c significant different to “prescribed”; * P<.05; ** P<.01; ¥ 























 EEN Adjusted P CDT Adjusted P 
Genera increased during both diets     
Actinobacteria     
Actinomyces 1.67 <.001 0.85 .003 
Eggerthella 2.06 <.001 0.90 .001 
Senegalimassilia 1.02 .008 0.63 .015 
Bacteroidetes     
Alistipes 1.01 .012 0.67 .024 
Butyricimonas 1.16 .020 0.76 .014 
Prevotella 1.83 <.001 0.57 .030 
Firmicutes     
Anaerofilum 1.65 <.001 0.93 .003 
Anaerotruncus 1.21 <.001 1.32 <.001 
Candidatus_Soleaferrea 1.09 <.001 0.71 .014 
Eisenbergiella 2.61 <.001 2.17 <.001 
Family_XIII_AD3011_group 0.99 <.001 0.80 <.001 
Flavonifractor 2.15 <.001 0.95 .003 
Hungatella 1.72 <.001 1.04 .002 
Lachnoclostridium 2.20 <.001 0.63 .002 
Oscillibacter 1.97 .001 1.02 .006 
Ruminiclostridium_5 0.96 .002 0.70 .014 
Tyzzerella_4 1.68 <.001 1.14 .015 
Proteobacteria     
Bilophila 0.80 .024 1.14 .002 
Escherichia/Shigella 1.71 <.001 1.59 .001 
     
Genera decreased during both diets     
Actinobacteria     
Bifidobacterium -1.66 <.001 -1.51 <.001 
Firmicutes     
Dialister -2.39 <.001 -1.00 .014 
Faecalibacterium -1.82 <.001 -0.63 .011 













Lachnospiraceae_UCG-004 -2.18 <.001 -0.95 .011 
Pseudobutyrivibrio -3.35 <.001 -1.27 .002 
Ruminiclostridium_6 -1.25 .004 -1.42 .018 
Ruminococcaceae_UCG-013 -1.94 <.001 -0.83 .011 
Ruminococcus_1 -3.00 <.001 -3.78 <.001 
     
Top 25 metabolites changed during both diets 




Metabolism of lipids     
3a,7a,12a-Trihydroxy-5b-cholestanoate 1.76 <.001 1.21 <.001 
3a,7a-Dihydroxy-5b-cholestanate 1.48 <.001 1.26 <.001 
[FA hydroxy(20:4)] 1.70 <.001 0.64 .023 
DG(15:0/20:4(5Z,8Z,11Z,14Z)/0:0) 2.73 <.001 1.75 <.001 
DG(15:0/18:2(9Z,12Z)/0:0) -2.95 <.001 -1.41 .042 
[ST hydroxy(3:2/3:0/3:0)] 2.01 <.001 1.06 .001 
11-acetoxy-3b,6a-dihydroxy-9,11-seco-5a-cholest-7-en-9-
one.  
1.56 <.001 1.21 <.001 
[ST hydroxy(4:0)] 1.45 <.001 1.23 <.001 
26-hydroxycholesterol 3-sulfate 2.07 <.001 1.47 <.001 
Metabolism of proteins     
Ala-Leu-Gln-Gln 3.43 <.001 3.79 <.001 
Lys-Ala-Gln -4.52 <.001 -5.12 <.001 
N2-Acetyl-L-aminoadipate -3.85 <.001 -1.63 .006 
N-Succinyl-LL-2,6-diaminoheptanedioate -3.49 <.001 -1.04 .010 
Metabolism of cofactors/vitamins     
(1R,6R)-6-Hydroxy-2-succinylcyclohexa-2,4-diene-1-
carboxylate 
-2.75 <.001 -1.24 <.001 
Biosynthesis of secondary metabolites     
Antheraxanthin -2.88 <.001 -1.73 .002 
Unknown     
Crotanecine -2.42 <.001 -1.05 <.001 
Glutamylalanine -2.14 <.001 -0.90 .002 
N-(3-hydroxybutanoyl)-L-homoserine -2.34 <.001 -0.84 .001 
Formylpyruvate -2.44 <.001 -0.50 .018 













Evodone 1.83 <.001 0.73 <.001 
Androstane-3,17-diol dipropionate 2.68 <.001 1.18 <.001 
13'-hydroxy-&a;-tocopherol 2.03 <.001 1.30 <.001 
(24R,24'R)-Fucosterol epoxide 2.10 <.001 1.17 <.001 
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P < .001 P =  .061 
P =  .038 
P < .001
P =  .053 
P =  .001 
P =  .008 P =  .063 
P =  .094 
P < .001










































































































































P =  .050 P =  .020 
P =  .057 
P =  .028 
P =  .061 
P < .001
P =  .003 
P =  .004 
P =  .015 









































































































































































































P =  .062 
P =  .091 






















P =  .001 

































































Table S1: A day’s menu of CD-TREAT diet for a boy with CD, 15 y, 48 kg and 170cm. 
Breakfast: 
1 multivitamin tablet 
Full fat milk (360ml) 
Rice breakfast cereals (45g) 
Apple juice (360ml) 
Morning snack: 
Pineapple juice (360ml) 
1 peeled apple 
Lunch: 
1 sandwich with white bread (2 slices), cheddar (45g) and cream cheese (45g), lettuce (20g) and peeled cucumber (20g) 
1 bowl chicken and rice soup 
Afternoon snack: 
1 rice pudding 
Dinner: 
1 portion grilled salmon (180g) with mashed potatoes (260g) and cheese sauce 



















Table S2. Body weight, fecal characteristics, metabolites and bacterial load before and after EEN and CD-TREAT in the crossover RCT in healthy volunteers 
(n=100 samples from 25 participants). 
 Pre EEN Post EEN$ ∆EEN Pre CD-TREAT$ Post CD-TREAT$ ∆CD-TREAT$$ 
Body weight (kg) 66.0, 11.3 65.2, 10.5 -0.7, 1.3 65.9, 11.2 65.5, 11.0 -0.4, 0.8 
Fecal water (%) 70.9, 5.3 67.1, 5.8a** -3.8, 5.2  71.5, 5.1 70.0, 6.1c* -1.5, 7.0 
Weight of bowel movement, g 94.2, 54.5 63.2, 38.4a* -31.0, 56.9 108.9, 60.8 74.9, 48.73a* -34.1, 88.3 
Bristol Stool Form Scale 3.8, 1.4 1.9, 1.3a¥ -1.9, 1.5 3.8, 1.6 2.1, 1.0a¥ -1.7, 1.7 
Fecal pH 6.9, 0.5 8.2, 0.3a¥ 1.3, 0.5 6.8, 0.7 7.7, 0.5a¥,c¥ 0.9, 0.6d** 
Ammonia, mg/g 1.4, 1.0 1.7, 0.8 0.2, 1.2 1.6, 1.1 1.7, 1.0 0.0, 1.4 
Free sulfide, nmol/g 7.6, 3.6 3.1, 4.2a¥ -4.5, 3.6 7.5, 4.3 8.8, 5.1c¥ 1.3, 4.5d¥ 
Total sulfide, nmol/g 62.4, 43.8 195.4, 75.8a¥ 133.0, 80.5 49.8, 26.8 104.0, 56.4a¥,c¥ 54.3, 47.0d¥ 
Acetate, µmol/g 79.1, 20.3 51.7, 15.5a¥ -27.4, 22.6 91.8, 25.4b* 70.2, 17.3a¥,c¥ -21.6, 20.4 
Propionate, µmol/g 18.5, 8.0 12.8, 6.2a¥ -5.7, 7.8 19.3, 8.0 14.2, 7.3a¥ -5.2, 7.9 
Butyrate, µmol/g 15.0, 6.8 8.1, 4.4a¥ -7.0, 7.4 18.8, 10.6 8.6, 4.2a¥ -10.2, 8.5 
Valerate, µmol/g 2.6, 1.8 2.5, 1.3 -0.1, 1.5 2.7, 1.3 1.9, 0.8a**,c* -0.7, 1.0 
Iso-butyrate, µmol/g 1.9, 0.8 3.0, 1.3a¥ 1.1, 1.4 2.1, 1.1 2.1, 0.7c** 0.1, 0.9d* 
Iso-valerate, µmol/g 2.0, 0.9 3.2, 1.5a¥ 1.2, 1.6 2.1, 1.3 2.3, 0.8c** 0.2, 1.0d* 
Total bacteria 11.3, 0.2 11.0, 0.2a¥ -0.3, 0.3 11.3, 0.2 11.0, 0.3a¥ -0.3, 0.3 
Data are displayed with means and standard deviations; a significant difference between Pre EEN and Post EEN or Pre CD-TREAT and Post CD-TREAT; b significant 
difference between Pre EEN with Pre CD-TREAT; c significant difference between Post EEN with Post CD-TREAT; d significant difference between ∆EEN and ∆CD-
TREAT; * P<.05; ** P<.01; ¥ P<.001; $P for Fisher pairwise comparisons following general linear model with Box-Cox transformation. $$P for paired t-tests on log-


















Table S3. EEN and CD-TREAT acceptability and gastrointestinal symptoms in healthy volunteers of 
the RCT (n=25). 
 EEN CD-TREAT P 
Acceptability    
Difficulty to stay on the diet (LS: 1-10)?   
 
Day 1 4.1, 2.0 2.7, 1.9 .005 
Day 2 4.1, 1.7 3.0, 1.8 .004 
Day 3 4.4, 1.9 3.2, 1.8 .031 
Day 4 4.7, 2.0 3.1, 1.9 .011 
Day 5 4.6, 1.9 3.6, 2.0 .040 
Day 6 4.4, 1.7 3.2, 2.1 .015 
Day 7 4.2, 1.8 2.9, 2.0 .019 
Hunger during the day (VAS: 0-100)?    
Day 1 37.5, 23.7 30.8, 28.2 .054 
Day 6 36.7, 26.9 27.8, 28.8 .023 
Satisfaction during the day (VAS: 0-100)?    
Day 1 49.3, 23.4 59.2, 29.0 .504 
Day 6 53.0, 24.1 66.3, 27.4 .236 
Fullness during the day (VAS: 0-100)?    
Day 1 57.2, 22.9 63.9, 28.3 .716 
Day 6 63.4, 21.6 70.5, 24.5 .470 
Prospective food consumption during the day (VAS: 0-
100)? 
   
Day 1 42.3, 24.0 41.5, 24.7 .950 
Day 6 43.8, 25.3 44.7, 23.7 .493 
Desire to eat during the day (VAS from 0-100)?    
Day 1 57.6, 25.8 50.0, 29.6 .242 
Day 6 57.8, 27.9 48.2, 27.0 .436 
 
   
Gastrointestinal side effects    
Self-reported symptoms (LS: 0-4)   
 
Pain in abdomen 0.8, 0.9 0.2, 0.5 .005 
Diarrhea 0.5, 0.9 0.0, 0.2 .005 
Constipation 1.8, 1.5 1.4, 1.4 .102 
Nausea 0.7, 1.0 0.4, 0.9 .165 
Vomiting 0.1, 0.3 0.0, 0.2 .574 
Discomfort in abdomen 0.9, 1.0 0.6, 0.8 .313 
Passing wind 0.6, 1.0 0.7, 1.0 .424 
Not feeling hungry 0.9, 1.3 1.4, 1.3 .020 
Bloating 1.1, 1.2 0.6, 1.2 .052 
Data are displayed with means and standard deviations. P for paired t-tests on log-transformed data indicating 

















Table S4: Number of genera which significantly (P<.05) changed during EEN or CD-TREAT in the crossover RCT in healthy volunteers (n=24) 
Intervention Overall Decreased Increased 
EEN 58 24 34 
CD-TREAT 38 12 26 
Both interventions similar direction 28 9 19 
EEN only 30 15 15 
CD-TREAT only 10 3 7 
Both interventions opposite direction 0 0 0 
48.28% (28 out of 58) of EEN induced genera changes are replicated by CD-TREAT 
37.5% (9 out of 24) of genera decreased during EEN were decreased during CD-TREAT 
55.88% (19 out of 34) of genera increased during EEN were increased during CD-TREAT 


















Table S5: Mean difference of log10 relative abundance for genera significantly (P<.05) and similarly changing during both EEN and CD-TREAT in the 
crossover RCT in healthy volunteers (n=24) 
Phylum Class Order Family Genus EEN Adjusted P CDT 
Adjusted 
P 
Increased during both dietary interventions 
Actinobacteria 
Actinobacteria Actinomycetales Actinomycetaceae Actinomyces 1.67 2.20E-05 0.85 2.67E-03 
Coriobacteriia Coriobacteriales Coriobacteriaceae Eggerthella 2.06 1.96E-06 0.90 5.79E-04 Senegalimassilia 1.02 8.41E-03 0.63 1.47E-02 
Bacteroidetes Bacteroidia Bacteroidales 
Porphyromonadaceae Butyricimonas 1.16 2.00E-02 0.76 1.44E-02 
Prevotellaceae Prevotella 1.83 1.66E-06 0.57 2.98E-02 
Rikenellaceae Alistipes 1.01 1.22E-02 0.67 2.42E-02 
Firmicutes Clostridia Clostridiales 
Family_XIII Family_XIII_AD3011_g
roup 0.99 1.83E-04 0.80 
1.48E-04 
Lachnospiraceae 
Eisenbergiella 2.61 4.91E-06 2.17 1.48E-04 
Hungatella 1.72 3.30E-05 1.04 2.01E-03 
Lachnoclostridium 2.20 5.28E-07 0.63 2.01E-03 
Tyzzerella_4 1.68 7.78E-05 1.14 1.47E-02 
Ruminococcaceae 
Anaerofilum 1.65 5.01E-05 0.93 3.49E-03 
Anaerotruncus 1.21 1.83E-04 1.32 2.08E-04 
Candidatus_Soleaferrea 1.09 5.01E-05 0.71 1.36E-02 
Flavonifractor 2.15 1.60E-05 0.95 2.67E-03 
Oscillibacter 1.97 9.27E-04 1.02 6.10E-03 
Ruminiclostridium_5 0.96 1.52E-03 0.70 1.36E-02 
Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Bilophila 0.80 2.35E-02 1.14 2.44E-03 Gammaproteobacteria Enterobacteriales Enterobacteriaceae Escherichia/Shigella 1.71 1.18E-04 1.59 1.02E-03 
Decreased during both dietary interventions 
Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium -1.66 4.53E-04 -1.51 3.33E-04 
Firmicutes Clostridia Clostridiales Lachnospiraceae 
Lachnospiraceae_FCS02
0_group -0.85 2.85E-02 -0.62 7.18E-04 
Lachnospiraceae_UCG-
004 -2.18 5.01E-05 -0.95 1.14E-02 
Pseudobutyrivibrio -3.35 1.66E-06 -1.27 1.60E-03 

















Ruminiclostridium_6 -1.25 4.43E-03 -1.42 1.76E-02 
Ruminococcaceae_UCG-
013 -1.94 1.70E-04 -0.83 1.13E-02 
Ruminococcus_1 -3.00 8.09E-05 -3.78 1.72E-05 


















Table S6: Mean difference of log10 relative abundance for genera significantly (P<.05) changing during CD-TREAT only or EEN only in the crossover RCT 
in healthy volunteers (n=24) 
Phylum Class Order Family Genus CDT/ EEN Adjusted P 
Increased during CD-TREAT 
Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Desulfovibrio 0.77 4.03E-02 
Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae Gordonibacter 0.50 2.40E-02 
Firmicutes 
Bacilli Lactobacillales Streptococcaceae Lactococcus 1.16 1.36E-02 
Negativicutes Selenomonadales Acidaminococcaceae Phascolarctobacterium 0.79 2.98E-02 
Clostridia Clostridiales Ruminococcaceae 
Ruminococcaceae_UCG-002 0.61 2.27E-02 
Ruminococcaceae_UCG-005 0.73 2.27E-02 
Ruminococcaceae_UCG-010 0.68 2.48E-02 
Decreased during CD-TREAT 
Firmicutes 
Bacilli Lactobacillales Lactobacillaceae Lactobacillus -0.96 3.85E-02 
Clostridia Clostridiales Lachnospiraceae Anaerostipes -0.81 1.48E-04 Ruminococcaceae Ruminiclostridium -0.98 1.02E-03 
Increased during EEN 
Firmicutes 
Bacilli Lactobacillales Carnobacteriaceae Granulicatella 1.40 3.84E-06 
Clostridia Clostridiales 
Lachnospiraceae 
Blautia 0.67 1.35E-02 
Dorea 1.16 1.83E-04 
Howardella 0.40 4.60E-02 
Lachnospiraceae_UCG-010 0.91 3.57E-02 
Peptococcaceae Peptococcus 0.70 2.92E-02 
Ruminococcaceae Intestinimonas 1.70 1.02E-06 
 Ruminococcaceae_UCG-004 0.88 6.52E-03 
Erysipelotrichia Erysipelotrichales Erysipelotrichaceae 
Catenibacterium 0.46 2.46E-02 
Erysipelatoclostridium 1.51 8.85E-05 
Fecalitalea 1.04 9.50E-03 
Holdemanella 0.79 1.02E-02 
Negativicutes Selenomonadales Veillonellaceae Megamonas 0.48 1.04E-02 
Fusobacteria Fusobacteriia Fusobacteriales Fusobacteriaceae Fusobacterium 0.96 2.73E-04 
Synergistetes Synergistia Synergistales Synergistaceae Cloacibacillus 0.39 1.01E-02 
Decreased during EEN 

















Firmicutes Clostridia Clostridiales 
Lachnospiraceae 
[Eubacterium]_ventriosum_group -2.28 1.96E-06 
Coprococcus_2 -1.43 2.39E-02 
Incertae_Sedis -1.88 3.17E-03 
Lachnospira -3.71 1.17E-07 
Lachnospiraceae_ND3007_group -1.44 1.34E-02 
Lachnospiraceae_UCG-001 -2.50 7.78E-05 
Lachnospiraceae_UCG-005 -1.66 1.42E-04 
Tyzzerella_3 -1.22 2.85E-02 
Peptostreptococcaceae Terrisporobacter -1.06 1.70E-02 
Ruminococcaceae 
Ruminococcaceae_UCG-003 -1.12 2.39E-02 
Ruminococcus_2 -3.29 6.55E-06 
Subdoligranulum -1.31 2.54E-03 
Negativicutes Selenomonadales Veillonellaceae Veillonella -1.33 4.71E-03 


















Table S7: Number of 3% OTU which significantly (P<.05) changed during EEN & CD-TREAT in the crossover RCT in healthy volunteers (n=24) 
Intervention Overall Decreased Increased 
EEN 109 35 74 
CD-TREAT 64 14 50 
Both interventions similar direction 47 11 36 
EEN only 62 24 38 
CD-TREAT only 17 3 14 
Both interventions opposite direction 0 0 0 
43.11% (47 out of 109) of EEN induced OTU changes were replicated by CD-TREAT 
31.43% (11 out of 35) of OTU decreased during EEN were decreased during CD-TREAT 
48.65% (36 out of 74) of OTU increased during EEN were increased during CD-TREAT 


















Table S8: Mean difference of log10 relative abundance for OTU significantly (P<.05) and similarly changing during both EEN and CD-TREAT in the 
crossover RCT in healthy volunteers (n=24) 




Increased during both dietary interventions 
OTU_164 Actinob
acteria 
Actinobacteria Actinomycetales Actinomycetaceae Actinomyces 1.71 1.05E-04 0.90 4.17E-03 
OTU_88 Coriobacteriia Coriobacteriales Coriobacteriaceae Eggerthella 2.07 4.46E-06 0.89 1.72E-03 
OTU_177 Bacteroi
detes Bacteroidia Bacteroidales 
Porphyromonadaceae Butyricimonas 1.13 4.85E-02 0.80 3.86E-02 




Bacilli Lactobacillales Streptococcaceae Streptococcus 1.23 1.60E-04 0.81 2.62E-02 
OTU_111 
Clostridia Clostridiales 




Lachnoclostridium 3.83 1.66E-06 2.33 2.21E-04 
OTU_21 Lachnoclostridium 2.30 2.11E-06 1.03 8.12E-04 
OTU_147 Eisenbergiella 2.79 4.16E-06 2.25 5.50E-04 
OTU_28 Lachnoclostridium 3.22 9.73E-06 0.80 4.42E-02 
OTU_528 Hungatella 1.69 8.06E-05 1.03 4.21E-03 
OTU_123 Tyzzerella_4 1.65 2.18E-04 1.13 2.51E-02 
OTU_103 Lachnoclostridium 1.76 3.27E-04 1.16 2.58E-03 
OTU_304 Lachnospiraceae_NK4A136_group 1.68 8.01E-04 0.94 8.73E-04 
OTU_159 Lachnoclostridium 2.14 1.18E-03 0.77 2.00E-02 
OTU_320 NA 1.14 3.38E-03 0.58 4.97E-02 
OTU_191 Lachnoclostridium 1.32 1.83E-02 0.56 3.94E-02 
OTU_127 Desulfovibrio 0.88 4.32E-02 1.04 3.34E-02 
OTU_19 
Ruminococcaceae 
Anaerofilum 2.38 2.11E-06 1.30 1.08E-03 
OTU_237 Intestinimonas 1.88 9.96E-06 0.88 1.28E-02 
OTU_300 NA 2.29 1.59E-05 1.04 4.21E-03 
OTU_90 Flavonifractor 2.29 3.50E-05 0.96 5.10E-03 
OTU_72 Oscillibacter 2.25 5.59E-04 1.16 7.41E-03 
OTU_83 Anaerofilum 1.38 1.49E-03 0.94 7.49E-03 
OTU_220 Anaerotruncus 1.29 3.94E-03 0.88 3.91E-02 

















OTU_149 NA 1.31 5.98E-03 0.81 6.99E-03 
OTU_415 Anaerotruncus 0.59 2.94E-02 1.89 8.73E-04 





Erysipelotrichaceae Erysipelatoclostridium 1.37 4.26E-05 0.44 4.68E-02 
OTU_14 Negativicutes Selenomonadale
s 








Bilophila 0.77 4.19E-02 1.13 4.75E-03 





Enterobacteriaceae Escherichia/Shigella 1.68 3.27E-04 1.58 2.45E-03 OTU_13 Alistipes 1.17 3.91E-02 0.98 1.51E-02 










Clostridiaceae_1 Clostridium_sensu_stricto_1 -1.27 3.21E-02 -1.35 4.75E-03 
OTU_7 
Lachnospiraceae 
Pseudobutyrivibrio -3.57 6.92E-07 -1.29 2.83E-03 
OTU_112 Incertae_Sedis -3.27 3.20E-06 -1.01 3.87E-02 
OTU_156 Lachnospiraceae_UCG-004 -2.23 6.89E-05 -0.98 1.55E-02 
OTU_200 Lachnospiraceae_FCS020_gr
oup -0.82 4.32E-02 -0.90 8.73E-04 
OTU_29 
Ruminococcaceae 
Subdoligranulum -2.63 1.66E-06 -0.53 4.42E-02 
OTU_26 Fecalibacterium -1.85 1.01E-05 -0.62 1.51E-02 
OTU_182 Ruminococcaceae_UCG-013 -2.02 8.01E-04 -0.73 3.91E-02 
OTU_65 Ruminococcus_1 -2.19 1.75E-03 -2.37 2.90E-03 


















Table S9: Mean difference of log10 relative abundance for OTU significantly (P<.05) changing during CD-TREAT only or EEN only in the crossover RCT in 
healthy volunteers (n=24) 
OTU Phylum Class Order Family Genus CDT/ 
EEN 
Adjusted P 
Increased during CD-TREAT only 
OTU_270 Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae Senegalimassilia 0.70 1.12E-02 OTU_316 Gordonibacter 0.52 1.55E-02 
OTU_40 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 1.61 2.62E-02 
OTU_382 
Firmicutes 
Bacilli Lactobacillales Streptococcaceae Lactococcus 1.17 2.18E-02 
OTU_376 
Clostridia Clostridiales 
Christensenellaceae Christensenellaceae_R-7_group 0.90 1.55E-02 
OTU_277 Family_XIII Family_XIII_AD3011_group 0.65 1.18E-02 OTU_468 Family_XIII_AD3011_group 0.51 4.97E-02 
OTU_190 Lachnospiraceae NA 1.03 6.48E-03 OTU_278 Blautia 0.99 9.40E-03 
OTU_271 
Ruminococcaceae 
Ruminiclostridium_5 1.66 2.73E-03 
OTU_359 Ruminiclostridium_5 0.70 3.95E-02 
OTU_361 Ruminiclostridium_5 1.25 1.18E-02 
OTU_44 Ruminococcaceae_UCG-005 0.98 3.50E-03 
OTU_46 Ruminococcaceae_UCG-002 0.76 1.51E-02 
Decreased during CD-TREAT only 
OTU_11 Firmicutes Clostridia Clostridiales Lachnospiraceae Anaerostipes -0.85 6.64E-04 
OTU_192 Ruminococcaceae Ruminiclostridium -1.24 4.98E-03 
OTU_119 Ruminococcus_1 -1.42 3.94E-02 
Increased during EEN only 
OTU_113 
Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae 
NA 0.45 4.80E-02 
OTU_285 Slackia 0.48 2.66E-02 
OTU_293 Collinsella 0.79 4.19E-02 
OTU_64 
Bacteroidetes Bacteroidia Bacteroidales 
Bacteroidaceae Bacteroides 0.45 2.69E-02 
OTU_193 Porphyromonadaceae Parabacteroides 0.94 3.91E-02 OTU_938 Barnesiella 0.78 2.61E-02 
OTU_201 Cyanobacteria Melainabacteria Gastranaerophilal
es 
NA NA 0.93 4.02E-02 
OTU_233 NA NA 0.41 2.19E-02 




















Lachnoclostridium 1.78 1.70E-02 
OTU_138 NA 1.33 2.31E-03 
OTU_143 Lachnospiraceae_UCG-010 1.17 4.85E-02 
OTU_153 Blautia 0.95 4.80E-02 
OTU_243 NA 2.38 2.60E-05 
OTU_301 Blautia 0.76 2.71E-02 
OTU_307 Lachnospiraceae_UCG-010 0.80 3.17E-02 
OTU_4 NA 1.67 1.94E-02 
OTU_422 NA 0.98 1.86E-02 
OTU_54 Dorea 1.56 2.63E-05 
OTU_68 Lachnoclostridium 1.64 4.60E-03 
OTU_74 NA 0.97 1.08E-02 
OTU_137 
Ruminococcaceae 
Ruminococcaceae_UCG-005 1.10 4.30E-02 
OTU_148 Ruminiclostridium_5 0.61 3.37E-02 
OTU_172 Ruminococcaceae_UCG-004 0.90 5.92E-03 
OTU_187 Ruminiclostridium_9 1.13 1.47E-02 
OTU_289 Ruminiclostridium_5 1.00 4.99E-04 
OTU_290 NA 0.84 4.19E-02 
OTU_319 Ruminiclostridium_5 0.80 3.67E-02 
OTU_104 
Erysipelotrichia Erysipelotrichales Erysipelotrichaceae 
Holdemanella 0.76 2.42E-02 
OTU_203 Fecalitalea 0.84 4.02E-02 
OTU_234 NA 1.07 1.70E-03 
OTU_279 Erysipelatoclostridium 0.89 4.02E-02 
OTU_302 Incertae_Sedis 1.75 6.36E-06 
OTU_32 
Negativicutes Selenomonadales 
Acidaminococcaceae Phascolarctobacterium 0.46 3.37E-02 
OTU_50 Veillonellaceae Megamonas 0.45 2.69E-02 OTU_61 Veillonella 0.50 2.11E-02 
OTU_197 Synergistetes Synergistia Synergistales Synergistaceae Cloacibacillus 0.36 2.94E-02 
OTU_296 NA NA NA NA NA 0.54 1.70E-02 
Decreased during EEN only 
OTU_1 
Bacteroidetes Bacteroidia Bacteroidales 
Prevotellaceae Prevotella_9 -1.49 2.69E-02 
OTU_9 Bacteroidaceae Bacteroides -1.67 8.92E-03 
OTU_175 Rikenellaceae Alistipes -1.16 3.38E-03 



















Lachnospira -2.60 9.86E-05 
OTU_178 Incertae_Sedis -2.51 2.65E-04 
OTU_194 Lachnoclostridium -0.77 2.16E-02 
OTU_207 Lachnospiraceae_UCG-001 -1.98 4.98E-03 
OTU_211 Marvinbryantia -0.73 4.04E-02 
OTU_35 [Eubacterium]_ventriosum_group -2.35 4.46E-06 
OTU_73 Lachnospiraceae_NK4A136_group -1.21 1.68E-02 
OTU_86 Lachnospiraceae_ND3007_group -1.47 2.13E-02 
OTU_912 Lachnospiraceae_UCG-005 -1.30 3.98E-03 
OTU_97 Lachnospira -3.07 3.38E-06 




up -1.18 7.09E-03 
OTU_23 Ruminococcus_2 -3.34 1.01E-05 
OTU_244 Ruminiclostridium_9 -1.31 1.06E-02 
OTU_250 Fecalibacterium -1.14 2.69E-02 
OTU_309 Ruminococcaceae_UCG-003 -1.11 9.24E-03 
OTU_313 Ruminiclostridium_9 -0.89 2.69E-02 
OTU_259 Negativicutes Selenomonadales Veillonellaceae Veillonella -1.60 4.46E-04 OTU_66 Dialister -2.71 1.03E-03 
OTU_184 Proteobacteria Gammaproteoba


















Table S10: Number of fecal metabolites which significantly (P<.05) changed during EEN & CD-TREAT in the crossover RCT in healthy volunteers (n=24) 
Intervention Overall Decreased Increased 
EEN 675 354 321 
CD-TREAT 573 290 283 
Both interventions similar direction 294 148 146 
EEN only 313 177 136 
CD-TREAT only 211 103 108 
Both interventions opposite direction 68 EEN: 29; CD-TREAT: 39 EEN: 39; CD-TREAT: 29 
43.56% (294 out of 675) of EEN induced metabolite changes are replicated by CD-TREAT 
41.81% (148 out of 354) of metabolites decreased during EEN were decreased during CD-TREAT 
45.48% (146 out of 321) of metabolites increased during EEN were increased during CD-TREAT 

















Table S11. Baseline measurements and weekly changes (%) of fecal water content, body weight and fecal metabolites during the 4 weeks of the dietary 











Body wt(g)      
Baseline 282.8, 80.6 261.5, 83.1 298.8, 75.3 295.3, 112.6 288.5, 89.0 
D1-D7 0.9, 1.0 8.2, 4.4b**,c* 12.9, 0.8b¥ 1.4, 1.5 6.4, 3.6d* 
D1-D14 0.8, 2.5 8.6, 2.5b**,c* 12.9, 2.0b¥ 0.2, 3.4 8.5, 4.2d** 
D1-D21 1.4, 1.8 10.2, 4.0b**,c† 15.9, 1.9b¥ -0.6, 4.2 11.1, 5.8d** 
D1-D28 -1.7, 1.4 9.3, 3.1b¥ 14.6, 4.0b¥ 1.2, 4.1 13.2, 5.8d¥ 
Fecal water%      
Baseline 80.0, 1.7 79.7, 4.1 77.3, 3.4 64.3, 3.2a** 59.9, 3.6 
D1-D7 2.0, 2.4 1.8, 4.5 6.5, 7.7 5.7, 9.3 20.3, 6.6d** 
D1-D14 -5.2, 2.6 -4.1, 7.4 3.2, 6.2b† -4.3, 9.3 11.6, 6.9d** 
D1-D21 -3.2, 6.0 -3.0, 7.8 3.0, 4.3 4.0, 15.1 25.4, 10.1d** 
D1-D28 -9.6, 6.0 -1.4, 6.8 -2.8, 7.7 1.2, 14.1 14.1, 7.2d* 
Acetate, µmol/g      
Baseline 78.2, 24.2 98.1, 17.3 135.6, 24.2 86.5, 5.8 86.1, 7.4 
D1-D7 20.1, 44.5 -37.5, 2.7b** -47.4, 10.9b¥ -2.7, `28.5 -51.0, 11.1d** 
D1-D14 38.1, 44.0 -23.9, 13.4b** -32.4, 21.6b** -14.8, 7.0 -58.0, 2.9d¥ 
D1-D21 40.8, 65.5 -37.3, 10.7b** -29.5, 19.1b** -5.7, 7.4 -55.2, 10.5d¥ 
D1-D28 60.4, 55.2 -46.8, 27.3b¥ -30.0, 20.0b** -10.6, 12.2 -61.2, 9.0d** 
Propionate, µmol/g      
Baseline 14.1, 3.6 17.0, 2.7 22.8, 5.4 12.8, 1.0 12.0, 3.3 
D1-D7 -5.9, 31.2 -41.1, 8.0b† -24.2, 17.0 1.0, 55.0 -31.2, 15.6 
D1-D14 8.5, 19.2 -27.8, 19.8b† -26.2, 30.5b† -17.4, 34.6 -45.9, 11.2 
D1-D21 17.8, 52.3 -29.7, 18.0 -18.1, 28.1 0.3, 45.4 -20.2, 39.7 
D1-D28 46.0, 54.9 -41.5, 25.3b** -32.1, 29.7b* -17.9, 12.1 -48.7, 15.8d† 
Butyrate, µmol/g      
Baseline 5.2, 1.4 8.4, 5.1 5.3, 1.8 12.3, 5.3a† 11.8, 4.3 
D1-D7 -7.9, 67.3 -23.6, 45.3 -6.5, 26.8 48.5, 38.4 -71.8, 5.17d¥ 
D1-D14 -22.9, 31.5 -20.6, 32.9 10.8, 45.8 -13.8, 37.9 -82.2, 3.7d¥ 
D1-D21 14.9, 105.7 -33.8, 34.5 14.9, 50.9 21.8, 15.1 -68.8, 15.1d** 

















Valerate, µmol/g      
Baseline 0.4, 0.1 0.6, 0.3 0.7, 0.2 0.6, 0.2 0.7, 0.2 
D1-D7 -27.1, 23.5 136.8, 126.7b¥,c† 40.7, 40.5b** 24.6, 21.2 9.6, 29.6 
D1-D14 11.2, 46.5 245.0, 255.0b**,c† 48.5, 44.5 -1.4, 33.2 -16.1, 20.8 
D1-D21 10.9, 83.0 165.8, 147.0b* 44.2, 45.3 -0.6, 14.9 23.4, 35.8 
D1-D28 84.0, 146.2 127.9, 176.9 26.4, 19.0 3.4, 47.2 -14.7, 30.5 
Iso-butyrate, µmol/g      
Baseline 0.3, 0.1 0.4, 0.1 0.4, 0.1 0.6, 0.3 0.6, 0.2 
D1-D7 -9.8, 43.3 324.6, 166.4b¥ 209.1, 140.3b** 30.8, 60.0 105.6, 46.3 
D1-D14 -14.4, 14.8 487.0, 227.0b¥,c* 201.1, 120.2b** 8.3, 53.4 97.8, 39.6d* 
D1-D21 -23.3, 42.2 411.5, 167.0b¥,c† 198.1, 102.3b¥ 5.5, 43.9 134.0, 54.6d** 
D1-D28 91.4, 171.7 350.0, 245.0b* 196.4, 28.7 36.9, 123.7 94.5, 54.7 
Iso-valerate, µmol/g      
Baseline 0.2, 0.1 0.2, 0.1 0.2, 0.1 0.5, 0.3a* 0.4, 0.1 
D1-D7 -10.0, 35.3 470.6, 107.0b¥,c** 182.5, 97.8b** 39.7, 84.3 93.1, 37.2d† 
D1-D14 -13.2, 21.6 753.0, 477.0b¥,c** 162.9, 95.8b** 24.5, 66.3 108.6, 51.4d† 
D1-D21 -11.1, 47.3 567.0, 355.0b¥,c** 137.8, 70.3b** 26.5, 64.8 137.3, 67.3d* 
D1-D28 109.3, 173.4 447.0, 497.0b† 156.0, 35.5 60.3, 130.9 93.4, 49.6 
Data are displayed with means and standard deviations. a significant difference between B27-CONTROL & B7-CONTROL; b significant difference between B27-CONTROL 
& B27-EEN or B27-CONTROL & B27-CD-TREAT; c significant difference between B27-EEN & B27-CD-TREAT; d significant difference between B7-CONTROL & B7-
EEN; † P<.1; * P<.05; ** P<.01; ¥ P<.001. P for Fisher pairwise comparisons following general linear model with Box-Cox transformation; D1: Baseline; D7: 7 days on 



















Table S12: Histopathology scores and relative expression of cytokines in gut tissues from rats treated with EEN, CD-TREAT or standard chow (in all cases 












Ileum histopathology 3.75, 0.87 2.50, 0.58b* 2.75, 0.87b* 1.50, 0.41a¥ 1.13, 0.63 
Colon histopathology 5.13, 1.40 5.38, 0.63 4.63, 1.11 1.00, 0.00a¥ 1.13, 0.25 
Colon I 1.63, 0.48 1.88, 0.25 1.75, 0.29 0.50, 0.00a¥ 0.63, 0.48 
Colon M 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 
Colon N/AB 0.88, 0.25 1.00, 0.00 0.88, 0.25 0.50, 0.00 a** 0.50, 0.00 
Colon H 1.38, 0.48 1.25, 0.29 1.00, 0.41b† 0.00, 0.00a¥ 0.00, 0.00 
Colon G 1.25, 0.29 1.25, 0.29 1.00, 0.41 0.00, 0.00a¥ 0.00, 0.00 
Ileum I 2.00, 0.00 1.75, 0.29 1.75, 0.50 1.38, 0.25 a** 1.00, 0.41 
Ileum V 0.50, 0.41 0.25, 0.29 0.00, 0.00b**,c† 0.00, 0.00 a** 0.00, 0.00 
Ileum H 1.25, 0.50 0.50, 0.00 1.00, 0.41 0.13, 0.25a** 0.13, 0.25 
Ileum N 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 
Ileal TNF-α 2.02, 0.96 1.67, 1.32 1.15, 0.64 1.39, 0.98 1.33, 0.77 
Ileal IL-6 3.44, 3.02 1.89, 1.07 0.72, 0.38b* 1.28, 0.96 4.12, 3.04d* 
Ileal IL-10 3.24, 1.89 1.21, 0.53 1.08, 0.83 1.57, 1.50 2.23, 2.11 
Ileal IL-1b 0.76, 0.34 0.92, 0.19 0.64, 0.19 1.16, 0.68 1.23, 0.20 
Ileal CXCL-1 2.47, 1.73 2.60, 2.31 0.87, 0.55b†,c† 1.45, 1.22 1.43, 0.43 
Data are displayed with means and standard deviations. a significant difference between B27-CONTROL & B7-CONTROL; b significant difference between B27-CONTROL 
& B27-EEN or B27-CONTROL & B27-CD-TREAT; c significant difference between B27-EEN & B27-CD-TREAT; d significant difference between B7-CONTROL & B7-
EEN; † P<.1; * P<.05; ** P<.01; ¥ P<.001. P for Fisher pairwise comparisons following general linear model with Box-Cox transformation. I: Infiltration with leukocytes in 
the lamina propria and tela submucosa; M: Mucosal defects and fibrose; N/AB: Neutrophile infiltration and crypt abscessation; H: Hyperplasia; G: Goblet cell depletion; V: 




















Table S13. Weight of cecal and colonic luminal contents, cecal SCFA at sacrifice and fecal and cecal 
luminal total bacterial load during the 4 weeks of intervention in the animal experiment in all cases 











Weight, g      
Cecum content 3.9, 1.3 1.0, 0.3b¥,c¥ 2.3, 0.6b* 3.1, 0.8 1.3, 0.2d** 
Colon content 0.8, 0.5 0.1, 0.1b**,c* 0.5, 0.2 1.2, 0.4 0.2, 0.2d** 
SCFA total µmol in cecum 
Acetate 413.0, 213.0 53.6, 6.9b¥,c¥ 229.9, 100.9b† 269.5, 122.9 66.4, 17.0d¥ 
Propionate 64.9, 33.3 11.8, 3.3b¥,c¥ 56.2, 22.7 39.6, 9.3 16.0, 3.6d** 
Butyrate 17.1, 8.7 4.4, 0.9b¥,c¥ 22.8, 8.9 106.6, 56.7a** 4.9, 1.4d¥ 
Valerate 1.3, 0.8 1.3, 0.1c* 3.6, 1.7b** 2.5, 0.9a* 1.2, 0.1d* 
Iso-butyrate 0.7, 0.3 1.3, 0.2b*, c* 2.9, 1.6b¥ 1.5, 0.5a* 1.1, 0.2 
Iso-valerate 0.4, 0.2 0.8, 0.2b†,c† 1.8, 1.1b** 1.0, 0.4a* 0.8, 0.2 
SCFA µmol/g cecum content 
Acetate 100.9, 19.1 49.0, 5.6b¥,c¥ 98.6, 23.5 84.2, 20.2 52.7, 9.2d** 
Propionate 15.9, 2.9 10.6, 1.82b**,c¥ 24.2, 6.0b* 12.9, 1.0 12.6, 1.1 
Butyrate 4.3, 1.4 4.1, 0.8c** 9.9, 3.0b** 32.8, 11.3a¥ 4.0, 1.4d¥ 
Valerate 0.3, 0.1 1.2, 0.2b¥ 1.5, 0.5b¥ 0.8, 0.1a¥ 1.0, 0.2 
Iso-butyrate 0.2, 0.0 1.2, 0.1b¥ 1.2, 0.4b¥ 0.5, 0.1a¥ 0.9, 0.2d* 
Iso-valerate 0.1, 0.0 0.7, 0.1b¥ 0.8, 0.3b¥ 0.3, 0.1a¥ 0.6, 0.1d* 
Total bacteria 
/g cecum content 10.7, 0.2 11.1, 0.2b** 11.2, 0.0b** 11.2, 0.1a** 11.2, 0.2 
/total cecum 
content 
11.2, 0.3 11.1, 0.4c* 11.5, 0.1b† 11.7, 0.2a** 11.3, 0.2d* 
/g feces Baseline 10.9, 0.3 11.0, 0.15 10.5, 0.2 11.1, 0.2 11.1, 0.2 
/g feces D1-D7% -8.3, 48.0 109.5, 80.1b* 134.6, 117.8b* 67.6, 114.9 -11.8, 25.5 
/g feces D1-D14% -18.4, 38.6 76.2, 37.6b* 168.1, 174.8b* 40.4, 67.5 -8.6, 14.17 
/g feces D1-D21% -16.7, 40.6 171.4, 68.7b**,c† 607.0, 468b¥ 10.4, 61.1 32.1, 116.9 
/g feces D1-D28% 10.3, 63.8 73.7, 76.9b†,c** 379.0, 265.0b¥ 30.3, 14.9 -21.2, 24.8 
Data are displayed with means and standard deviations. a significant difference between B27-CONTROL & B7-CONTROL; 
b
 significant difference between B27-CONTROL & B27-EEN or B27-CONTROL & B27-CD-TREAT; c significant 
difference between B27-EEN & B27-CD-TREAT; d, significant difference between B7-CONTROL & B7-EEN; † P<.1; * 


















Table S14: Relative abundance (ln) of genera, in feces, which significantly (P<.10) differed between B27-CONTROL and B7-CONTROL at intervention 
initiation (in all cases data from all studied animals were included, n=8) 




Significantly higher than B7-CONTROL group 
Firmicutes 
Bacilli Lactobacillales Streptococcaceae Streptococcus -6.58 -5.58 5.54E-02 
Clostridia Clostridiales 
Lachnospiraceae 
Anaerostipes -9.70 -5.54 3.12E-04 
Blautia -6.10 -1.36 3.37E-02 
Coprococcus_3 -9.70 -7.04 1.73E-03 
Eisenbergiella -9.25 -6.91 1.47E-02 
Fusicatenibacter -9.60 -2.46 2.74E-04 
Lachnoclostridium -5.19 -3.83 8.94E-02 
Ruminococcaceae 
Flavonifractor -9.32 -6.43 1.68E-02 
Oscillospira -9.87 -5.44 8.55E-04 
Ruminococcaceae_UCG-008 -9.70 -3.79 2.74E-04 
Erysipelotrichia Erysipelotrichale
s 
Erysipelotrichaceae Erysipelatoclostridium -9.87 -7.44 3.37E-02 
Negativicutes Selenomonadale
s 
Acidaminococcaceae Phascolarctobacterium -7.13 -3.50 9.83E-02 
Significantly lower than B7-CONTROL group 
Actinobacteria Actinobacteria Corynebacteriale
s 
Corynebacteriaceae Corynebacterium_1 -8.39 -9.69 1.47E-02 
Bacteroidetes Bacteroidia Bacteroidales 
Porphyromonadaceae Odoribacter -6.99 -9.59 1.83E-03 
Prevotellaceae 
Prevotellaceae_Ga6A1_group -3.90 -8.55 7.03E-02 
Prevotellaceae_NK3B31_grou
p 
-2.30 -4.00 3.52E-02 
Rikenellaceae Alistipes -4.82 -7.50 7.26E-03 
Firmicutes 
Bacilli Bacillales Staphylococcaceae Jeotgalicoccus -7.65 -9.59 3.67E-02 
Clostridia Clostridiales 
Defluviitaleaceae Defluviitaleaceae_UCG-011 -7.81 -9.87 1.28E-02 




-7.10 -8.28 3.67E-02 



















-2.74 -7.28 2.49E-02 
Lachnospiraceae_UCG-001 -4.01 -9.07 4.99E-03 
Lachnospiraceae_UCG-006 -6.42 -9.87 5.47E-03 
Peptococcaceae Peptococcus -7.42 -9.87 1.20E-02 
Peptostreptococcacea
e 
Romboutsia -4.47 -8.28 8.44E-02 
Ruminococcaceae 
Anaerofilum -7.78 -8.76 7.87E-02 
Anaerotruncus -5.75 -7.62 1.47E-02 
Butyricicoccus -6.29 -9.87 1.28E-02 
Oscillibacter -4.41 -6.05 5.84E-02 
Ruminiclostridium_5 -5.35 -7.20 3.37E-02 
Ruminiclostridium_6 -5.24 -9.69 2.02E-03 
Ruminococcaceae_NK4A214_
group 
-5.24 -9.00 7.85E-03 
Ruminococcaceae_UCG-002 -7.46 -9.59 5.13E-02 
Ruminococcaceae_UCG-003 -5.84 -8.21 9.83E-02 
Ruminococcaceae_UCG-009 -7.24 -9.14 3.67E-02 
Ruminococcaceae_UCG-010 -6.71 -9.46 3.82E-02 
Ruminococcus_1 -3.88 -8.31 3.37E-02 
Erysipelotrichia Erysipelotrichale
s 
Erysipelotrichaceae Turicibacter -3.61 -9.87 1.68E-02 























TableS15: Relative abundance (ln) of genera, in cecal contents, which significantly (P<.10) differed between B27-CONTROL and B7-CONTROL at 
intervention initiation (in all cases data from all studied animals were included, n=8) 





Significantly higher than B7-CONTROL group 
Firmicutes 
Bacilli Lactobacillales Streptococcaceae Streptococcus -7.86 -5.15 3.04E-02 
Clostridia Clostridiales 
Clostridiaceae_1 Candidatus_Arthromitus -9.07 -6.15 7.74E-02 
Lachnospiraceae 
Anaerostipes -9.12 -5.70 2.13E-03 
Blautia -7.46 -1.28 2.13E-02 
Fusicatenibacter -9.20 -4.20 5.85E-02 
Ruminococcaceae 
Flavonifractor -9.47 -7.05 7.12E-02 
Oscillospira -9.47 -5.62 1.87E-02 
Ruminococcaceae_UCG-008 -8.18 -4.44 5.17E-02 
Proteobacter
ia 
Betaproteobacteria Burkholderiales Alcaligenaceae Parasutterella -6.75 -4.61 4.99E-02 
Significantly lower than B7-CONTROL group 
Bacteroidete
s 
Bacteroidia Bacteroidales Prevotellaceae Prevotellaceae_Ga6A1_group -3.45 -9.90 4.79E-03 
Bacteroidia Bacteroidales Rikenellaceae Alistipes -5.88 -7.91 3.31E-02 
Firmicutes 
Bacilli Bacillales Staphylococcaceae Jeotgalicoccus -7.78 -9.62 3.40E-02 
Clostridia Clostridiales 
Family_XIII Anaerovorax -8.19 -9.90 5.17E-02 
Lachnospiraceae 
Acetatifactor -4.90 -9.90 7.99E-03 
Lachnospiraceae_FCS020_grou
p -7.83 -9.62 
5.85E-02 
Lachnospiraceae_NK4A136_gr
oup -1.57 -8.46 
4.79E-03 
Lachnospiraceae_UCG-001 -3.28 -9.90 2.19E-03 
Lachnospiraceae_UCG-006 -5.26 -9.90 7.99E-03 
Tyzzerella -7.63 -9.90 5.85E-02 
Peptococcaceae Peptococcus -7.12 -9.90 1.91E-02 
Ruminococcaceae 
Anaerotruncus -5.55 -8.28 3.16E-02 
Butyricicoccus -5.81 -9.90 4.99E-02 
Oscillibacter -4.37 -6.03 4.99E-02 

















Ruminococcaceae_UCG-003 -4.90 -9.28 2.13E-02 
Ruminococcaceae_UCG-005 -4.61 -9.62 3.23E-02 
Ruminococcaceae_UCG-009 -6.58 -9.22 1.87E-02 
Ruminococcaceae_UCG-010 -7.02 -9.73 1.43E-02 
Ruminococcus_1 -4.29 -8.11 4.99E-02 



























Table S16: Relative abundance (ln) of 3% OTU, in feces, which significantly (P<.10) differed between B27-CONTROL and B7-CONTROL at intervention 
initiation (in all cases data from all studied animals were included, n=8) 









Significantly higher than B7-CONTROL group 
OTU_129 
Bactero
idetes Bacteroidia Bacteroidales 
Bacteroidaceae 
Bacteroides -7.68 -5.95 7.67E-02 
OTU_62 Bacteroides -9.89 -7.45 1.29E-02 
OTU_4 Bacteroides -9.02 -4.27 1.23E-02 




Bacilli Lactobacillales Streptococcaceae Streptococcus -6.92 -5.83 8.54E-02 
OTU_419 
Clostridia Clostridiales Lachnospiraceae 
Anaerostipes -10.07 -8.00 2.17E-02 
OTU_14 Anaerostipes -9.89 -5.73 9.40E-04 
OTU_784 Blautia -9.79 -5.57 2.82E-02 
OTU_8 Blautia -6.71 -1.70 5.08E-02 
OTU_3 Blautia -9.62 -3.72 1.67E-02 
OTU_165 Coprococcus_1 -9.89 -6.01 1.60E-02 
OTU_106 Coprococcus_3 -9.89 -7.14 2.95E-03 
OTU_48 Eisenbergiella -9.44 -7.02 1.67E-02 
OTU_19 Fusicatenibacter -9.79 -2.56 7.22E-04 
OTU_617 Incertae_Sedis -9.72 -7.92 2.34E-02 
OTU_277 Lachnoclostridium -8.72 -5.39 1.67E-02 
OTU_35 Lachnoclostridium -9.79 -5.57 1.61E-02 
OTU_65 Lachnoclostridium -9.49 -4.81 1.67E-02 
OTU_46 Marvinbryantia -10.07 -7.39 1.55E-02 
OTU_197 NA -9.89 -8.28 2.07E-02 
OTU_126 NA -10.07 -7.35 6.50E-03 
OTU_314 NA -9.62 -6.27 4.14E-02 
OTU_271 NA -9.17 -5.72 5.12E-02 
OTU_18 NA -7.91 -4.01 1.79E-02 
OTU_30 NA -9.62 -5.67 3.47E-03 



















Flavonifractor -9.52 -6.53 1.74E-02 
OTU_156 NA -10.07 -5.81 2.95E-03 
OTU_38 Oscillibacter -10.07 -7.57 5.82E-02 
OTU_247 Oscillospira -10.07 -6.96 3.53E-03 
OTU_369 Ruminiclostridium_5 -10.07 -8.56 4.23E-02 
OTU_102 Ruminococcaceae_UCG-008 -9.89 -3.89 7.22E-04 
OTU_176 Erysipelotrichia Erysipelotrichal
es 






ales Desulfovibrionaceae Desulfovibrio -8.04 -6.43 5.50E-02 





Corynebacteriaceae Corynebacterium_1 -8.61 -9.80 2.46E-02 
OTU_298 
Bactero
idetes Bacteroidia Bacteroidales 
Bacteroidales_S24-
7_group 
NA -6.54 -9.97 3.47E-03 
OTU_193 NA -5.91 -9.05 3.31E-02 
OTU_273 NA -6.43 -9.35 1.79E-02 
OTU_145 NA -4.79 -7.27 3.74E-02 
OTU_209 NA -7.14 -9.31 7.79E-02 
OTU_346 NA -7.26 -9.31 2.46E-02 
OTU_447 NA -7.54 -9.28 4.90E-02 
OTU_240 NA -6.52 -7.95 6.44E-02 
OTU_228 NA -5.95 -6.86 5.82E-02 
OTU_357 NA NA -7.45 -8.66 5.92E-02 
OTU_150 Porphyromonadaceae Odoribacter -7.18 -9.70 3.47E-03 
OTU_10 
Prevotellaceae 
Prevotellaceae_Ga6A1_group -4.09 -8.66 7.95E-02 
OTU_11 Prevotellaceae_NK3B31_group -2.49 -4.10 4.48E-02 
OTU_269 
Rikenellaceae 
Alistipes -6.64 -9.52 1.67E-02 
OTU_76 Alistipes -6.51 -8.95 2.46E-02 
OTU_138 Alistipes -6.27 -8.46 9.76E-02 
OTU_289 Alistipes -7.48 -9.45 9.29E-02 





























NA -7.67 -9.97 3.09E-02 
OTU_536 NA -7.90 -9.97 3.39E-02 




oup -7.51 -8.38 6.69E-02 
OTU_184 Acetatifactor -7.53 -9.97 5.45E-02 
OTU_347 Acetatifactor -8.49 -9.97 4.66E-02 
OTU_83 Coprococcus_1 -8.02 -9.97 2.17E-02 
OTU_125 Lachnoclostridium -5.91 -9.97 2.95E-03 
OTU_72 Lachnoclostridium -7.85 -9.97 1.62E-02 
OTU_23 Lachnospiraceae_NK4A136_group -4.25 -9.45 3.47E-03 
OTU_93 Lachnospiraceae_NK4A136_group -5.15 -9.03 7.89E-02 
OTU_61 Lachnospiraceae_NK4A136_group -7.19 -9.97 6.42E-02 
OTU_67 Lachnospiraceae_NK4A136_group -7.49 -9.97 1.06E-02 
OTU_398 Lachnospiraceae_NK4A136_group -7.76 -9.97 8.70E-02 
OTU_232 Lachnospiraceae_UCG-006 -7.40 -9.97 1.61E-02 
OTU_177 NA -6.96 -9.97 1.82E-02 
OTU_255 NA -7.00 -9.97 1.23E-02 
OTU_223 NA -7.12 -9.97 2.87E-02 
OTU_77 NA -7.55 -9.97 8.24E-02 
OTU_469 NA -7.55 -9.97 1.06E-02 
OTU_178 NA -7.63 -9.97 1.67E-02 
OTU_140 NA -7.36 -9.63 2.70E-02 
OTU_270 NA -7.80 -9.97 2.90E-02 
OTU_265 NA -7.98 -9.97 2.46E-02 
OTU_222 NA -8.01 -9.97 1.79E-02 
OTU_348 NA -7.91 -9.80 6.36E-02 

















OTU_239 NA -8.21 -9.97 1.79E-02 
OTU_319 NA -8.25 -9.97 6.52E-02 
OTU_457 NA -8.49 -9.97 5.58E-02 
OTU_411 NA -8.25 -9.70 6.52E-02 
OTU_220 Roseburia -6.77 -9.97 1.62E-02 
OTU_86 Roseburia -7.32 -9.97 8.78E-02 
OTU_258 Peptococcaceae NA -6.62 -9.97 9.75E-02 OTU_260 Peptococcus -7.61 -9.97 1.60E-02 




nes_group -8.45 -9.97 6.17E-02 
OTU_486 Anaerotruncus -7.70 -9.70 5.68E-02 
OTU_353 Anaerotruncus -8.00 -9.80 4.71E-02 
OTU_152 Butyricicoccus -6.48 -9.97 1.61E-02 
OTU_69 NA -5.40 -9.97 3.56E-03 
OTU_119 NA -6.44 -9.97 2.34E-02 
OTU_236 NA -6.47 -9.97 6.50E-03 
OTU_73 NA -5.48 -8.73 5.31E-02 
OTU_426 NA -6.84 -9.97 1.67E-02 
OTU_190 NA -7.21 -9.97 1.67E-02 
OTU_578 NA -8.14 -9.97 1.67E-02 
OTU_139 Oscillibacter -5.08 -9.17 6.02E-02 
OTU_201 Oscillibacter -7.38 -9.97 4.85E-02 
OTU_318 Oscillibacter -7.78 -9.97 2.93E-02 
OTU_276 Oscillibacter -7.48 -9.63 2.46E-02 
OTU_310 Ruminiclostridium_5 -7.88 -9.97 2.46E-02 
OTU_480 Ruminiclostridium_5 -7.90 -9.80 4.69E-02 
OTU_442 Ruminiclostridium_5 -8.35 -9.97 2.90E-02 
OTU_127 Ruminiclostridium_6 -5.94 -9.97 8.61E-03 
OTU_429 Ruminiclostridium_9 -7.26 -9.63 1.79E-02 
OTU_300 Ruminiclostridium_9 -5.97 -8.26 7.87E-02 
OTU_103 Ruminiclostridium_9 -5.64 -7.88 3.47E-03 
OTU_430 Ruminiclostridium_9 -7.74 -9.97 1.23E-02 


















_group -5.64 -9.97 1.86E-03 
OTU_421 Ruminococcaceae_UCG-002 -7.65 -9.97 1.61E-02 
OTU_290 Ruminococcaceae_UCG-009 -7.68 -9.97 2.49E-02 
OTU_414 Ruminococcaceae_UCG-010 -7.47 -9.97 1.28E-02 
OTU_282 Ruminococcaceae_UCG-013 -6.73 -9.29 2.46E-02 
OTU_388 Ruminococcaceae_UCG-013 -7.69 -9.97 8.75E-02 
OTU_121 Ruminococcaceae_UCG-014 -7.27 -9.97 1.23E-02 
OTU_387 Ruminococcaceae_UCG-014 -7.33 -9.97 2.17E-02 
OTU_562 Ruminococcaceae_UCG-014 -7.72 -9.97 1.23E-02 
OTU_259 Ruminococcaceae_UCG-014 -8.05 -9.97 1.67E-02 
OTU_130 Ruminococcus_1 -4.70 -9.80 1.23E-03 
OTU_34 Erysipelotrichia Erysipelotrichal
es 
























Table S17: Relative abundance (ln) of 3% OTU, in cecal contents, which significantly (P<.10) differed between B27-CONTROL and B7-CONTROL at 
intervention initiation (in all cases data from all studied animals were included, n=8) 






Significantly higher than B7-CONTROL group 
OTU_133 Bacteroi
detes Bacteroidia Bacteroidales Bacteroidaceae 
Bacteroides -8.92 -7.37 5.32E-02 
OTU_129 Bacteroides -8.57 -6.27 4.62E-02 




Bacilli Lactobacillales Lactobacillaceae Lactobacillus -7.09 -3.13 1.14E-02 OTU_50 Streptococcaceae Streptococcus -8.40 -5.33 2.90E-02 
OTU_142 
Clostridia Clostridiales 
Clostridiaceae_1 Candidatus_Arthromitus -9.28 -6.23 8.69E-02 
OTU_14 
Lachnospiraceae 
Anaerostipes -9.34 -5.89 2.69E-03 
OTU_784 Blautia -9.69 -5.65 1.79E-02 
OTU_8 Blautia -8.08 -2.23 1.14E-02 
OTU_3 Blautia -9.24 -2.40 6.58E-03 
OTU_165 Coprococcus_1 -9.69 -6.61 5.70E-02 
OTU_19 Fusicatenibacter -9.41 -4.29 7.47E-02 
OTU_65 Lachnoclostridium -9.34 -4.34 1.14E-02 
OTU_51 NA -9.51 -7.20 2.76E-02 
OTU_126 NA -9.41 -6.84 1.26E-02 
OTU_30 NA -9.28 -5.33 1.42E-03 
OTU_271 NA -9.69 -5.26 1.52E-02 
OTU_49 
Ruminococcaceae 
Flavonifractor -9.69 -7.14 7.94E-02 
OTU_156 NA -9.69 -5.89 1.96E-02 
OTU_38 Oscillibacter -9.20 -6.99 2.08E-02 
OTU_71 Oscillibacter -9.69 -7.08 8.69E-02 
OTU_247 Oscillospira -9.69 -7.48 8.13E-02 
OTU_102 Ruminococcaceae_UCG
-008 -8.39 -4.52 7.17E-02 
OTU_215 Erysipelotrichia Erysipelotrichales Erysipelotrichaceae NA -8.83 -6.72 8.69E-02 

















acteria a s 
Significantly lower than B7-CONTROL group 
OTU_235 
Bacteroi
detes Bacteroidia Bacteroidales 
Bacteroidales_S24-
7_group 
NA -5.91 -9.16 2.33E-02 
OTU_298 NA -7.20 -9.99 2.33E-02 
OTU_145 NA -5.94 -8.48 9.61E-02 
OTU_273 NA -7.40 -9.36 7.45E-02 
OTU_193 NA -7.88 -9.64 1.96E-02 
OTU_10 Prevotellaceae Prevotellaceae_Ga6A1_group -3.67 -9.99 1.14E-02 









NA -7.19 -9.99 7.17E-02 
OTU_641 NA -7.88 -9.81 1.52E-02 
OTU_408 Family_XIII Anaerovorax -8.40 -9.99 8.13E-02 
OTU_267 
Lachnospiraceae 
Acetatifactor -6.32 -9.99 1.19E-02 
OTU_83 Coprococcus_1 -6.94 -9.99 1.79E-02 
OTU_291 Incertae_Sedis -5.89 -8.49 8.69E-02 
OTU_125 Lachnoclostridium -5.29 -9.99 6.74E-03 
OTU_72 Lachnoclostridium -6.57 -9.99 6.38E-02 
OTU_23 Lachnospiraceae_NK4A136_group -3.74 -9.71 1.79E-02 
OTU_12 Lachnospiraceae_NK4A136_group -4.35 -9.99 7.47E-02 
OTU_93 Lachnospiraceae_NK4A136_group -5.32 -9.99 8.69E-02 
OTU_111 Lachnospiraceae_UCG-001 -5.66 -9.99 2.08E-02 
OTU_94 Lachnospiraceae_UCG-001 -5.83 -9.99 9.75E-02 
OTU_232 Lachnospiraceae_UCG-006 -6.53 -9.99 1.73E-02 
OTU_16 NA -4.88 -9.99 6.38E-02 
OTU_177 NA -5.81 -9.99 1.14E-02 

















OTU_140 NA -6.60 -9.54 6.38E-02 
OTU_202 NA -6.69 -9.58 5.17E-02 
OTU_222 NA -7.30 -9.99 4.38E-02 
OTU_178 NA -7.33 -9.99 7.21E-02 
OTU_239 NA -7.42 -9.99 7.17E-02 
OTU_270 NA -7.42 -9.99 8.32E-02 
OTU_266 Tyzzerella -7.85 -9.99 8.69E-02 
OTU_260 Peptococcaceae Peptococcus -7.34 -9.99 2.26E-02 
OTU_315 
Ruminococcaceae 
Anaerotruncus -7.60 -9.99 8.69E-02 
OTU_299 Anaerotruncus -7.70 -9.99 5.70E-02 
OTU_486 Anaerotruncus -7.91 -9.99 7.21E-02 
OTU_152 Butyricicoccus -6.02 -9.99 6.38E-02 
OTU_69 NA -5.18 -9.99 1.79E-02 
OTU_73 NA -4.33 -9.07 1.51E-03 
OTU_236 NA -5.92 -9.99 5.70E-02 
OTU_426 NA -6.05 -9.99 1.14E-02 
OTU_119 NA -6.22 -9.99 1.79E-02 
OTU_190 NA -7.14 -9.99 2.75E-02 
OTU_139 Oscillibacter -5.36 -9.99 1.26E-02 
OTU_276 Oscillibacter -7.24 -9.71 5.90E-02 
OTU_736 Oscillibacter -7.52 -9.81 5.92E-02 
OTU_393 Oscillibacter -7.86 -9.81 8.69E-02 
OTU_340 Ruminiclostridium_5 -7.16 -9.99 1.79E-02 
OTU_310 Ruminiclostridium_5 -7.95 -9.99 6.38E-02 
OTU_103 Ruminiclostridium_9 -5.78 -8.26 3.75E-02 
OTU_114 Ruminiclostridium_9 -6.81 -8.99 7.94E-02 
OTU_429 Ruminiclostridium_9 -7.50 -8.95 2.18E-02 
OTU_110 Ruminococcaceae_NK4A214_group -6.32 -9.99 4.38E-02 
OTU_57 Ruminococcaceae_UCG
-003 -5.12 -9.36 2.76E-02 
OTU_27 Ruminococcaceae_UCG
-005 -5.01 -9.99 4.55E-02 










































Table S18: Number of genera in cecal contents, collected at sacrifice, which significantly (P<.10) differed in relative abundance between B27-CONTROL 
group with B27-EEN and B27-CD-TREAT groups (in all cases data from all studied animals were included, n=12). 
Intervention Number of genera 
EEN 27 
CD-TREAT 25 
Both interventions similar direction 13 
EEN only 13 
CD-TREAT only 11 
Both interventions opposite direction 1 
48.15% (13 out of 27) of EEN induced genera changes were replicated by CD-TREAT 


















Table S19: Relative abundance (ln) of genera in cecal contents, collected at sacrifice, which differed (P<.10) similarly for B27-EEN and B27-CD-TREAT 
when compared with the B27-CONTROL group (in all cases data from all studied animals were included, n=12) 



















Bacteroidaceae Bacteroides -3.02 -1.40 0.040 -1.16 0.042 
Porphyromonadac
eae 
Butyricimonas -8.56 -4.04 0.001 -4.99 0.004 
Rikenellaceae Alistipes -7.91 -4.65 0.013 -4.93 0.015 
Firmicutes Clostridia Clostridiales 
Lachnospiraceae Hungatella -9.55 -5.40 0.013 -7.42 0.042 
Ruminococcaceae 
Oscillibacter -6.03 -4.57 0.026 -3.95 0.015 
Anaerotruncus -8.28 -5.55 0.026 -5.94 0.042 
[Eubacterium]_coprosta
noligenes_group -7.45 -4.18 0.017 -6.01 0.092 
Ruminococcaceae_UCG







Rhodospirillaceae Thalassospira -8.50 -6.07 0.026 -6.37 0.042 








Lactobacillaceae Lactobacillus -2.98 -6.36 0.013 -5.76 0.015 


















Table S20: Relative abundance (ln) of genera in cecal contents, collected at sacrifice, which differed (P<.10) between B27-CONTROL with B27-EEN or 
B27-CD-TREAT group only (in all cases data from all studied animals were included, n=12) 










Significantly higher for B27-EEN than B27-CONTROL group 
Actinobacteri
a 
Actinobacteria Actinomycetales Actinomycetaceae Actinomyces -7.71 -9.73 8.00E-02 
Firmicutes 
Clostridia Clostridiales 
Family_XIII [Eubacterium]_nodatum_group -5.31 -8.08 3.16E-02 Family_XIII_AD3011_group -7.16 -9.03 3.16E-02 
Lachnospiraceae [Ruminococcus]_gauvreauii_group -3.50 -8.07 8.00E-02 
Ruminococcaceae Anaerofilum -5.51 -7.85 8.00E-02 
 Ruminiclostridium_5 -5.40 -7.13 1.38E-02 
Erysipelotrichia Erysipelotrichale
s 
Erysipelotrichaceae Erysipelatoclostridium -6.38 -9.05 9.09E-02 Holdemania -7.41 -9.45 2.60E-02 
Significantly lower for B27-EEN than B27-CONTROL group 
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella_9 -9.09 -2.44 1.85E-02 Prevotellaceae_UCG-001 -9.38 -2.50 1.16E-03 
Firmicutes 
Clostridia Clostridiales Lachnospiraceae 
Anaerostipes -9.51 -5.70 1.23E-03 
Fusicatenibacter -9.17 -4.20 6.28E-02 
Ruminococcaceae Ruminococcaceae_UCG-008 -6.78 -4.44 2.70E-03 
Negativicutes Selenomonadales Acidaminococcacea
e 
Phascolarctobacterium -5.31 -3.46 8.00E-02 
Significantly higher for B27-CD-TREAT than B27-CONTROL group 
Firmicutes 
Bacilli Lactobacillales Leuconostocaceae Leuconostoc -6.18 -9.90 9.26E-03 Streptococcaceae Lactococcus -7.58 -9.90 3.37E-02 
Clostridia Clostridiales Lachnospiraceae 
Anaerostipes -4.10 -5.70 1.48E-02 
Lachnospiraceae_NK4A136_group -4.85 -8.46 6.77E-02 
Lachnospiraceae_UCG-010 -6.13 -8.59 8.96E-02 
Marvinbryantia -4.69 -7.78 1.48E-02 
Tyzzerella -7.43 -9.90 3.27E-02 


















p -5.07 -8.40 2.55E-02 
Ruminococcaceae_UCG-009 -7.07 -9.22 6.56E-02 
Proteobacteria Betaproteobacteri
a 
Burkholderiales Alcaligenaceae Parasutterella -3.82 -4.61 9.22E-02 
Significantly lower for B27-CD-TREAT than B27-CONTROL group 


















Table S21: Number of genera in fecal samples (collected four weeks post treatment initiation) which significantly (P<.10) differed in relative abundance 
between B27-CONTROL group with B27-EEN and B27-CD-TREAT groups (in all cases data from all studied animals were included, n=12) 
 Number of genera 
EEN 17 
CD-TREAT 12 
Both interventions similar direction 5 
EEN only 12 
CD-TREAT only 7 
Both interventions opposite direction 0 
29.41% (5 out of 17) of EEN induced genera changes were replicated by CD-TREAT 



















Table S22: Relative abundance (ln) of genera in feces, collected four weeks post treatment initiation, which differed (P<.10) similarly for B27-EEN and B27-
CD-TREAT when compared with the B27-CONTROL group (in all cases data from all studied animals were included, n=12) 










Significantly higher than B27-CONTROL group for both dietary interventions  
Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae Senegalimassilia -9.41 -7.27 8.27E-02 -7.12 9.17E-02 
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Butyricimonas -9.31 -4.34 9.34E-03 -5.86 9.20E-02 
Firmicutes Clostridia Clostridiales Ruminococcaceae Anaerofilum -8.37 -5.31 7.08E-02 -5.49 1.94E-02 
Significantly lower than B27-CONTROL group for both dietary interventions  
Firmicutes Clostridia Clostridiales Lachnospiraceae Fusicatenibacter -4.12 -9.89 5.42E-02 -8.58 9.20E-02 



















Table S23: Relative abundance (ln) of genera in feces, collected four weeks post treatment initiation, which differed (P<.10) between B27-CONTROL with 
B27-EEN or B27-CD-TREAT group only (in all cases data from all studied animals were included, n=12) 








Significantly higher for B27-EEN than B27-CONTROL group 
Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae Alistipes -4.59 -7.98 8.27E-02 




-3.40 -8.27 9.88E-02 




-4.30 -8.03 9.40E-02 
Ruminiclostridium_5 -5.41 -6.95 8.27E-02 
Ruminococcaceae_UCG-014 -3.36 -6.54 8.27E-02 
Significantly lower for B27-EEN than B27-CONTROL group 
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella_9 -8.44 -2.02 3.29E-02 Prevotellaceae_UCG-001 -9.89 -2.79 9.34E-03 
Firmicutes 
Bacilli Lactobacillales Lactobacillaceae Lactobacillus -6.68 -3.74 8.27E-02 
Clostridia Clostridiales 
Clostridiaceae_1 Candidatus_Arthromitus -10.06 -7.24 8.27E-02 
Lachnospiraceae Anaerostipes -9.05 -5.38 8.27E-02 
Ruminococcaceae Ruminococcaceae_UCG-008 -6.39 -4.36 6.65E-02 
Significantly higher for B27-CD-TREAT than B27-CONTROL group 
Firmicutes 
Bacilli Lactobacillales Leuconostocaceae Leuconostoc -4.36 -9.93 7.58E-03 Streptococcaceae Lactococcus -6.94 -9.93 3.90E-02 
Clostridia Clostridiales 
Lachnospiraceae Marvinbryantia -4.24 -7.23 5.67E-02 
Ruminococcaceae 
Oscillibacter -4.01 -5.69 6.72E-02 
Ruminiclostridium_9 -3.47 -6.13 9.20E-02 























Table S24: Number of genera in fecal samples (collected one week post treatment initiation) which significantly (P<.10) differed in relative abundance 
between B27-CONTROL group with B27-EEN and B27-CD-TREAT groups (in all cases data from all studied animals were included, n=12). 
 Number of genera 
EEN 24 
CD-TREAT 32 
Both interventions similar direction 16 
EEN only 8 
CD-TREAT only 16 
Both interventions opposite direction 0 
66.67% (16 out of 24) of EEN induced genera changes were replicated by CD-TREAT 


















Table S25: Relative abundance (ln) of genera in feces, collected one week post treatment initiation, which differed (P<.10) similarly for B27-EEN and B27-
CD-TREAT when compared with the B27-CONTROL group (in all cases data from all studied animals were included, n=12) 










Significantly higher than B27-CONTROL group for both dietary interventions  
Bacteroidet
es 
Bacteroidia Bacteroidales Rikenellaceae Alistipes -8.12 -4.03 1.91E-02 -5.27 7.00E-04 
Firmicutes 
Clostridia Clostridiales 
Family_XIII Family_XIII_AD3011_group -9.50 -7.11 1.11E-02 -7.39 1.76E-02 




noligenes_group -7.68 -3.80 6.97E-02 -4.52 9.58E-02 
Anaerofilum -8.75 -3.82 9.92E-03 -5.03 1.90E-02 
Anaerotruncus -7.84 -6.03 1.11E-02 -6.38 1.90E-02 
Intestinimonas -9.68 -8.42 4.76E-02 -6.97 3.41E-03 
Oscillibacter -6.24 -4.04 8.92E-02 -3.91 1.90E-02 
Ruminiclostridium_5 -7.87 -5.77 4.76E-02 -5.41 5.27E-02 
Ruminiclostridium_9 -6.19 -4.24 6.08E-02 -4.33 3.04E-02 
Ruminococcaceae_UC







Allobaculum -7.86 -4.36 5.10E-03 -5.50 2.30E-02 
Holdemania -9.23 -7.34 7.34E-03 -7.50 8.11E-02 
Significantly lower than B27-CONTROL group for both dietary interventions  
Bacteroidet
es 
Bacteroidia Bacteroidales Prevotellaceae Prevotella_9 -1.90 -9.21 5.68E-03 -7.38 2.38E-02 


















Table S26: Relative abundance (ln) of genera in feces, collected one week post treatment initiation, which differed (P<.10) between B27-CONTROL with 
B27-EEN or B27-CD-TREAT group only (in all cases data from all studied animals were included, n=12) 










Significantly higher for B27-EEN than B27-CONTROL group 
Actinobacteri
a 
Actinobacteria Actinomycetales Actinomycetaceae Actinomyces -7.59 -9.68 4.65E-02 
Coriobacteriia Coriobacteriales Coriobacteriaceae Collinsella -7.50 -9.16 8.61E-02 
Firmicutes Clostridia Clostridiales Lachnospiraceae 
Coprococcus_1 -5.49 -6.26 1.72E-02 
Lachnospiraceae_FCS020_group -8.55 -9.68 5.95E-02 
Ruminococcaceae Candidatus_Soleaferrea -7.63 -9.00 8.92E-02 
Significantly lower for B27-EEN than B27-CONTROL group 
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotellaceae_NK3B31_group -9.14 -4.81 3.66E-02 Prevotellaceae_UCG-001 -9.31 -3.28 6.80E-03 
Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus -6.77 -3.56 5.68E-03 
Significantly higher for B27-CD-TREAT than B27-CONTROL group 
Bacteroidetes Bacteroidia Bacteroidales 
Bacteroidaceae Bacteroides -1.37 -2.77 7.10E-02 
Porphyromonadacea
e 
Butyricimonas -6.11 -9.23 1.06E-02 
Firmicutes 
Bacilli Lactobacillales Leuconostocaceae Leuconostoc -6.60 -9.68 9.83E-02 Streptococcaceae Lactococcus -6.56 -9.68 2.79E-03 
Clostridia Clostridiales 
Lachnospiraceae 
Anaerostipes -3.02 -5.26 2.05E-02 
Coprococcus_3 -5.19 -7.32 6.18E-02 
Lachnospiraceae_UCG-004 -5.15 -8.48 1.90E-02 
Marvinbryantia -3.91 -8.34 3.25E-03 
Tyzzerella -6.32 -9.68 1.06E-02 
Ruminococcaceae 
Ruminococcaceae_NK4A214_grou
p -4.75 -8.25 1.76E-02 
Ruminococcaceae_UCG-009 -7.14 -9.40 9.82E-02 
Ruminococcus_2 -3.74 -8.26 7.71E-02 
Proteobacteria Betaproteobacteri
a 






















Bifidobacteriaceae Bifidobacterium -7.93 -4.56 2.01E-02 


















Table S27: Number of 3% OTU in cecal content samples (collected at sacrifice) which significantly (P<.10) differed in relative abundance between B27-
CONTROL group with B27-EEN and B27-CD-TREAT groups (in all cases data from all studied animals were included, n=12). 
 Number of 3% OTU 
EEN 31 
CD-TREAT 43 
Both interventions similar direction 16 
EEN only 14 
CD-TREAT only 26 
Both interventions opposite direction 1 
51.61% (16 out of 31) of EEN induced OTU changes were replicated by CD-TREAT 


















Table S28: Relative abundance (ln) of 3% OTU genera in cecal contents, collected at sacrifice, which differed (P<.10) similarly for B27-EEN and B27-CD-
TREAT when compared with the B27-CONTROL group (in all cases data from all studied animals were included, n=12) 










Significantly higher than B27-CONTROL group for both dietary interventions  
OTU_52 Bacteroi
detes Bacteroidia Bacteroidales 
Porphyromonada
ceae 
Butyricimonas -8.64 -4.19 1.26E-02 -5.29 6.32E-03 






Hungatella -9.64 -5.54 2.61E-02 -7.72 8.33E-02 
OTU_168 Lachnoclostridium -9.24 -5.39 1.26E-02 -6.88 8.18E-02 
OTU_51 NA -7.20 -4.31 1.26E-02 -5.13 1.23E-02 






-9.09 -4.32 2.61E-02 -6.31 5.79E-02 
OTU_56 Ruminococcaceae









Thalassospira -8.59 -6.21 6.32E-02 -6.76 7.17E-02 







Bifidobacterium -5.22 -7.30 6.96E-02 -8.85 6.07E-03 
OTU_228 Bacteroidetes Bacteroidia Bacteroidales 
Bacteroidales_S










mitus -6.23 -9.93 2.61E-02 -8.68 6.26E-02 
OTU_3 
Lachnospiraceae 
Blautia -2.40 -7.66 7.21E-02 -4.55 6.26E-02 
OTU_784 Blautia -5.65 -9.31 6.32E-02 -7.99 4.36E-02 

















Table S29: Relative abundance (ln) of 3% OTU in cecal contents, collected at sacrifice, which differed (P<.10) between B27-CONTROL with B27-EEN or 
B27-CD-TREAT group only (in all cases data from all studied animals were included, n=12) 








Significantly higher for B27-EEN than B27-CONTROL group 
OTU_378 Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae Senegalimassilia -7.08 -9.36 6.05E-02 








atum_group -5.46 -8.17 6.96E-02 
OTU_418 Family_XIII_AD3011_group -7.99 -9.36 7.28E-02 
OTU_227 Ruminococcaceae Anaerotruncus -6.94 -9.10 2.61E-02 
OTU_463 Erysipelotri
chia Erysipelotrichales Erysipelotrichaceae Holdemania -7.55 -9.54 6.32E-02 
Significantly lower for B27-EEN than B27-CONTROL group 
OTU_183 
Bacteroidetes Bacteroidia Bacteroidales 
Bacteroidales_S24-
7_group 
NA -9.76 -5.80 2.61E-02 
OTU_167 NA -9.93 -7.09 6.96E-02 
OTU_37 
Prevotellaceae 
Alloprevotella -9.93 -4.35 2.61E-02 
OTU_5 Prevotella_9 -9.24 -2.52 3.97E-02 
OTU_26 Prevotellaceae_UCG-001 -9.93 -3.87 2.42E-02 
OTU_14 
Firmicutes Clostridia Clostridiales 
Lachnospiraceae Anaerostipes -9.93 -5.89 2.61E-02 OTU_165 Coprococcus_1 -7.48 -6.61 4.05E-02 
OTU_102 Ruminococcaceae Ruminococcaceae_UCG-008 -6.93 -4.52 1.26E-02 
Significantly higher for B27-CD-TREAT than B27-CONTROL group 
OTU_145 
Bacteroidetes Bacteroidia Bacteroidales Bacteroidales_S24-7_group 
NA -5.70 -8.48 9.64E-02 
OTU_170 NA -5.83 -8.69 2.79E-02 
OTU_240 NA -6.04 -8.25 3.64E-02 

















OTU_36 Prevotellaceae NA -3.66 -4.51 4.54E-02 
OTU_269 Rikenellaceae Alistipes -6.71 -9.64 4.69E-02 
OTU_54 Cyanobacteria Melainabacteria Gastranaerophilales NA NA -4.67 -9.10 6.07E-03 
OTU_116 
Firmicutes 




Anaerostipes -4.40 -5.89 3.82E-02 
OTU_84 Lachnospiraceae_NK4A136_group -5.32 -9.99 8.18E-02 
OTU_144 Marvinbryantia -6.92 -9.99 3.82E-02 
OTU_46 Marvinbryantia -5.54 -7.94 8.18E-02 
OTU_539 Marvinbryantia -7.95 -9.71 3.82E-02 
OTU_229 NA -8.10 -9.99 9.84E-02 
OTU_30 NA -3.98 -5.33 3.07E-02 
OTU_266 Tyzzerella -7.83 -9.99 9.30E-02 
OTU_174 
Ruminococcaceae 
Anaerofilum -8.40 -9.81 4.36E-02 
OTU_353 Anaerotruncus -8.01 -9.99 7.54E-02 
OTU_343 Intestinimonas -7.51 -9.99 4.34E-02 
OTU_73 NA -5.67 -9.07 4.36E-02 
OTU_306 Oscillibacter -6.30 -8.82 2.56E-02 
OTU_103 Ruminiclostridium
_9 -5.94 -8.26 6.56E-02 
OTU_114 Ruminiclostridium
_9 -4.63 -8.99 6.07E-03 
OTU_429 Ruminiclostridium
_9 -6.47 -8.95 6.32E-03 
OTU_137 Ruminococcaceae_NK4A214_group -5.38 -8.49 4.36E-02 


















Table S30: Number of 3% OTU in fecal samples (collected four weeks post treatment initiation) which significantly (P<.10) differed in relative abundance 
between B27-CONTROL group with B27-EEN and B27-CD-TREAT groups (in all cases data from all studied animals were included, n=12). 
 Number of 3% OTU 
EEN 22 
CD-TREAT 15 
Both interventions similar direction 4 
EEN only 18 
CD-TREAT only 11 
Both interventions opposite direction 0 
18.18% (4 out of 22) of EEN induced OTU changes were replicated by CD-TREAT 


















Table S31: Relative abundance (ln) of 3% OTU genera in feces, collected four weeks post treatment initiation, which differed (P<.10) similarly for B27-EEN 
and B27-CD-TREAT when compared with the B27-CONTROL group (in all cases data from all studied animals were included, n=12) 









Significantly higher than B27-CONTROL group for both dietary interventions  
OTU_52 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Butyricimonas -9.39 -4.50 2.27E-02 -5.76 3.85E-02 
OTU_51 Firmicutes Clostridia Clostridiales Lachnospiraceae NA -7.26 -4.07 2.27E-02 -4.99 3.85E-02 
Significantly lower than B27-CONTROL group for both dietary interventions  


















Table S32: Relative abundance (ln) of 3% OTU in feces, collected four weeks post treatment initiation, which differed (P<.10) between B27-CONTROL with 
B27-EEN or B27-CD-TREAT group only (in all cases data from all studied animals were included, n=12) 









Significantly higher for B27-EEN than B27-CONTROL group 
OTU_76 Bacteroid









enes_group -4.47 -8.95 5.31E-02 
OTU_108 Ruminiclostridium_5 -5.90 -8.54 5.31E-02 
OTU_56 Ruminococcaceae_UCG-014 -4.62 -8.60 3.48E-02 
Significantly lower for B27-EEN than B27-CONTROL group 
OTU_183 
Bacteroid
etes Bacteroidia Bacteroidales 
Bacteroidales_S2
4-7_group 
NA -10.05 -5.84 3.48E-02 
OTU_167 NA -10.23 -6.96 4.37E-02 
OTU_37 
Prevotellaceae 
Alloprevotella -10.05 -4.36 3.48E-02 
OTU_36 NA -9.46 -4.62 5.31E-02 
OTU_5 Prevotella_9 -8.88 -2.11 3.48E-02 








Anaerostipes -9.57 -5.58 4.78E-02 
OTU_3 Blautia -8.03 -2.39 5.31E-02 
OTU_19 Fusicatenibacter -10.05 -4.21 4.77E-02 
OTU_102 Ruminococcacea
e 
Ruminococcaceae_UCG-008 -6.56 -4.45 4.77E-02 
Significantly higher for B27-CD-TREAT than B27-CONTROL group 
OTU_149 Bacteroid




























Leuconostoc -4.67 -10.02 2.33E-02 





NA -7.71 -10.02 8.96E-02 
OTU_539 Lachnospiraceae Marvinbryantia -7.18 -9.57 7.53E-02 OTU_144 Marvinbryantia -6.69 -10.02 4.97E-02 
OTU_73 Ruminococcacea
e 
NA -5.62 -9.74 3.85E-02 
OTU_114 Ruminiclostridium_9 -4.33 -9.39 3.85E-02 
Significantly lower for B27-CD-TREAT than B27-CONTROL group 





Bifidobacterium -8.50 -5.20 7.03E-02 
OTU_228 Bacteroid
etes Bacteroidia Bacteroidales 
Bacteroidales_S2


















Table S33: Number of 3% OTU in fecal samples (collected one week post treatment initiation) which significantly (P<.10) differed in relative abundance 
between B27-CONTROL group with B27-EEN and B27-CD-TREAT groups (in all cases data from all studied animals were included, n=12). 
 Number of 3% OUT 
EEN 36 
CD-TREAT 38 
Both interventions similar direction 11 
EEN only 25 
CD-TREAT only 27 
Both interventions opposite direction 0 
30.56% (11 out of 36) of EEN induced OTU changes were replicated by CD-TREAT 


















Table S34: Relative abundance (ln) of 3% OTU in feces, collected one week week post treatment initiation, which differed (P<.10) similarly for B27-EEN 
and B27-CD-TREAT when compared with the B27-CONTROL group (in all cases data from all studied animals were included, n=12). 














Significantly higher than B27-CONTROL group for both dietary interventions  
OTU_76 Bacteroidete
s 





Eisenbergiella -7.07 -3.72 1.74E-02 -5.19 5.67E-02 





-9.21 -6.10 1.74E-02 -5.92 7.20E-03 
OTU_51 NA -7.68 -4.44 2.84E-02 -4.66 3.86E-02 
OTU_13
6 Peptococcaceae NA -7.98 -5.10 2.74E-02 -5.50 3.23E-03 









Allobaculum -9.17 -4.70 1.19E-02 -6.16 1.87E-02 
Significantly lower than B27-CONTROL group for both dietary interventions  
OTU_5 Bacteroidete
s 
Bacteroidia Bacteroidales Prevotellaceae Prevotella_9 -2.01 -9.51 1.74E-02 -7.66 5.67E-02 
OTU_19 
Firmicutes Clostridia Clostridiales Lachnospiraceae 
Fusicatenibacter -2.53 -9.24 1.19E-02 -6.71 5.83E-03 
OTU_31


















Table S35: Relative abundance (ln) of 3% OTU in feces, collected one week post treatment initiation, which differed (P<.10) between B27-CONTROL with 
B27-EEN or B27-CD-TREAT group only (in all cases data from all studied animals were included, n=12) 
OTU Phylu
m 













Bacilli Lactobacillales Streptococcaceae Streptococcus -7.28 -8.62 4.46E-02 
OTU_397 
Clostridia Clostridiales 
Christensenellaceae NA -7.53 -9.79 3.14E-02 
OTU_418 Family_XIII Family_XIII_AD3011_group -7.68 -9.79 2.84E-02 
OTU_75 
Lachnospiraceae 
Lachnoclostridium -5.08 -8.05 6.73E-02 
OTU_197 NA -5.68 -8.14 7.54E-02 




s_group -4.01 -8.10 6.73E-02 
OTU_43 Anaerofilum -4.16 -9.09 1.74E-02 
OTU_227 Anaerotruncus -6.74 -8.81 8.87E-02 
OTU_108 Ruminiclostridium_5 -6.56 -9.51 1.74E-02 
OTU_300 Ruminiclostridium_9 -5.55 -7.94 7.54E-02 















Desulfovibrio -5.66 -7.00 3.12E-02 
Significantly lower for B27-EEN than B27-CONTROL group 
OTU_228 
Bacter
oidetes Bacteroidia Bacteroidales 
Bacteroidales_S24-
7_group NA -9.69 -6.60 7.05E-02 
OTU_37 
Prevotellaceae 
Alloprevotella -9.11 -4.15 7.05E-02 
OTU_36 NA -9.29 -4.28 5.17E-02 
OTU_11 Prevotellaceae_NK3B31_group -9.34 -4.92 6.11E-02 
OTU_26 Prevotellaceae_UCG-001 -9.51 -4.09 3.02E-02 
OTU_66 Firmic
utes Bacilli Lactobacillales Lactobacillaceae 
Lactobacillus -9.86 -5.15 1.74E-02 

















OTU_98 Lactobacillus -9.86 -6.65 2.84E-02 
OTU_60 Lactobacillus -7.00 -4.55 8.87E-02 




Erysipelotrichaceae NA -7.23 -6.02 6.73E-02 







Coriobacteriales Coriobacteriaceae NA -7.33 -9.61 1.22E-02 
OTU_133 
Bacter
oidetes Bacteroidia Bacteroidales 
Bacteroidaceae Bacteroides -5.47 -7.76 7.47E-02 
OTU_240 Bacteroidales_S24-
7_group 
NA -6.41 -8.24 5.53E-02 
OTU_170 NA -6.19 -8.20 1.87E-02 
OTU_648 NA -7.42 -9.61 8.61E-02 
OTU_52 Porphyromonadace
ae 








Anaerostipes -3.25 -5.48 5.67E-02 
OTU_404 Blautia -7.31 -8.54 7.53E-02 
OTU_172 Blautia -5.89 -8.79 6.92E-02 
OTU_79 Lachnospiraceae_UCG-004 -5.37 -8.76 5.67E-02 
OTU_46 Marvinbryantia -4.48 -8.76 1.63E-03 
OTU_30 NA -3.74 -5.54 4.87E-02 
OTU_266 Tyzzerella -6.54 -9.79 2.40E-02 
OTU_174 
Ruminococcaceae 
Anaerofilum -7.21 -9.61 4.44E-02 
OTU_43 Anaerofilum -5.46 -9.09 3.86E-02 
OTU_343 Intestinimonas -7.25 -9.79 1.46E-02 
OTU_73 NA -7.19 -9.61 4.44E-02 
OTU_306 Oscillibacter -6.83 -9.27 8.50E-02 
OTU_103 Ruminiclostridium_9 -6.22 -8.01 7.47E-02 
OTU_114 Ruminiclostridium_9 -5.46 -9.06 7.41E-02 
OTU_137 Ruminococcaceae_NK4A214_g
roup -4.97 -8.36 4.44E-02 
OTU_115 Ruminococcaceae_UCG-014 -5.15 -9.09 4.87E-02 






















cteria Burkholderiales Alcaligenaceae Parasutterella -3.80 -4.63 5.33E-02 









Bifidobacteriaceae Bifidobacterium -8.15 -4.67 4.87E-02 
OTU_102 Firmic


















Table S36. Age, anthropometry, disease activity, blood inflammatory markers, fecal calprotectin and disease characteristics of the patients with CD enrolled 
in the open label trial (n=5) 
Age, years 13.3, 3.2 
Gender, n (%) males 4/5, 80% 
Weight,  kg 40.8, 13.4 
Weight z-score, SD -0.89, 0.51 
Height z-score, SD -0.67, 0.66 
BMI z-score, SD -0.71, 0.58 
Disease duration, years 1.8, 2.3 
wPCDAI 30.5, 7.8 
Raised wPCDAI (>12.5), n (%) 5/5 (100%) 
Albumin, g/L 37.8, 4.0 
Low albumin (<35 g/L), n (%) 1/5 (20%) 
C-reactive protein, mg/L 5.2, 6.0 
Raised C-reactive protein (>10 mg/L), n (%) 1/5 (20%) 
Fecal calprotectin (mg/kg) 1973, 957 
Raised fecal calprotectin (> 250 mg/kg), n (%) 5/5 (100%) 
  
Concurrent treatment    
Thiopurine monotherapy, n (%) 3/5 (60%) 
Anti-TNF/thiopurine combination, n (%) 1/5 (20%) 
  
Paris classification  
Patient 1 A1a, L3, B1, G0 
Patient 2 A1b, L2, B1, G0 
Patient 3 A1b, L3 + L4a, B1, G0 
Patient 4 A1b, L3 + L4a, B1, G0 
Patient 5 A1b, L2 + L4a, B1, G0 
Data are displayed with means and standard deviations, unless stated otherwise; BMI: Body mass index; 
wPCDAI: weighted pediatric Crohn’s disease activity index; TNF: Tumor necrosis factor; Baseline diagnostic 
























8 weeks  
post CD-TREAT 
Weight, kg 37.6, 13.1 38.5, 12.8 39.4, 13.2 
Weight z-score, SD -1.05, 0.41 -0.96, 0.20 -0.86, 0.32 
Height z-score, SD -0.82, 0.66 -0.85, 0.72 -0.83, 0.70 
BMI z-score, SD -0.88, 0.52 -0.71, 0.71 -0.61, 0.96 
wPCDAI 32.5, 7.4 11.3, 9.2a* 7.5, 7.4a** 
Albumin, g/L 36.8, 3.8 38.3, 4.6 39.0, 4.8 
Abnormal albumin (<35 g/L) 1/4, 25% 0/4, 0% 0/4, 0% 
C-reactive protein, mg/L 6.3, 6.4 4.3, 3.8 3.0, 2.5 
Abnormal C-reactive protein (>10 mg/L) 1/4, 25% 0/4, 0% 0/4, 0% 
Fecal calprotectin, mg/kg 1960, 1104 981, 690a** 1042, 776a** 
Fecal calprotectin % change from baseline - -53.0, 14.9 -55.4, 24.2 
Fecal calprotectin > 50% reduction - 3/4, 75% 3/4, 75% 
Data are displayed with means and standard deviations; a significant difference between Pre CD-TREAT vs Post CD-TREAT (4 weeks) or Pre CD-TREAT vs Post CD-
TREAT (8 weeks); * P<.05; ** P<.01; ¥ P<.001. P for Fisher pairwise comparisons following general linear model with Box-Cox transformation. BMI: Body mass index; 
wPCDAI: weighted pediatric Crohn’s disease activity index 
 
References 
1. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris 








































Figure S2. Non-metric multidimensional scaling (NMDS) using weighted UniFrac distances of the 3% operational taxonomic unit (OTU) community 
structures during dietary interventions on healthy human fecal microbiome (n=24). 
 
Adonis for A-B: R2 = 0.11, Adjusted P=.001 
Adonis for C-D: R2 = 0.03, Adjusted P=.031 





































Figure S4. Representative hematoxylin and eosin stained sections of the colon of: i) EEN, ii) CD-TREAT, iii) CONTROL treated HLA-B27 rats and i) EEN, 
ii) CONTROL treated HLA-B7 rats. Colon tissue sections were visualized and digital images were captured using an EVOS FL Auto Cell Imaging System 


















Figure S5. Non-metric multidimensional scaling (NMDS) using Bray-Curtis distances of the 3% OTU community structures of B27-CONTROL, B27-EEN, 
B27-CD-TREAT, B7-CONTROL and B7-EEN animals’: (a) cecum tissue microbiome (n=19), (b) colon tissue microbiome (n=10) and (c) colon content 



















Figure S6. Non-metric multidimensional scaling (NMDS) using weighted Unifrac distances of the 3% operational taxonomic unit (OTU) community 
structures of the rat cecal luminal content microbiome at sacrifice (n=20). 
Adonis for B27-EEN-B27-CONTROL: R2 = 0.45, Adjusted P=.038 
Adonis for B27-CD-TREAT-B27-CONTROL: R2 = 0.79, Adjusted P=.038 
Adonis for B27-CONTROL-B7-CONTROL: R2 = 0.35, Adjusted P=.094 


















Figure S7. Non-metric multidimensional scaling (NMDS) using weighted Unifrac distances of the 3% operational taxonomic unit (OTU) community 
structures of the rat fecal microbiome during the course of dietary interventions (n=20). 
 
Time Group 1 Group 2 R2 Adjusted P 
Day 0 B27-CONTROL B7-CONTROL 0.515736 .315 
Day 7 B27-EEN B27-CONTROL 0.389642 .066 
Day 7 B27-CD-TREAT B27-CONTROL 0.434009 .066 
Day 7 B27-CONTROL B7-CONTROL 0.445806 .066 
Day 7 B7-EEN B7-CONTROL 0.540451 .066 
Day 14 B27-EEN B27-CONTROL 0.416568 .080 
Day 14 B27-CD-TREAT B27-CONTROL 0.238897 .148 
Day 14 B27-CONTROL B7-CONTROL 0.330802 .148 
Day 14 B7-EEN B7-CONTROL 0.650334 .080 
Day 21 B27-EEN B27-CONTROL 0.440758 .067 
Day 21 B27-CD-TREAT B27-CONTROL 0.604733 .039 
Day 21 B27-CONTROL B7-CONTROL 0.562680 .039 
Day 21 B7-EEN B7-CONTROL 0.704100 .039 
Day 28 B27-EEN B27-CONTROL 0.584165 .070 
Day 28 B27-CD-TREAT B27-CONTROL 0.291496 .188 
Day 28 B27-CONTROL B7-CONTROL 0.230795 .201 















“An exploratory study on the impact of a food-based restrictive diet and liquid exclusive enteral 
nutrition (milk-based diet) on healthy gut microbiota composition (bugs) and metabolic activity 
(chemical markers)” 
Name of Researcher:  Mr Vaios Svolos, PhD Student, University of Glasgow. 
 
Study Number:      Exclusive Enteral Nutrition      OR      CD-TREAT 
 
Please answer the following questions by placing a vertical mark through the line for each question. 
Regard the end of each line as indicating the most extreme sensation you have ever felt and mark 




1. How hungry did you feel (during the day)? 
            
          
                                                                                        
2. How satisfied did you feel (during the day)? 
   
                                                                                                                 
                      
 
 




            
 
4. How much did you think you could eat (during the day)? 
 
 
                    
 
 
            5. How strong was your desire to eat (during the day)? 
 
 
               










Not at all 



















“An exploratory study on the impact of a food-based restrictive diet and liquid exclusive enteral nutrition (milk-based diet) on healthy gut 
microbiota composition (bugs) and metabolic activity (chemical markers)” 
Name of Researcher:  Mr Vaios Svolos, PhD Student, University of Glasgow. 
 
Study Number:           Exclusive Enteral Nutrition      OR      CD-TREAT 
 
In the past ONE week, how often have you had difficulty with… 
 
Gastrointestinal Symptoms (PROBLEMS WITH…) 






1. Pain in your abdomen or stomach 0 1 2 3 4 
2. Diarrhoea 0 1 2 3 4 
3. Constipation 0 1 2 3 4 
4. Nausea 0 1 2 3 4 
5. Vomiting 0 1 2 3 4 
6. Discomfort in your abdomen or stomach 0 1 2 3 4 
7. Passing wind 0 1 2 3 4 

























“An exploratory study on the impact of a food-based restrictive diet and liquid exclusive enteral nutrition (milk-based diet) on healthy gut 
microbiota composition (bugs) and metabolic activity (chemical markers)” 
Name of Researcher:  Mr Vaios Svolos, PhD Student, University of Glasgow. 
  Exclusive Enteral Nutrition      OR      CD-TREAT 
 
Questions Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Except for tea, coffee, 7up, water, Foxes glacier 
mints or chewing gum, did you need to eat other 
foods or have additional drinks while on EEN? 
       
What type of drinks did you have? 
How often did you take these drinks? 
       
What kind of foods did you have? 
How often did you take these foods? 
       
On a scale of 1-10 where 1 is very easy and 10 is 
almost impossible; 
How difficult was it to stay on the liquid diet so 
far? 






















RCT in healthy volunteers 
Acceptability of interventions 
Appetite, gastrointestinal symptoms and adherence to the experimental diets were assessed by self-
reported questionnaire. This was compiled and checked for content validity by the research team and 
for readability by lay people. The questionnaire collected information from each participant on their 
appetite on days one and six of each intervention, using Visual Analogue Scales extracted from an 
existing questionnaire1. Gastrointestinal symptoms and the level of adherence to the diet were also 
assessed at the end of each intervention, using Likert scales from a validated questionnaire2. 
Additional meals outside the experimental diets were recorded. 
Fecal sample collection 
The entire bowel movement was collected, stored immediately under anaerobic (Oxoid™ 
AnaeroGen™ Sachet) cold conditions, and processed within 60 minutes of defecation. The entire 
bowel movement was weighed, homogenized and stored appropriately for the downstream methods. 
Untargeted fecal metabolomics 
Extraction 
Freeze-dried fecal samples were extracted by chloroform/methanol/water at a volume ratio of 1:3:1. 
The extraction was carried out by mixing 800µl extraction mixture with 20mg freeze dried fecal 
sample. The supernatant was recovered to another vial and the extracts were stored at -80oC until LC-
MS analysis. 
Solvents and Chemicals 
HPLC-grade acetonitrile, chloroform and water were obtained from Fisher Scientific, UK. 
Ammonium carbonate and methanol were purchased from Sigma-Aldrich, UK. HPLC grade water 
was produced in house by a Direct-Q 3 Ultrapure water purification system (Millipore, Watford, UK). 
The metabolite standards were obtained from Sigma-Aldrich, UK and were prepared as previously 
described3. 
HPLC conditions 
Mobile phase and column: The mobile phase solutions were freshly prepared and stored at room 
temperature for up to 48 hours as follows: Mobile phase A: (20mM Ammonium carbonate buffer, pH 
9.2) was prepared by dissolving 1.92 g of ammonium carbonate in 800 ml of HPLC-grade water 
followed by adjustment to pH 9.2 with ammonia solution and then made up to 1L. Mobile phase B: 













bead support) column from Hichrom Ltd, Reading, UK. The column was attached to a ZIC®-pHILIC 
guard column. 
HPLC setup: A gradient elution method (Table 1) was used as described previously3. The flow rate 
was set to 0.3 mL/min. 
Table 1 Gradient elution programme applied for ZICpHILIC column in LC-MS analysis. 
Time (min) Mobile phase A% Mobile phase B % Flow rate (ml/min) 
0 20 80 0.3 
30 80 20 0.3 
31 92 8 0.3 
36 92 8 0.3 
37 20 80 0.3 
46 20 80 0.3 
 
Orbitrap Exactive Mass-Spectrometer setup: Samples were analysed using an Accela HPLC 
system connected to an Orbitrap Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). The quality of the data and identified metabolites were confirmed by standard mixtures 
introduced within the running sequence4. During the analysis, peak characteristics such as width and 
height were determined using relative standard deviation (RSD) values. The acceptable value of RSD 
was set not exceeding 20% for each standard and the retention time shift should not be more than 0.3 
min between the initial and final sample in a sequence.  
Data extraction 
The raw files for the samples were extracted and processed using mzMatch/Peak ML: metabolomics 
data analysis5. IDEOM provided a free data extraction application that is able to identify spectrum 
peaks while considering noise sources in the LC/MS analysis. This macro-based spreadsheet was 
obtained from http://mzmatch.sourceforge.net/ideom.htm and the analysis depends on the LC/MS data 
extraction method6. The R package from http://www.r-project.org was pre-installed to create a 
readable environment for LC/MS processing7. The identified metabolites and quality of peaks were 
examined manually using different databases including HMDB (http://www.hmdb.ca/), KEGG 
(http://www.genome.jp/kegg/) and LIPID MAPS (http://www.lipidmaps.org/). 
Animal experiments 
Gut histopathology  
Colonic and ileal specimens were fixed in 10% formalin until the tissue was paraffin-embedded, 
stained with hematoxylin and eosin and evaluated by two pathologists (RK and JS) in a blinded 
manner. Tissue sections (5µm) were stained with hematoxylin and eosin, imaged (EVOS FL Auto 














The colon was assessed for leukocyte infiltration, mucosal damage, neutrophil infiltration, crypt 
abscesses or hyperplasia and goblet cell depletion. The ileum was assessed for leukocyte infiltration, 
villous fusion, shortening or hyperplasia, and mucosal necrosis, erosion and ulceration. Each 
parameter was scored from 0 to 3 (0=no; 1=mild; 2=moderate; 3=severe presence). The sum of the 
individual parameters generated an ileal (min-max score: 0-12) and colonic (min-max score: 0-15) 
inflammatory score8. 
Expression of cytokines in ileum 
The expression of the following genes was quantified TNF-α (GenBank accession number 
Rn99999017_m1), Il-6 (GenBank accession number Rn01410330_m1), IL-10 (GenBank accession 
number Rn01483988_g1), IL-1b (GenBank accession number Rn00580432_m1), CXCL-1 (GenBank 
accession number Rn00578225_m1). Amplification reactions were analyzed by relative quantification 
using the comparative CT method and using the housekeeping genes GAPDH (GenBank accession 
number Rn01775763_g1) and RPLNO (GenBank accession number Rn03302271_gH) as endogenous 
controls. Data are displayed as fold change of gene expression against the average of B7-CONTROL 
samples. 
Bioinformatics 
We retained the paired-end reads between 225bp and 275bp length, overlapped the reads and 
performed OTU clustering on dereplicated reads after removing singletons and using 98% similarity. 
Afterwards, we removed chimera based on both de-novo (utilizing the most abundant dereplicated 
reads) and reference-based approach (as mentioned in the link) finally generating OTU at 97% 
similarity with taxonomy assigned using functions given in Dada2 pipeline after filtering out OTU 
with mean proportional abundance<0.01%. 
Statistics 
Power calculation 
The power calculation for the RCT in health volunteers was revised after completion of the first 10 
participants at which point we were already powered to detect significant changes for SCFA and 
bacterial load both during EEN and CD-TREAT (Table 1). However, we continued recruitment to our 
original target number of 25 participants to maximize statistical power for secondary outcomes of the 
study where higher inter-individual variation and potentially smaller effect size (i.e. 16S rRNA 
sequencing, metabolome) were expected. 
Table 1. Fecal sample characteristics, metabolites and bacterial load before and after dietary EEN and 
CD-TREAT in the first 10 participants who completed the healthy volunteers RCT (n=40 fecal 














 Pre EEN Post EEN Pre CD-TREAT Post CD-TREAT 
Bristol Stool Form Scale 3.7, 1.6 1.6, 1.0a** 3.0, 1.3 1.9, 0.9a† 
Fecal pH 7.0, 0.5 8.2, 0.2a¥ 7.0, 0.6 7.7, 0.4a**,c** 
Acetate, µmol/g 67.6, 11.9 48.6, 14.4a* 76.9, 17.6 65.5, 19.8a†,c** 
Propionate, µmol/g 15.6, 5.4 9.9, 4.9a** 15.8, 5.8 13.3, 9.2a* 
Butyrate, µmol/g 11.9, 5.0 6.3, 2.5a** 14.1, 10.3 7.9, 5.4a** 
Valerate, µmol/g 2.2, 0.6 2.0, 0.8 2.4, 1.5 1.9, 1.1 
Iso-butyrate, µmol/g 1.7, 0.8 2.4, 1.0a* 2.0, 1.1 2.1, 1.0 
Iso-valerate, µmol/g 1.8, 1.0 2.7, 1.1a** 2.1, 1.4 2.3, 1.1 
Free sulfide, nmol/g 5.1, 2.6 1.5, 1.6a¥ 4.2, 1.0 6.0, 4.7c¥ 
Total sulfide, nmol/g 82.2, 62.9 250.4, 83.7a¥ 66.5, 30.6 141.4, 69.8a**,c** 
Total bacteria 11.3, 0.2 11.1, 0.2a** 11.2, 0.2 11.0, 0.3a* 
Data are displayed with means and standard deviations. a significant difference between Pre EEN & Post EEN 
or Pre CD-TREAT & Post CD-TREAT; b significant difference between Pre EEN & Pre CD-TREAT; c 
significant difference between Post EEN & Post CD-TREAT; † p<0.1; * p<0.05; ** p<0.01; ¥ p<0.001. p for 
Fisher pairwise comparisons following general linear model with Box-Cox transformation; Total bacteria, log10 
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CD-TREAT diet Checklist 
Study Number: Date: 
Please tick the choice that you/your child chose and how many quarters of the portion you/your child ate? 
Breakfast: 
1 Multivitamin Tablet                                 □ yes              □ no 
 
1 ½ cup (360ml) lactofree milk With ¾ cup (45g): 
□ rice krispies        □ corn flakes 
□ honey hoops      □ rice and corn flakes 
 
1 cup (240ml) pure juice: 
□ pineapple juice                                  □ apple juice 
□ apple & raspberry juice                     □ cranberry juice 







1 cup (240ml) pure juice: 
□ pineapple juice                                  □ apple juice 
□ apple & raspberry juice                     □ cranberry juice 








Please write the meal number mentioned on your lunch pack 
 
Afternoon snack 










Please write the meal number mentioned on your dinner pack 
 








“An open label pilot study of the CD-TREAT diet as a novel therapy for active 
luminal Crohn’s disease” 













Log2 mean post/pre intervention ratio of metabolites significantly and similarly decreased (purple) or increased (green) during both EEN and CD-TREAT (p-value<0.05) Map type No % No Increasing No Decreasing
Mass RT Putative.metabolite Map Pathway logfold_EEN p_adj_EEN logfold_CDT p_adj_CDT Energy Metabolism 1 0.34 0 1
159.1259132 9.302301844 DL-2-Aminooctanoicacid Unknown Unknown -3.98 9.82E-06 -5.06 6.76E-06 Protein 47 15.99 12 35
461.3351327 7.710846012 D-Glucosylsphingosine Unknown Unknown -1.61 7.77E-05 -3.34 6.76E-06 Amino Acid Metabolism 29 9.86 8 21
285.132474 10.66530857 Glycylprolylhydroxyproline Unknown Unknown -2.88 2.19E-04 -2.57 1.68E-02 Peptide 1 0.34 0 1
463.3509259 7.717860051 D-Glucosyldihydrosphingosine Unknown Unknown -2.02 3.15E-05 -2.34 5.31E-06 Peptide(di-) 7 2.38 1 6
308.1987125 3.421228196 5-O-Methylembelin Unknown Unknown -2.40 4.73E-02 -2.24 2.83E-02 Peptide(tetra-) 3 1.02 3 0
202.0953609 8.82846782 Coprine Unknown Unknown -1.50 4.84E-04 -2.00 6.76E-06 Peptide(tri-) 7 2.38 0 7
133.0738119 10.63565642 3-nitro-2-pentanol Unknown Unknown -2.10 6.65E-05 -1.92 2.88E-05 Lipids 90 30.61 63 27
267.0966956 9.505194433 Zidovudine Xenobiotics Drugs etcUnknown -1.51 4.01E-03 -1.91 4.96E-04 Lipid Metabolism 12 4.08 11 1
329.1583282 8.91427358 Valclavam Unknown Unknown -2.17 7.77E-05 -1.73 6.50E-05 Lipids: Fatty Acyls 27 9.18 16 11
183.1008239 10.43808729 Nalpha,Nalpha-Dimethyl-L-histidine Unknown Unknown -1.07 4.84E-04 -1.66 7.61E-05 Lipids: Glycerolipids 10 3.40 5 5
246.1216126 13.7006538 2,4-diacetamido-2,4,6-trideoxy-&beta;-L-altropyranose Unknown Unknown -1.81 2.38E-03 -1.64 4.05E-03 Lipids: Glycerophospholipids 6 2.04 4 2
159.0895539 7.797860257 2-Methylbutyrylglycine Unknown Unknown -2.16 1.45E-05 -1.64 6.50E-05 Lipids: Polyketides 1 0.34 1 0
215.0794557 10.27386739 Succinyl proline Unknown Unknown -1.80 9.00E-05 -1.62 1.77E-05 Lipids: Prenols 1 0.34 1 0
189.100107 8.781424646 2 -(Butylamido)-4-hydroxybutanoic acid Unknown Unknown -1.75 9.82E-06 -1.58 3.72E-05 Lipids: Sphingolipids 10 3.40 7 3
287.1478181 9.231367538 N-Acetyl-ala-ala-ala-methylester Unknown Unknown -1.43 3.75E-04 -1.45 6.50E-05 Lipids: Sterol lipids 23 7.82 18 5
197.0801124 17.20363561 N-Acetyl-L-histidine Unknown Unknown -2.87 3.66E-06 -1.45 2.64E-04 Carbohydrates 8 2.72 1 7
161.0687789 8.770953855 O-Acetylhomoserine Unknown Unknown -0.92 4.43E-03 -1.42 1.86E-03 Carbohydrate Metabolism 8 2.72 1 7
287.1114945 10.10605263 N-Ribosylhistidine Unknown Unknown -3.12 5.02E-06 -1.39 4.96E-04 Biosynthesis of Polyketides and Nonribosomal Peptides 4 1.36 1 3
202.120554 7.771541122 Diethyl adipate Unknown Unknown -0.84 3.61E-02 -1.35 1.95E-04 Biosynthesis of Secondary Metabolites 9 3.06 4 5
256.1058824 9.407315849 1-(beta-D-Ribofuranosyl)-1,4-dihydronicotinamide Unknown Unknown -0.60 1.96E-03 -1.29 8.26E-06 Metabolism of Cofactors and Vitamins 7 2.38 2 5
215.0794471 11.25416413 Succinyl proline Unknown Unknown -1.67 1.40E-04 -1.26 6.50E-05 Nucleotide Metabolism 5 1.70 0 5
415.3450705 7.534361697 Tomatidine Unknown Unknown -1.95 1.20E-04 -1.25 5.50E-04 Xenobiotics Drugs etc 1 0.34 0 1
188.0796839 9.88859299 N-Acetylglutamine Unknown Unknown -1.27 4.84E-04 -1.24 4.96E-04 Unknown 122 41.50 63 59
236.0797012 7.712420989 N-Formyl-D-kynurenine Unknown Unknown -0.80 9.05E-03 -1.22 5.31E-06
301.0798623 8.237972972 4-Nitrophenol-alpha-D-galactopyranoside Unknown Unknown -1.09 1.07E-02 -1.22 4.20E-02
159.0545186 10.19149662 1-N6-ethenoadenine Unknown Unknown -1.36 1.03E-04 -1.21 6.20E-03
177.1001916 13.39165345 validamine Unknown Unknown -1.12 4.22E-04 -1.14 8.68E-04
299.0865627 9.245739615 8-Hydroxyguanosine Unknown Unknown -2.16 4.65E-05 -1.13 3.44E-02
243.1834194 6.430587268 N-Undecanoylglycine Unknown Unknown -0.61 2.54E-02 -1.12 1.51E-05
324.1057248 13.4723093 Bis-D-fructose 2',1:2,1'-dianhydride Unknown Unknown -1.11 8.33E-03 -1.12 8.14E-03
204.1110354 16.87941277 N5-(L-1-Carboxyethyl)-L-ornithine Unknown Unknown -2.31 9.05E-03 -1.11 4.48E-02
171.0894964 9.525746725 Crotanecine Unknown Unknown -2.42 1.86E-06 -1.05 4.42E-04
103.0633233 11.77589228 (R)-3-Amino-2-methylpropanoate Unknown Unknown -0.66 9.05E-03 -1.02 8.68E-04
172.0848327 14.7470088 L-prolyl-L-glycine Unknown Unknown -2.19 8.95E-04 -1.01 1.06E-02
179.0794017 13.0773976 Nojirimycin Unknown Unknown -1.85 2.20E-05 -0.94 1.33E-03
218.0902371 9.709760938 Glutamylalanine Unknown Unknown -2.14 1.86E-06 -0.90 2.47E-03
197.0801452 7.9604078 N-Acetyl-L-histidine Unknown Unknown -0.96 1.63E-04 -0.87 2.47E-03
205.0950355 19.18703215 N-(3-hydroxybutanoyl)-L-homoserine Unknown Unknown -2.34 1.86E-06 -0.84 1.26E-03
204.0749237 9.769781541 L-beta-aspartyl-L-alanine Peptide Unknown -2.04 9.82E-06 -0.82 1.49E-03
341.1321961 13.80180316 6-(alpha-D-Glucosaminyl)-1D-myo-inositol Unknown Unknown -1.22 1.75E-03 -0.81 4.77E-02
480.3446076 3.305519124 24-epibrassinolide Unknown Unknown -0.67 2.96E-03 -0.76 8.14E-03
197.0801844 5.510486303 Methyl5-(but-3-en-1-yl)amino-1,3,4-oxadiazole-2-carboxylate Unknown Unknown -0.46 7.69E-03 -0.75 1.57E-02
199.1208293 11.55634551 Tussilagine Unknown Unknown -1.04 5.86E-03 -0.75 1.16E-02
534.2629656 3.566080041 GV 150013X Unknown Unknown -1.22 1.48 -02 -0.75 3.67E-02
189.063753 8.10698139 Glutarylglycine Unknown Unknown -1.00 1.75E-03 -0.72 1.49E-03
167.1058465 8.463854458 2-Dimethylamino-5,6-dimethylpyrimidin-4-ol Unknown Unknown -2.19 4.86E-03 -0.67 9.65E-03
87.03208142 9.311784067 2-Oxazolidinone Unknown Unknown -1.74 5.02E-06 -0.64 2.29E-02
188.1160847 15.71344864 6-Acetamido-3-aminohexanoate Unknown Unknown -0.90 2.38E-03 -0.62 7.38E-03
133.0738015 16.88099912 1-deoxyxylonojirimycin Unknown Unknown -2.02 1.03E-04 -0.61 1.68E-02
205.095073 20.41689338 N-Acetyl-D-fucosamine Unknown Unknown -1.80 3.87E-05 -0.59 3.03E-03
191.0793476 8.149115618 2-amino-3,7-dideoxy-D-threo-hept-6-ulosonate Unknown Unknown -1.24 1.12E-03 -0.58 1.33E-03
116.0109609 9.223293324 Formylpyruvate Unknown Unknown -2.44 1.86E-06 -0.50 1.83E-02
205.0950583 10.01735143 N-Acetyl-D-fucosamine Unknown Unknown -1.05 4.22E-04 -0.47 6.79E-03
218.1153692 7.751126952 3-Hydroxysebacicacid Lipids: Fatty AcylsUnknown -0.78 1.75E-03 -0.46 1.83E-02
242.1516734 3.830911535 2-isocapryloyl-3R-hydroxymethyl-&gamma;-butyrolactone Unknown Unknown -0.74 4.43E-03 -0.18 1.86E-03
304.1270055 14.61754232 2'-Deoxymugineic acid Unknown Unknown -2.43 2.38E-03 -0.08 1.98E-02
155.0581514 9.085799321 (3S,5S)-carbapenam Biosynthesis of Secondary Metabolites(5R)-carbapenem biosynthesis -0.58 4.15E-02 -1.60 5.92E-05
317.1220627 12.92344131 Asp-Pro-Ser Peptide(tri-) Acidic peptide -4.14 2.64E-05 -2.88 3.35E-03
301.1270383 8.075187017 Glu-Gly-Pro Peptide(tri-) Acidic peptide -1.05 2.96E-03 -0.95 2.31E-05
341.1587283 14.66280329 Glu-Pro-Pro Peptide(tri-) Acidic peptide -1.88 9.00E-05 -0.83 6.20E-03
319.1378315 8.463554734 Glu-Ala-Thr Peptide(tri-) Acidic peptide -2.06 3.15E-05 -0.68 3.35E-03
203.1158474 8.08735 O-Acetylcarnitine Amino Acid MetabolismAlanine and aspartate metabolism -0.97 3.29E-03 -0.83 6.20E-03
240.1472965 11.13396931 Slaframine Biosynthesis of Secondary MetabolitesAlkaloid biosynthesi  II -1.67 1.87E-02 -1.39 1.35E-02
185.1052286 12.38917308 Ecgonine Biosynthesis of Secondary MetabolitesAlkaloid biosynthesi  II -1.26 8.08E-06 -0.73 2.05E-03
161.0509341 9.325163278 allylcysteine Unknown alliin degradation __ isoalliin degradation-3.42 3.28E-04 -4.24 3.47E-04
175.0480199 8.0181692 [FA amino,oxo(6:0/2:0)] 2-amino-3-oxo-hexanedioic acid Lipids: Fatty AcylsAmino Fatty Acids -2.86 8.08E-06 -0.91 5.77E-03
341.1321715 12.90969371 Lactosamine Carbohydrate MetabolismAminosugars metabolism -1.08 1.58E-03 -1.28 2.05E-03
295.1056395 10.24001817 (R)-Prunasin Unknown amygdalin and prunasin degradation -1.53 2.64E-05 -2.23 4.30E-05
111.0320316 9.756398226 Pyrrole-2-carboxylate Amino Acid MetabolismArginine and proline metabolism -1.16 2.20E-05 -0.99 2.64E-04
232.1059317 15.54882069 N2-Succinyl-L-ornithine Amino Acid MetabolismArginine and proline metabolism -3.01 1.03E-04 -0.91 3.35E-03













297.0897361 7.689520957 5'-Methylthioadenosine Amino Acid MetabolismArginine and proline metabolism__Methionine metabolism__Zeatin biosynthesis-1.77 2.20E-05 -1.22 6.50E-05
133.0375184 9.412715922 2-hydroxysuccinamate Amino Acid Metabolismasparagine degradation II -2.05 1.80E-05 -0.39 3.95E-02
345.2009056 10.39373695 Lys-Ala-Gln Peptide(tri-) Basic peptide -4.52 2.70E-06 -5.12 5.31E-06
252.1223873 17.15060582 Pro-His Peptide(di-) Basic peptide -1.73 6.23E-04 -1.16 4.77E-03
275.1480825 12.77117152 L-a-glutamyl-L-Lysine Peptide(di-) Basic peptide -2.06 1.03E-04 -0.86 1.45E-02
408.2879223 3.63083525 Cholate Lipids: Sterol lipidsBile acid biosynthesis -0.62 2.36E-02 -1.08 8.89E-05
452.3501507 2.990986445 [ST (5:0)] 5alpha-Cholestane-3alpha,7alpha,12alpha,23,25-pentol Lipids: Sterol lipidsBile acids and derivatives -1.80 1.03E-04 -1.56 5.15E-05
436.3552508 2.980072191 [ST (4:0)] 5alpha-Cholestane-3alpha,7alpha,12alpha,25-tetrol Lipids: Sterol lipidsBile acids and derivatives -1.50 1.43E-03 -1.04 3.67E-02
469.303592 3.688417553 Neomethymycin Biosynthesis of Polyketides and Nonribosomal PeptidesBiosynthesis of 12-, 14- and 16-membered macrolides-2.35 2.89E-04 -2.96 5.15E-05
509.3348822 3.471792316 Narbomycin Biosynthesis of Polyketides and Nonribosomal PeptidesBiosynthesis of 12-, 14- and 16-membered macrolides-0.78 1.90E-04 -1.09 5.92E-05
464.3504643 3.363946874 Castasterone Biosynthesis of Secondary MetabolitesBrassinosteroid b osynthesis -0.97 1.01E-03 -0.49 3.24E-02
88.0523584 6.636192078 Butanoic acid Carbohydrate MetabolismButanoate metabolism -1.48 5.29E-03 -1.31 4.77E-03
584.4227325 4.049625963 Antheraxanthin Biosynthesis of Secondary MetabolitesCarotenoid biosynthesis -2.88 1.86E-06 -1.73 1.66E-03
199.0958009 9.909350139 gamma-Glutamyl-beta-aminopropiononitrile Amino Acid MetabolismCyanoamino acid metabolism -2.61 1.23E-05 -2.29 1.09E-05
128.0585046 9.581445078 gamma-Amino-gamma-cyanobutanoate Amino Acid MetabolismCyanoamino acid metabolism -1.00 1.90E-04 -0.95 2.28E-04
160.0847652 10.01642562 D-Alanyl-D-alanine Amino Acid MetabolismD-Alanine metabolism__Peptidoglycan biosynthesis-1.47 6.65E-05 -1.37 5.92E-05
574.4594231 3.242153893 DG(15:0/18:4(6Z,9Z,12Z,15Z)/0:0) Lipids: GlycerolipidsDiradylglycerols -1.78 7.77E-05 -1.74 8.26E-06
288.2376011 3.079684892 DG(15:0/18:3(6Z,9Z,12Z)/0:0) Lipids: GlycerolipidsDiradylglycerols -2.51 8.08E-06 -1.54 6.50E-05
578.4911987 3.353483429 DG(15:0/18:2(9Z,12Z)/0:0) Lipids: GlycerolipidsDiradylglycerols -2.95 2.70E-06 -1.41 4.20E-02
572.4443908 3.108477339 DG(13:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)[iso2] Lipids: GlycerolipidsDiradylglycerols -1.06 6.23E-04 -1.36 1.45E-05
354.2408034 3.683804085 [FA trihydroxy(2:0)] 9S,11R,15S-trihydroxy-5Z,13E-prostadienoic acidLipids: Fatty AcylsEicosanoids -1.87 2.20E-05 -1.89 9.68E-04
427.2938045 3.673390479 [FA hydroxy,trihydroxy(3:0/2:0)] N-(1,3-dihydroxypropan-2-yl)-9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl amineLipids: Fatty AcylsEicosanoids -1.99 1.07E-02 -1.50 5.31E-06
326.2091547 3.738243366 [FA trihydroxy(2:0)] 9S,11R,15S-trihydroxy-2,3-dinor-5Z,13E-prostadienoic acid-cyclo[8S,12R]Lipids: F tty AcylsEicosanoids -0.64 1.07E-02 -0.09 2.15E-02
240.1725355 3.109870795 7-oxo-11E-Tetradecenoic acid Lipids: Fatty AcylsFatty Acids and Conjugates -0.44 4.43E-02 -0.50 1.35E-02
296.2348963 3.496000734 (9Z,12Z)-(8S)-Hydroxyoctadeca-9,12-dienoic acid Lipids: Fatty AcylsFatty Acids and Conjugates -1.27 4.84E-04 -0.37 7.38E-03
321.2668644 3.853784679 [FA (18:3)] N-(6Z,9Z,12Z-octadecatrienoyl)-ethanolamine Lipids: Fatty AcylsFatty amides -0.08 1.07E-02 -1.30 2.05E-03
560.4804293 3.243218498 Mayolene-18 Lipids: Fatty AcylsFatty esters -1.61 3.75E-04 -0.67 9.65E-03
666.2223729 18.21921141 Stachyose Carbohydrate MetabolismGalactose metabolism -0.42 2.36E-02 -0.62 2.65E-02
179.0792938 17.0093603 D-Galactosamine Carbohydrate MetabolismGalactose metabolism -1.20 2.89E-04 -0.49 2.65E-02
92.04733891 10.66403185 Glycerol Carbohydrate MetabolismGalactose metabolism__Glycerolipid metabolism-1.78 4.86E-03 -0.23 3.95E-02
90.03164967 7.855049726 Glycerone Lipid Metabolism Glycerolipid metabolism__Methane metabolism-1.56 1.48E-02 -1.19 2.83E-02
481.3171733 4.77189162 [PC (15:0)] 1-pentadecanoyl-sn-glycero-3-phosphocholine Lipids: GlycerophospholipidsGlycerophosphocholines -0.76 1.26E-02 -0.68 5.24E-03
677.4996303 4.172659414 [PC (14:0/14:0)] 1,2-ditetradecanoyl-sn-glycero-3-phosphocholine Lipids: GlycerophospholipidsGlycerophosphocholines -3.70 3.15E-05 -0.53 4.20E-02
525.329635 3.498284336 Pikromycin Biosynthesis of Polyketides and Nonribosomal PeptidesGlycerophosphoi ositols -1.01 1.63E-04 -0.92 4.30E-05
390.1318003 7.705678935 Piceid Unknown Glycerophosphoinositols -2.15 2.20E-05 -0.71 2.29E-02
174.064078 9.416509234 N-Formimino-L-glutamate Amino Acid MetabolismHistidine metabolism -1.30 2.20E-05 -0.62 1.25E-02
279.1218928 10.70603872 Phe-Asn Peptide(di-) Hydrophobic peptide -0.80 1.80E-05 -1.75 8.26E-06
268.106073 9.559515133 Ser-Tyr Peptide(di-) Hydrophobic peptide -1.47 8.33E-03 -0.94 4.42E-04
282.121507 12.87576648 Thr-Tyr Peptide(di-) Hydrophobic peptide -1.38 1.40E-05 -0.62 8.90E-03
270.1214804 8.722775298 L-gamma-Glutamyl-L-hypoglycin Unknown hypoglycin biosynthesis -1.08 2.64E-05 -0.46 3.24E-02
194.0789793 13.33023958 1-O-Methyl-myo-inositol Carbohydrate MetabolismInositol phosphate metabolism -1.83 4.86E-03 -0.10 2.47E-03
278.2244767 3.482000003 [FA (18:3)] 6Z,9Z,12Z-octadecatrienoic acid Lipids: Fatty AcylsLinoleic acid metabolism__Biosynthesis of unsaturated fatty acids-1.27 8.95E-04 -1.50 7.06E-04
280.2400869 3.575579392 Linoleate Lipids: Fatty AcylsLinoleic acid metabolism__Biosynthesis of unsaturated fatty acids-0.82 6.41E-03 -1.22 4.05E-03
203.0794423 7.891399649 N2-Acetyl-L-aminoadipate Amino Acid MetabolismLysine biosynthesis -3.85 2.70E-06 -1.63 6.20E-03
290.1112926 16.09209429 N-Succinyl-LL-2,6-diaminoheptanedioate Amino Acid MetabolismLysine biosynthesis -3.49 2.70E-06 -1.04 9.65E-03
145.0738643 8.604488356 [FA oxo,amino(6:0)] 3-oxo-5S-amino-hexanoic acid Amino Acid MetabolismLysine degradation -1.48 1.40E-04 -1.60 1.42E-04
145.1102559 10.25660882 3-Dehydroxycarnitine Amino Acid MetabolismLysineDegradation -1.37 3.29E-03 -2.75 7.61E-05
161.0688172 11.54921379 N-Methyl-L-glutamate Energy MetabolismMethane metabolism -1.53 2.20E-05 -0.93 4.05E-03
115.0269183 9.520075643 Maleamate Metabolism of Cofactors and VitaminsNi otin te and nicotinamide metabolism-1.37 3.75E-04 -0.50 2.29E-02
115.0269108 8.13079825 Maleamate Metabolism of Cofactors and VitaminsNi otin te and nicotinamide metabolism-1.24 7.77E-05 -0.43 2.29E-02
123.0320337 7.750220997 Nicotinate Metabolism of Cofactors and VitaminsNi otin te and nicotinamide metabolism__Alkaloid biosynthesis II-1.46 1.96E-03 -0.85 1.33E-03
244.1786793 10.92193371 N-(6-Aminohexanoyl)-6-aminohexanoate Unknown nylon-6 oligomer degradation -1.88 1.75E-03 -1.34 7.77E-04
122.0367725 7.776715143 Benzoate Amino Acid MetabolismPhenylalanine metabolism__Benzoate degradation via hydroxylation__Biphenyl degradation__Toluene and xylene degradation__Benzoate degradation via CoA ligation__Alkaloid biosynthesis II-1.20 6.23E-04 -0.57 9.65E-03
299.1480177 12.72707919 Pro-Pro-Ser Peptide(tri-) Polar peptide -1.07 2.38E-03 -0.66 3.64E-03
229.1064606 7.913243333 Asn-Pro Peptide(di-) Polar peptide -1.30 6.41E-03 -0.54 3.64E-03
300.1433635 16.03331103 Ala-Asn-Pro Peptide(tri-) Polar peptide -2.55 1.03E-04 -0.26 3.24E-02
154.0030538 8.257191933 Propanoyl phosphate Carbohydrate MetabolismPropanoate metabolism__C5-Branched dibasic acid metabolism-3.44 2.50E-04 -2.06 4.42E-04
136.0385033 10.40510423 Hypoxanthine Nucleotide MetabolismPurine metabolism -0.92 1.26E-02 -0.90 3.03E-02
135.0545141 9.952622142 Adenine Nucleotide MetabolismPurine metabolism__Zeatin biosynthesis-1.38 2.17E-03 -1.24 2.47E-03
135.0544992 9.535693941 Adenine Nucleotide MetabolismPurine metabolism__Zeatin biosynthesis-0.99 1.16E-02 -1.18 5.77E-03
243.0855975 12.37500836 Cytidine Nucleotide MetabolismPyri idine metabolism -2.51 8.08E-06 -1.14 2.41E-03
114.042955 9.417732803 5,6-Dihydrouracil Nucleotide MetabolismPyri idine metabolism__beta-Alanine metabolism__Pantothenate and CoA biosynthesis-0.65 6.99E-03 -0.91 9.68E-04
115.0633451 8.990068392 3-acetamidopropanal Unknown spermine and spermidine degradation -1.06 1.73E-02 -0.95 2.26E-03
431.2881281 3.664923993 [SP amino,trihydroxy(20:0)] 2S-amino-5S-acetoxy-3R,4R,14R-trihydroxyeicos-6E-enoic acidLipids: SphingolipidsSphingoid bases -1.29 3.75E-04 -1.43 5.31E-06
389.277692 3.724764006 [SP amino,hydroxy(4:0/20:0)] 2S-amino-3R,4R,5S,14R-tetrahydroxyeicos-6E-enoic acidLipid : Sphi golipidsSphingoid bases -0.65 5.86E-03 -0.52 1.45E-02
461.3349962 3.628980715 Psychosine Lipids: SphingolipidsSphingolipid metabolism -2.21 5.52E-04 -1.13 6.20E-03
424.2977085 4.145224006 Norselic acid C Lipids: Sterol LipidsSterols -1.50 7.77E-05 -1.08 4.30E-05
456.2878104 4.276026275 Minabeolide-7 Lipids: Sterol LipidsSterols -1.17 3.15E-05 -0.81 9.68E-04













638.5478461 3.361079808 TG(12:0/12:0/12:0) Lipids: GlycerolipidsTriradylglycerols -3.90 2.89E-04 -1.98 3.67E-02
232.1211551 9.108959894 Melatonin Amino Acid MetabolismTryptophan metabolism -0.67 1.61E-02 -1.08 3.35E-03
224.0797658 8.054386429 3-Hydroxy-L-kynurenine Amino Acid MetabolismTryptophan metabolism -0.95 8.95E-04 -0.60 1.45E-02
141.0425692 11.71893664 2-Aminomuconate semialdehyde Amino Acid MetabolismTryptophan metabolism__Naphthalene and anthracene degradation-1.45 5.29E-03 -1.34 8.68E-04
197.0688227 12.68434083 N-Hydroxy-L-tyrosine Amino Acid MetabolismTyrosine metabolism -1.42 3.64E-03 -0.83 1.83E-02
154.0265523 8.199065045 2,5-Dihydroxybenzoate Amino Acid MetabolismTyrosine metabolism__Benzoate degradation via hydroxylation__Naphthalene and anthracene degradation-1.38 2.96E-03 -0.49 2.83E-02
240.0634757 7.748184685 (1R,6R)-6-Hydroxy-2-succinylcyclohexa-2,4-diene-1-carboxylate Metabolism of Cofactors and VitaminsUbiquinone biosynthesis -2.75 1.86E-06 -1.24 6.50E-05
183.0532736 8.001917261 4-Pyridoxate Metabolism of Cofactors and VitaminsVitamin B6 metabolism -0.60 1.87E-02 -1.03 6.76E-06
408.2875104 3.966167864 Bile salt Unknown Unknown 1.46 2.38E-03 0.14 4.77E-02
440.3291516 4.261203297 Pfaffic acid Unknown Unknown 0.64 2.17E-03 0.20 3.44E-02
142.0031784 13.43931761 ethyleneglycol-P Unknown Unknown 0.31 6.99E-03 0.24 6.20E-03
215.1885539 15.05609672 Heptanoylcholine Unknown Unknown 0.32 3.64E-03 0.33 2.37E-03
101.047739 13.6578758 2-Aminobutan-4-olide Unknown Unknown 0.44 4.73E-02 0.38 2.47E-02
142.0031779 13.91444559 ethyleneglycol-P Unknown Unknown 0.19 1.87E-02 0.39 5.50E-04
142.003192 14.37547361 ethyleneglycol-P Unknown Unknown 0.32 1.87E-02 0.39 5.50E-04
411.3711192 4.306682121 Vaccenylcarnitine Unknown Unknown 1.12 5.02E-06 0.39 1.35E-02
462.2978655 3.735949667 3-Dehydroecdysone Biosynthesis of Secondary MetabolitesInsect hormone biosynthesis 0.66 2.54E-02 0.42 3.59E-03
356.2713352 3.762271265 (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid ethyl ester Unknown Unknown 1.33 1.58E-03 0.43 1.68E-02
244.2039327 3.569521523 2S-Hydroxytetradecanoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 0.74 4.22E-04 0.43 8.68E-04
100.0524393 4.19452089 glutaraldehyde Unknown Unknown 1.17 2.50E-04 0.43 1.98E-02
117.9358187 8.372453256 chromate Unknown Unknown 0.22 2.93E-02 0.43 2.05E-03
223.1056742 14.01654831 N-acetyl -D- glucosaminitol Unknown Unknown 1.84 3.28E-04 0.45 2.83E-02
285.1939937 4.221222261 2-Octenoylcarnitine Unknown Unknown 0.34 5.52E-04 0.47 6.76E-06
147.0321188 6.047015442 Indole-5,6-quinone Amino Acid MetabolismTyrosine metabolism 1.22 4.22E-04 0.48 8.36E-04
252.1361621 3.906795858 ubiquinol-1 Unknown Unknown 1.82 7.98E-04 0.49 9.65E-03
136.0524819 4.183133883 4-Hydroxyphenylacetaldehyde Amino Acid MetabolismTyrosine metabolism__Alkaloid biosynthesis I1.25 7.06E-04 0.49 4.96E-04
418.272092 3.484230341 3alpha,12alpha-Dihydroxy-5beta-pregnan-20-one diacetate Unknown Unknown 0.76 4.43E-02 0.50 4.65E-02
458.3397646 3.700247645 Stoloniferone J Lipids: Sterol LipidsSterols 1.29 1.03E-04 0.50 2.50E-04
372.2662432 3.789970128 3-Ethoxyandrosta-3,5-dien-17beta-ol propanoate Unknown Unknown 1.25 9.05E-03 0.52 3.03E-02
468.3453344 5.514754538 Scymnol Unknown Unknown 1.78 9.82E-06 0.52 2.26E-03
258.219764 3.496484947 [FA hydroxy(15:0)] 2-hydroxy-pentadecanoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 1.62 2.64E-05 0.53 1.16E-02
476.3502615 4.176850375 11-acetoxy-3beta,6alpha-dihydroxy-9,11-seco-5alpha-cholest-7-en-9-one. Lipids: Sterol LipidsSterols 1.03 1.40E-04 0.53 1.22E-03
252.1109918 10.22253836 Ala-Tyr Peptide(di-) Hydrophobic peptide 1.44 3.66E-06 0.54 1.49E-03
256.2401145 3.599792032 [FA trimethyl(13:0)] 4,8,12-trimethyl-tridecanoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 0.60 1.73E-02 0.55 2.41E-03
161.1051288 13.80886209 L-Carnitine Amino Acid MetabolismLysine degradation 1.93 9.82E-06 0.56 3.44E-02
203.0794421 13.81607362 2-acetamidoglucal Unknown Unknown 0.54 8.33E-03 0.56 2.15E-02
494.3606465 4.357819207 (22R,23R)-28-homobrassinolide Unknown Unknown 1.47 6.50E-06 0.57 7.77E-04
200.1775977 3.689958839 [FA methyl(11:0)] 10-methyl-undecanoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 1.75 4.65E-05 0.60 3.03E-02
327.2774812 4.415744798 Margaroylglycine Unknown Unknown 4.54 6.50E-06 0.61 1.33E-03
275.1732248 4.896408928 [FA hydroxy(10:0)] N-(3S-hydroxydecanoyl)-L-serine Lipids: Fatty AcylsUnknown 0.73 3.64E-03 0.61 2.83E-02
436.3552734 5.354878503 [ST (4:0)] 5beta-Cholestane-3alpha,7alpha,12alpha,26-tetrol Lipids: Sterol lipidsBile acid biosynthesis 1.99 3.15E-05 0.62 3.95E-02
195.0895864 3.898386793 Damascenine Unknown Unknown 1.57 6.41E-03 0.63 6.20E-03
334.2144439 3.724085363 [FA hydroxy(20:4)] 5S-hydroxy-12-keto-6Z,8E,10E,14Z-eicosatetraenoic acidLipids: Fatty AcylsEicosanoids 1.70 1.86E-06 0.64 2.29E-02
96.99304467 12.77703293 Phosphoramidate Unknown Unknown 0.69 4.15E-02 0.66 4.48E-02
163.0632842 4.104498784 o-formaminoacetophenone Unknown Unknown 1.36 2.64E-05 0.67 1.22E-03
438.3345393 6.347381657 27-Nor-5b-cholestane-3a-7a-12a-24-25-pentol Unknown Unknown 2.11 1.20E-04 0.68 1.17E-02
209.068822 4.855264782 N-Benzyloxycarbonylglycine Unknown Unknown 1.72 1.45E-05 0.68 6.79E-03
290.1266189 4.855828531 6-hydroxy-indole-3-acetyl-valine Unknown IAA degradation V 1.53 1.86E-06 0.68 1.09E-03
480.3087883 3.814085065 20-Hydroxyecdysone Biosynthesis of Secondary MetabolitesInsect hormone biosynthesis 0.58 1.16E-02 0.69 4.42E-04
188.1201156 4.288249892 [FA (13:1/2:0)] 2-tridecene-4,7-diynal Lipids: Fatty AcylsFatty aldehydes 0.96 3.64E-03 0.70 1.71E-03
163.0632736 4.662172185 5-(3-pyridyl)-tetrahydro-furan-2-one Unknown Unknown 2.27 1.23E-05 0.70 5.50E-04
465.3454172 3.761879552 LysoSM(d18:1) Lipids: SphingolipidsCeramide phosphocholines (sphingomyelins)0.96 2.19E-04 0.71 4.77E-03
452.3503845 5.557107395 5b-Cholestane-3a-7a-12a-24-25-pentol Unknown Bile acids and derivatives 2.00 1.23E-05 0.72 4.08E-03
164.0836891 4.192348216 Evodone Unknown Unknown 1.83 1.86E-06 0.73 4.42E-04
433.3195107 3.901965585 Glycolithocholate Unknown Unknown 1.24 1.63E-04 0.73 5.24E-03
127.063292 13.99170879 2,3,4,5-Tetrahydropyridine-2-carboxylate Amino Acid MetabolismLysine degradation 0.88 6.99E-03 0.74 5.77E-03
131.0945221 11.80624063 (3R)-beta-Leucine Amino Acid MetabolismValine, leucine and isoleucine degradation0.70 2.75E-02 0.75 4.42E-03
330.1900863 7.952454352 Ala-Leu-Ala-Gly Peptide(tetra-) Hydrophobic peptide 0.81 2.03E-02 0.75 1.68E-02
630.5221663 3.44453699 DG(15:0/22:4(7Z,10Z,13Z,16Z)/0:0) Lipids: GlycerolipidsDiradylglycerols 0.77 1.16E-02 0.77 3.64E-03
438.3345879 5.619787023 27-Nor-5b-cholestane-3a-7a-12a-24-25-pentol Unknown Unknown 2.04 2.50E-04 0.77 1.66E-03
424.3703616 4.098015305 [PR (2:0)] (+)-cycloarta-7,24-dien-3beta-ol Lipids: Prenols Isoprenoids 0.60 1.48E-02 0.78 7.61E-05
115.063337 13.30951105 D-Proline Amino Acid MetabolismArginine and proline metabolism 0.81 1.73E-02 0.79 3.02E-04
632.5379604 3.742028236 [GL (17:2/20:1)] 1-(9Z,12Z-heptadecadienoyl)-2-(11Z-eicosenoyl)-sn-glycerolLipids: GlycerolipidsDiradylglycerols 0.78 9.06E-03 0.79 2.26E-03
452.3503249 5.997258013 5a-Cholestane-3a-7a-12a-23-25-pentol Unknown Unknown 2.01 4.65E-05 0.80 8.23E-04
467.3612151 3.828310006 [SP] sphinganine-1-phosphocholine Lipids: SphingolipidsSphingoid bases 1.36 6.65E-05 0.81 3.03E-03
394.2724377 4.005189497 Tylactone Biosynthesis of Polyketides and Nonribosomal PeptidesBiosynthesis of 12-, 14- and 16-membered macrolides1.39 4.65E-05 0.81 6.97E-03
86.03669003 4.669442949 Diacetyl Carbohydrate MetabolismButanoate metabolism 1.10 1.90E-04 0.81 7.38E-03
452.3503225 7.53564391 5b-Cholestane-3a-7a-12a-23R-25-pentol Unknown Unknown 2.42 9.82E-06 0.82 3.03E-02













312.302802 3.488966762 Phytanate Lipid Metabolism OxidationofBranchedFattyAcids 1.47 1.80E-05 0.86 7.38E-03
254.2245561 3.612308888 (9Z)-Hexadecenoic acid Lipid Metabolism Fatty acid biosynthesis 1.52 1.19E-04 0.87 1.35E-02
383.142751 15.28954709 D-Galactosyl-3-N-acetyl-beta-D-galactosamine Unknown Unknown 1.53 7.77E-05 0.87 1.16E-02
430.2024193 3.602710081 Ptilosteroid B Lipids: Sterol LipidsSteroids 1.39 1.20E-04 0.87 5.50E-04
392.2927096 3.829878028 [ST hydrox] 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic Acid Lipids: Sterol lipidsBile acids and derivatives 1.62 1.80E-05 0.88 1.02E-03
226.1933706 3.663476286 (9Z)-Tetradecenoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 2.78 6.50E-06 0.90 1.68E-02
143.058228 13.83661759 Vinylacetylglycine Unknown Unknown 1.62 6.65E-05 0.91 1.49E-03
136.0195061 5.275372709 S-Methyl-1-thio-D-glycerate Unknown Unknown 1.51 1.63E-04 0.91 4.77E-03
569.5379766 4.066480709 Cer(d18:0/h17:0) Lipids: SphingolipidsCeramides 0.62 1.56E-02 0.91 1.33E-03
420.3602967 4.686924213 [ST (3:0)] 5beta-Cholestane-3alpha,7alpha,26-triol Lipid Metabolism Bile acid biosynthesis 2.10 8.08E-06 0.92 3.24E-02
352.334105 3.4215599 [FA (23:1)] 22-tricosenoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 1.34 3.15E-05 0.92 9.68E-04
532.3067357 3.604415993 5beta-Cyprinolsulfate Lipids: Sterol lipidsBile acid biosynthesis 2.03 1.23E-05 0.95 2.29E-02
412.1919667 3.388333329 17-Hydroxypregnenolonesulfate Unknown Unknown 2.44 6.23E-04 0.96 2.74E-03
131.0945969 11.37354617 L-Isoleucine Amino Acid MetabolismValine, leucine and isoleucine degradation__Valine, leucine and isoleucine biosynthesis__Alkaloid biosynthesis II0.61 4.99E-02 0.98 4.42E-04
494.3607344 4.000693721 (22R,23R)-28-homobrassinolide Unknown Unknown 1.58 1.58E-03 0.98 3.02E-04
264.1473428 11.99222444 Subaphyllin Unknown Unknown 1.49 8.33E-03 1.00 2.65E-02
329.2930081 4.361934523 Dihydroceramide Lipids: SphingolipidsSphingolipid metabolism 2.13 6.50E-06 1.01 4.42E-03
302.1630505 3.783517867 Trichostatin Lipids: PolyketidesLinear polyketides 1.88 7.06E-04 1.01 1.35E-02
795.5162703 3.211702841 [SP] (3'-sulfo)Galbeta-Cer(d18:1/2-OH-16:0) Lipids: SphingolipidsAcidic glycosphingolipids 1.59 5.29E-03 1.01 1.06E-02
406.2717813 3.870985271 3alpha,7alpha-Dihydroxy-12-oxo-5beta-cholanate Unknown Unknown 1.75 1.73E-02 1.02 3.67E-02
296.271309 3.534342768 Oleic acid methyl ester Unknown Unknown 0.98 3.75E-04 1.02 1.95E-04
478.3656778 4.030560142 [ST hydroxy(3:0)] (7E)-(1R,2S,3R)-2-(3-hydroxypropoxy)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triolLipids: Sterol lipidsSecost roids 0.71 2.74E-02 1.02 1.08E-04
436.3188258 3.774963925 Varanicacid Unknown Unknown 0.59 2.03E-02 1.03 1.42E-04
145.1102185 13.91090109 Acetylcholine Lipid Metabolism Glycerophospholipid metabolism 0.80 1.07E-02 1.04 5.24E-03
165.0789879 11.78988684 3-Pyridinebutanoicacid Unknown Unknown 1.51 1.01E-03 1.04 7.77E-04
406.3076401 3.755958472 MG(0:0/22:4(7Z,10Z,13Z,16Z)/0:0) Lipids: GlycerolipidsMonoradylglycerols 1.17 9.88E-03 1.06 5.50E-04
186.1618554 3.713063347 [FA (11:0)] undecanoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 1.72 9.82E-06 1.06 3.02E-04
462.3710384 4.162255674 [ST hydroxy(3:2/3:0/3:0)] (5Z,7E)-(1R,2R,3R)-3-(hydroxy-propyl)-19-nor-9,10-seco-5,7-cholestadien-1,3,25-triolLipids: Sterol lipidsSecost roi s 2.01 1.86E-06 1.06 9.73E-04
376.2977212 3.772606164 3alpha-Hydroxy-5beta-cholanate Lipids: Sterol lipidsBile acid biosynthesis 1.30 4.22E-04 1.07 5.83E-04
197.105264 4.831298043 Tenuazonic acid Unknown Unknown 2.96 2.64E-05 1.08 2.29E-02
383.1428536 13.87966242 N-Acetyllactosamine Unknown Unknown 1.75 1.45E-05 1.08 7.06E-04
213.1001372 4.982918519 [FA oxo(6:0)] N-(3-oxo-hexanoyl)-homoserine lactone Lipids: Fatty AcylsFatty amides 1.27 7.77E-05 1.10 3.02E-04
390.2771406 3.762777616 Bis(2-ethylhexyl)phthalate Unknown Unknown 1.42 7.06E-04 1.11 6.24E-04
163.0844422 14.32375768 Deoxymannojirimycin Unknown Unknown 0.90 8.08E-06 1.13 4.96E-04
416.3292307 3.565764994 [ST (3:0)] (5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triolLipids: Sterol lipidsSecosteroids 1.12 1.43E-03 1.13 6.50E-05
240.2089131 3.641693703 [FA dimethyl(13:0)] 2,5-dimethyl-2E-tridecenoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 1.96 3.66E-06 1.15 1.66E-03
428.3654646 4.148328544 (24R,24'R)-Fucosterol epoxide Unknown Unknown 2.10 2.70E-06 1.17 1.05E-05
460.3551626 3.633587878  (20S,24S)-24-ethylthornasterol Lipids: Sterol LipidsSterols 1.27 2.64E-05 1.17 1.24E-04
151.0632815 13.42709654 N-Methylanthranilate Biosynthesis of Secondary MetabolitesAcri one alkaloid biosynthesis 1.45 1.61E-02 1.17 5.15E-05
404.2926354 3.564521308 Androstane-3,17-diol dipropionate Unknown Unknown 2.68 1.86E-06 1.18 3.02E-04
448.3188325 3.793085556 Convallagenin A Unknown Unknown 1.00 3.87E-05 1.19 2.28E-04
438.3345098 7.597059191 27-Nor-5b-cholestane-3a-7a-12a-24-25-pentol Unknown Unknown 3.08 9.82E-06 1.20 1.45E-02
434.3027849 3.635281905 [ST (4:0)] (5Z,7E)-(1S,3R,24R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24,25-tetrolLipids: Sterol lipidsSec steroids 1.00 2.17E-03 1.20 3.47E-04
151.0633913 4.280362111 N-Acetoxyarylamine Unknown Unknown 0.75 2.36E-02 1.21 2.65E-02
476.3498529 3.616498593 11-acetoxy-3beta,6alpha-dihydroxy-9,11-seco-5alpha-cholest-7-en-9-one. Lipids: Sterol LipidsSterols 1.56 1.86E-06 1.21 8.11E-05
450.3344387 3.838106764 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestanoate Lipid Metabolism Bile acid biosynthesis 1.76 1.86E-06 1.21 2.67E-05
466.3290773 3.756740149 [ST hydroxy(4:0)] 2beta,3alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholestan-26-oic acidLipids: S erol lipidsBile acids and derivatives 1.45 1.86E-06 1.23 7.50E-06
511.4968258 4.07298735 [SP (14:0)] N-(tetradecanoyl)-sphinganine Lipids: SphingolipidsCeramides 0.81 6.99E-03 1.23 5.92E-05
434.3393705 3.84912821 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestan-26-al Lipid Metabolism Bile acid biosynthesis 1.19 3.15E-05 1.24 1.09E-05
466.3113153 3.252489005 Cholesterolsulfate Lipids: Sterol lipidsUnknown 0.95 5.02E-06 1.24 1.09E-05
434.3394824 4.185017331 3alpha,7alpha-Dihydroxy-5beta-cholestanate Lipid Metabolism Bile acid biosynthesis 1.48 1.86E-06 1.26 1.09E-04
412.3704666 4.178507444 [ST dimethyl(2:0)] 4,4-dimethyl-cholesta-8,24-dien-3beta-ol Lipids: Sterol lipidsSterols 1.49 6.99E-03 1.26 1.68E-04
716.4615023 3.882206366 PG(12:0/20:3(8Z,11Z,14Z)) Lipids: GlycerophospholipidsGlycerophosphoglycerols 1.83 1.26E-02 1.27 4.30E-05
446.3759103 4.121251122 13'-hydroxy-&alpha;-tocopherol Unknown Unknown 2.03 1.86E-06 1.30 8.95E-05
153.042563 4.96520879 Salicylhydroxamic acid Unknown Unknown 2.05 2.19E-04 1.31 8.90E-03
187.1208617 5.328334979 N-Heptanoylglycine Unknown Unknown 2.65 9.82E-06 1.35 7.06E-04
242.2245947 3.646504576 Pentadecanoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 1.35 1.12E-03 1.35 4.96E-04
292.1317483 3.061091433 Bilirubin Metabolism of Cofactors and VitaminsPorphyri  and chlorophyll metabolism 1.21 8.95E-04 1.35 7.61E-05
286.2507055 3.45686887 3-Hydroxy-palmitic acid methyl ester Unknown Unknown 1.91 5.63E-05 1.36 1.49E-03
147.0353148 15.39895652 Thiomorpholine 3-carboxylate Unknown Unknown 2.62 8.08E-06 1.37 1.09E-05
324.3026701 3.47578698 [FA (3:2/18:0)] 2-propyl-9Z-octadecenoic Acid Lipids: Fatty AcylsFatty Acids and Conjugates 2.53 2.64E-05 1.38 1.68E-02
228.2089482 3.654710623 2-6-10-Trimethylundecanoicacid Unknown Unknown 2.25 3.66E-06 1.40 1.24E-04
555.5224966 4.109483969 [SP hydroxy(16:0)] N-(hexadecanoyl)-4S-hydroxysphinganine Lipids: SphingolipidsCeramides 1.31 1.58E-03 1.42 5.77E-03
374.2820699 3.72553462 3-Oxo-5beta-cholanate Unknown Unknown 1.89 1.03E-04 1.44 4.96E-04
181.0739439 11.53803752 3-Amino-3-(4-hydroxyphenyl)propanoate Amino Acid MetabolismTyrosine metabolism 1.73 2.74E-02 1.45 1.86E-03
418.3449552 3.718760593 3alpha,7alpha-Dihydroxy-5beta-cholestan-26-al Lipid Metabolism Bile acid biosynthesis 1.80 1.80E-05 1.46 5.31E-06
482.3063624 3.294196239 26-hydroxycholesterol 3-sulfate Lipids: Sterol LipidsSteroid conjugates 2.07 2.70E-06 1.47 6.50E-05
179.0946203 3.761524805 Xylylcarb Unknown Unknown 1.58 5.52E-04 1.50 4.30E-05













384.3396329 4.550116366 Cholest-4-en-3-one Lipid Metabolism Bile acid biosynthesis 1.33 1.16E-02 1.61 2.26E-03
155.0946829 5.223672048 Arecoline Unknown Unknown 3.44 5.02E-06 1.62 2.47E-03
618.5219712 3.741510172 [GL (18:1/18:2)] 1-(9Z-octadecenoyl)-2-(9Z,12Z-octadecadienoyl)-sn-glycerolLipids: GlycerolipidsDiradylglycerols 1.23 8.95E-04 1.67 8.89E-05
313.1657811 3.291746279 [PC diethyl(2:0)] 1,2-diethyl-sn-glycero-3-phosphocholine Lipids: GlycerophospholipidsGlycerophosphocholines 2.10 3.28E-04 1.67 5.92E-05
153.0425579 13.29317949 3-Hydroxy-2-methylpyridine-5-carboxylate Metabolism of Cofactors and VitaminsVitamin B6 metabolism 1.22 2.74E-02 1.68 7.77E-04
448.268587 12.84179824 Ala-Leu-Phe-Val Peptide(tetra-) Hydrophobic peptide 2.28 7.93E-05 1.71 1.45E-05
430.3806661 4.063769423 [PR] Vitamin E Lipid Metabolism Biosynthesis of steroids 2.57 3.15E-05 1.73 1.66E-03
602.4909842 3.61162392 DG(15:0/20:4(5Z,8Z,11Z,14Z)/0:0) Lipids: GlycerolipidsDiradylglycerols 2.73 1.86E-06 1.75 4.42E-04
199.1208746 4.732843111 4-(1-methyl-2-pyrrolidinyl)-3-oxobutanoate methyl ester Biosynthesis of Secondary Metabolitescaine biosynthesi 2.66 5.02E-06 1.79 2.31E-05
312.176097 3.257258153 Spongipregnoloside A Lipids: Sterol LipidsSteroids 1.92 2.19E-04 1.81 3.47E-04
418.3081967 3.618991955 Diisononyl phthalate Unknown Unknown 1.66 1.23E-05 2.12 4.30E-05
308.2714841 3.50844918 Icosadienoic acid Lipid Metabolism Biosynthesis of unsaturated fatty acids 2.15 1.63E-04 2.22 8.26E-06
332.2716472 3.479858157 [FA (22:4)] 7Z,10Z,13Z,16Z-docosatetraenoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 2.21 6.23E-04 2.28 6.76E-06
728.4980602 3.811453796 PG(O-16:0/18:4(6Z,9Z,12Z,15Z)) Lipids: GlycerophospholipidsGlycerophosphoglycerols 1.91 1.36E-02 2.80 2.88E-05
334.2871208 3.480254029 13,16,19-Docosatrienoic acid Lipids: Fatty AcylsFatty Acids and Conjugates 2.25 1.87E-02 3.01 1.77E-05












ACCEPTED MANUSCRIPTLog2 mean post/pre intervention ratio of metabolites significantly changing during both EEN and CD-TREAT, with opposite direction (p-value<0.05)
Mass RT Putative.metabolite Map Pathway logfold_EEN p_adj_EEN logfold_CDT p_adj_CDT
318.153961 18.07660593 Ala-Ala-Ala-Ser Peptide(tetra-) Polar peptide -3.39 3.15E-05 0.18 2.74E-03
232.1060301 8.746668225 gamma-Glutamyl-gamma-aminobutyraye Amino Acid Metabolism Arginine and proline metabolism -0.81 1.87E-02 0.31 4.20E-02
159.1258487 14.0646082 Methacholine Unknown Unknown -1.42 1.39E-05 0.45 7.14E-03
89.04774167 15.88714344 beta-Alanine Nucleotide Metabolism Pyrimidine metabolism__Alanine and aspartate metabolism__beta-Alanine metabolism__Propanoate metabolism__Pantothenate and CoA biosynthesis-0.79 3.37E-02 0.47 2.15E-02
95.98796158 15.59325605 Methanesulfonic acid Unknown dimethylsulfide degradation II (oxidation) __ methanesulfonate degradation -0.52 2.66E-03 0.49 7.06E-04
139.9777625 15.60803957 Sulfoacetate Amino Acid Metabolism Taurine and hypotaurine metabolism -0.66 5.29E-03 0.57 4.77E-03
332.1694779 13.9939568 Ala-Thr-Ala-Ala Peptide(tetra-) Polar peptide -0.91 1.36E-02 0.62 1.68E-02
354.3133553 3.364780936 [FA oxo(22:0)] 10-oxo-docosanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.88 1.58E-03 0.63 4.77E-03
100.0524842 14.08625222 Tiglic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -1.96 2.20E-05 0.68 1.35E-02
226.1205018 4.415478037 3,7-Dimethyl-2E,6E-decadien-1,10-dioic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.37 4.01E-03 0.68 7.17E-04
205.1313618 14.06416257 Pantothenol Metabolism of Cofactors and Vitamins Pantothenate and CoA biosynthesis -2.00 2.19E-04 0.70 1.57E-02
552.3309692 4.686326273 Pandamine Unknown Unknown -1.54 2.93E-02 0.70 1.98E-02
102.0317111 10.48060027 (S)-Methylmalonate semialdehyde Amino Acid Metabolism Valine, leucine and isoleucine degradation__Propanoate metabolism -0.86 1.58E-03 0.71 2.74E-03
394.2216986 15.20158896 Lys-Phe-Thr Peptide(tri-) Basic peptide -3.17 3.66E-06 0.84 3.37E-03
147.0895077 12.90614398 Fagomine Unknown Unknown -1.60 2.17E-03 0.91 2.29E-02
302.1590564 17.04038959 Ala-Ala-Ala-Ala Peptide(tetra-) Nonpolar peptide -1.46 4.15E-02 0.91 4.48E-02
177.1001212 14.51400279 validamine Unknown Unknown -1.21 1.03E-04 1.13 6.50E-05
261.1324619 14.53546609 Gammaglutamylornithine Peptide Unknown -1.39 1.12E-03 1.30 2.47E-02
240.1222375 14.12708198 beta-Alanyl-N(pi)-methyl-L-histidine Amino Acid Metabolism Histidine metabolism__beta-Alanine metabolism -0.60 1.61E-02 1.37 3.03E-03
228.1222362 15.56397448 Deoxyguanidinoproclavaminic acid Biosynthesis of Secondary Metabolites Clavulanic acid biosynthesis -1.66 3.37E-02 1.43 3.44E-02
140.0585568 8.049310051 Methylimidazoleacetic acid Amino Acid Metabolism Histidine metabolism -0.79 4.73E-02 1.49 5.50E-04
196.096015 14.73413307 3,5-dihydro-5-methylidene-4H-imidazol-4-one Unknown Unknown -2.86 3.87E-05 1.51 6.20E-03
232.1423 14.833248 Spermic acid 2 Unknown Unknown -0.75 9.05E-03 1.87 1.98E-02
241.1174797 16.74594264 Tetrahydrobiopterin Metabolism of Cofactors and Vitamins Folate biosynthesis -2.18 4.84E-04 2.51 1.42E-04
207.0531657 5.5479609 2-Formaminobenzoylacetate Amino Acid Metabolism Tryptophan metabolism -1.21 1.58E-03 2.79 1.24E-04
207.0531551 7.87080576 4-(2-Aminophenyl)-2,4-dioxobutanoate Amino Acid Metabolism Tryptophan metabolism -2.04 2.89E-04 3.04 5.92E-05
169.0851136 14.18800227 Nalpha-Methylhistidine Unknown Unknown -2.99 9.82E-06 3.04 7.77E-04
240.1222024 16.93166851 Homocarnosine Amino Acid Metabolism Arginine and proline metabolism -2.79 5.63E-05 3.42 2.28E-04
445.2165464 8.309677559 Ala-Glu-Asn-Ile Peptide(tetra-) Hydrophobic peptide -0.89 4.73E-02 3.92 4.30E-05
321.266943 4.301985491 Alpha-Linolenoyl ethanolamide Unknown Unknown 0.03 0.025360054 -2.90 1.09E-05
98.04805973 10.31663746 Imidazole-4-methanol Unknown Unknown 1.46 0.001958387 -2.16 5.31E-06
355.2150525 9.816756985 Spirasine I Unknown Unknown 3.25 2.7028E-06 -2.14 4.77E-03
173.0688355 9.457315646 N-Acetyl-L-glutamate 5-semialdehyde Amino Acid Metabolism Arginine and proline metabolism 1.11 0.005294201 -1.96 1.83E-02
148.0848169 9.742861648 N5-hydroxy-L-ornithine Unknown Unknown 4.29 5.62586E-05 -1.96 4.42E-03
363.2773483 7.754692715 [FA (20:3)] N-((+/-)-14(15)-epoxy-5Z,8Z,11Z-eicosatrienoyl)-ethanolamineLipids: Fatty Acyls Fatty amides 5.73 1.85817E-06 -1.71 8.68E-04
325.2981104 4.248626372 [FA (18:0)] N-(9Z-octadecenoyl)-ethanolamine Lipids: Fatty Acyls Fatty amides 1.82 0.020261187 -1.63 1.95E-04
397.3194828 4.78228376 trans-Hexadec-2-enoylcarnitine Unknown Unknown 0.49 0.033679404 -1.61 6.20E-03
371.303623 4.877817939 Tetradecanoylcarnitine Unknown Unknown 1.71 0.041456303 -1.59 1.77E-05
399.3348028 4.755299225 [FA] O-Palmitoyl-R-carnitine Lipids: Fatty Acyls Fatty acyl carnitines 2.63 4.64544E-05 -1.48 1.57E-02
330.240517 3.742450173 [FA trihydroxy(18:1)] 9S,12S,13S-trihydroxy-10E-octadecenoic acidLipids: Fatty Acyls Octadecanoids 1.62 0.025360054 -1.25 8.89E-05
279.1834104 11.3139499 Serratine Unknown Unknown 3.35 1.85817E-06 -1.18 2.28E-04
425.3505125 4.669353193 Oleoylcarnitine Unknown Unknown 1.53 0.006408571 -1.18 1.35E-02
198.0793402 8.758491255 Harmalol Unknown beta-carboline biosynthesis 0.90 0.004007902 -1.05 9.65E-03
279.1833693 9.005132941 Serratine Unknown Unknown 0.71 0.023568157 -1.02 1.06E-02
167.0582187 11.48701066 3-Methoxyanthranilate Amino Acid Metabolism Tryptophan metabolism 0.79 0.001432683 -0.97 3.99E-04
357.2881709 7.715200528 N-palmitoyl threonine Lipids: Fatty Acyls Fatty amides 1.17 0.011604285 -0.92 3.44E-02
280.1423953 5.062759971 Val-Tyr Peptide(di-) Hydrophobic peptide 0.71 0.027350649 -0.91 3.02E-04
281.1123701 11.19629145 1-Methyladenosine Unknown Unknown 1.24 0.003640851 -0.87 4.20E-02
187.0633784 8.211676295 Indoleacrylicacid Unknown Unknown 0.89 0.033679404 -0.83 1.33E-03
181.0739962 5.138880123 &alpha;-aminooxy-&beta;-phenylpropionate Unknown Unknown 1.10 0.016097326 -0.82 1.45E-02
214.1317919 8.647778952 Dethiobiotin Metabolism of Cofactors and Vitamins Biotin metabolism 0.90 0.002382329 -0.72 1.09E-03
194.1055683 9.739849088 6-Hydroxypseudooxynicotine Metabolism of Cofactors and Vitamins Nicotinate and nicotinamide metabolism 0.97 0.010692706 -0.72 2.74E-03
292.1422874 5.02508238 Phenylbutyrylglutamine Unknown Unknown 0.75 0.021918011 -0.69 3.47E-04
214.0953631 12.5097927 Pyrimidine nucleoside Unknown Unknown 0.73 5.02209E-06 -0.67 1.15E-03
268.1211414 8.894515044 Lysergic acid Unknown Unknown 1.18 9.81677E-06 -0.67 3.03E-03
299.2825117 4.347956324 [FA (16:2)] N-hexadecyl-ethanolamine Lipids: Fatty Acyls Fatty amides 2.80 0.004007902 -0.66 3.44E-02
443.3610397 4.914061149 12-Hydroxy-12-octadecanoylcarnitine Unknown Unknown 0.69 0.03607199 -0.65 4.20E-02
228.1110077 13.09216648 Prolylhydroxyproline Amino Acid Metabolism Unknown 2.16 2.7028E-06 -0.59 7.38E-03
167.0582687 5.232094197 Isopyridoxal Metabolism of Cofactors and Vitamins Vitamin B6 metabolism 1.67 0.004858688 -0.58 6.79E-03
113.0477176 10.80384695 1-Pyrroline-2-carboxylate Amino Acid Metabolism Arginine and proline metabolism__D-Arginine and D-ornithine metabolism 1.36 3.65543E-06 -0.57 5.17E-04
226.0952993 12.36588613 carbidopa Unknown Unknown 3.40 1.85817E-06 -0.51 1.35E-02
165.0789975 9.013807519 Benzocaine Xenobiotics Drugs etc Unknown 1.72 0.001581278 -0.50 2.65E-02
171.0894496 10.91027769 N-Butyryl-L-homoserine lactone Lipids: Fatty Acyls Fatty amides 1.38 5.02209E-06 -0.50 4.91E-03
228.1110046 11.37539595 (S)-ATPA Unknown Unknown 1.24 5.02209E-06 -0.49 1.60E-02
257.1626861 11.1192107 2-Hexenoylcarnitine Unknown Unknown 0.55 0.000189519 -0.42 4.42E-03
169.0738824 12.43067842 L-Noradrenaline Amino Acid Metabolism Tyrosine metabolism 1.26 1.85817E-06 -0.38 1.98E-02
153.0789332 10.41682941 Dopamine Amino Acid Metabolism Tyrosine metabolism__Indole and ipecac alkaloid biosynthesis__Alkaloid biosynthesis I1.18 0.018709924 -0.33 1.45E-02












ACCEPTED MANUSCRIPTLog2 mean post/pre intervention ratio of metabolites significantly decreased (purple) or increased (green) only during CD-TREAT (p-value<0.05)
Mass RT Putative.metabolite Map Pathway logfold_CDT p_adj_CDT
118.0630128 7.76481715 5-Hydroxypentanoate Lipids: Fatty Acyls Fatty Acids and Conjugates -0.97 4.77E-03
715.5152889 3.204900407 PE(14:0/20:2(11Z,14Z)) Lipids: Glycerophospholipids Glycerophosphoethanolamines -0.95 4.77E-03
215.1158461 5.087763737 2-Amino-9,10-epoxy-8-oxodecanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.88 3.44E-02
521.3480938 4.749511636 1-Oleoylglycerophosphocholine Uknown Uknown -0.82 6.79E-03
539.323087 4.958885663 PS(19:0/0:0) Lipids: Glycerophospholipids Glycerophosphoserines -0.78 3.67E-02
323.2825145 4.26479149 [FA (18:2)] N-(9Z,12Z-octadecadienoyl)-ethanolamine Lipids: Fatty Acyls Fatty amides -0.76 5.92E-05
271.2510813 4.807151561 Undecanoylcholine Uknown Uknown -0.69 3.03E-02
441.3454133 4.948111513 3-Hydroxy-11Z-octadecenoylcarnitine Uknown Uknown -0.65 6.24E-04
155.0695451 13.54391547 D-Histidine Uknown Uknown -0.63 2.05E-03
317.2112967 5.121784617 11R-HEPE Uknown Uknown -0.55 9.68E-04
125.0588825 10.6280757 5-Methylcytosine Nucleotide Metabolism Pyrimidine metabolism -0.55 6.50E-05
179.0581321 10.18131335 Hippurate Amino Acid Metabolism Phenylalanine metabolism -0.54 5.31E-06
142.0742362 12.52910113 Ectoine Amino Acid Metabolism Glycine, serine and threonine metabolism -0.53 2.74E-03
125.05889 9.851745628 2-O-Methylcytosine Uknown Uknown -0.49 1.42E-04
155.0694448 7.773234987 3-(Pyrazol-1-yl)-L-alanine Uknown beta-pyrazole-1-ylalanine biosynthesis -0.44 3.03E-03
214.09542 10.05674908 Pyrimidine nucleoside Uknown Uknown -0.44 8.68E-04
186.1368566 7.541163361 N-(3-acetamidopropyl)-4-aminobutanal Uknown Uknown -0.43 2.47E-02
257.1375959 10.21364719 Ala-Ala-Pro Peptide(tri-) Nonpolar peptide -0.42 1.42E-04
151.0633373 9.256922103 (Z)-4-Hydroxyphenylacetaldehyde-oxime Amino Acid Metabolism Tyrosine metabolism -0.39 2.31E-05
231.1469828 8.947028862 O-Butanoylcarnitine Lipids: Fatty Acyls Fatty acyl carnitines -0.38 3.64E-03
125.0476825 10.68056337 N-Furfurylformamide Uknown Uknown -0.37 1.68E-04
162.0528359 10.66733722 3-Ethylmalate Carbohydrate Metabolism Glyoxylate and dicarboxylate metabolism -0.37 2.65E-02
259.1782472 11.03593198 Hexanoylcarnitine Uknown Uknown -0.36 5.15E-05
246.1368249 9.100056049 Hypaphorine Uknown Uknown -0.35 1.33E-03
125.0476812 7.994577007 N-Ethylmaleimide Uknown Uknown -0.35 2.64E-04
359.2056931 5.137408395 Glu-Leu-Val Peptide(tri-) Hydrophobic peptide -0.35 5.77E-03
226.0953402 8.187503574 Porphobilinogen Metabolism of Cofactors and Vitamins Porphyrin and chlorophyll metabolism -0.34 1.24E-04
209.105216 8.632449644 Propoxur Xenobiotics Drugs etc Uknown -0.33 4.77E-03
271.2147451 5.819595963 Tridecanoylglycine Uknown Uknown -0.33 1.68E-04
190.0953107 9.728429505 N5-acetyl-N5-hydroxy-L-ornithine Uknown Uknown -0.33 3.64E-03
202.1318021 12.81953097 N-&alpha;-acetyl lysine methyl ester Uknown Uknown -0.32 1.68E-02
316.2612264 3.687155158 (9R,10R)-Dihydroxyoctadecanoic acid Uknown Uknown -0.31 2.05E-03
181.0739822 7.685541755 D-Tyrosine Amino Acid Metabolism Uknown -0.31 6.20E-03
391.272997 4.737874311 [FA (20:4)] N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-D-serine Lipids: Fatty Acyls Fatty amides -0.30 4.77E-02
346.2353251 3.850528181 [FA hydroxy(18:0)] 9-hydroperoxy-12,13-dihydroxy-10-octadecenoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.30 1.95E-04
176.0585536 10.4137174 4-Hydroxyaminoquinoline N-oxide Uknown Uknown -0.30 1.33E-03
153.0789867 8.074466493 vanillylamine Biosynthesis of Secondary Metabolites capsaicin biosynthesis -0.30 8.89E-05
213.1000898 10.09932727 [FA oxo(6:0)] N-(3-oxo-hexanoyl)-homoserine lactone Lipids: Fatty Acyls Fatty amides -0.29 1.09E-05
247.1419808 12.07920603 Hydroxybutyrylcarnitine Uknown Uknown -0.29 7.06E-04
112.027269 8.159242327 Uracil Nucleotide Metabolism Pyrimidine metabolism__beta-Alanine metabolism__Pantothenate and CoA biosynthesis-0.29 1.57E-02
115.0269393 10.66286441 Maleamate Metabolism of Cofactors and Vitamins Nicotinate and nicotinamide metabolism -0.29 2.26E-03
152.0473298 7.775788832 4-Hydroxyphenylacetate Amino Acid Metabolism Tyrosine metabolism__Phenylalanine metabolism -0.29 1.45E-02
169.073878 8.736612159 6-Hydroxydopamine Uknown Uknown -0.29 1.24E-04
331.126582 14.53830274 5'-O-beta-D-Glucosylpyridoxine Uknown Uknown -0.28 5.24E-03
109.0528003 7.744072695 4-Hydroxyaniline Xenobiotics Biodegradation and Metabolism gamma-Hexachlorocyclohexane degradation__2,4-Dichlorobenzoate degradation-0.28 2.64E-04
372.237215 7.720075285 Ala-Ile-Gly-Ile Peptide(tetra-) Hydrophobic peptide -0.28 4.20E-02
246.1466105 7.700699042 3-Hydroxydodecanedioicacid Lipids: Fatty Acyls Uknown -0.28 2.47E-03
437.29064 4.848931255 [PE (16:1)] 1-(1Z-hexadecenyl)-sn-glycero-3-phosphoethanolamine Lipids: Glycerophospholipids Glycerophosphoethanolamines -0.28 1.25E-02
164.0586298 13.76026245 Ricinine Uknown Uknown -0.27 2.29E-02
220.0847389 11.39417393 5-Hydroxytryptophan Uknown serotonin and melatonin biosynthesis -0.27 1.33E-03
252.1109595 8.32074189 3-Hydroxyhexobarbital Uknown Uknown -0.26 2.88E-05
164.0320953 8.242033752 2-Dehydro-D-xylonate Uknown Uknown -0.26 1.16E-02
148.0736047 7.777232604 [FA methyl,hydroxy(5:0)] 3R-methyl-3,5-dihydroxy-pentanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.26 7.38E-03
109.0527835 10.47768273 2-Aminophenol Amino Acid Metabolism Tryptophan metabolism__Naphthalene and anthracene degradation-0.25 4.42E-03
246.1003672 8.639951299 N-Acetyl-D-tryptophan Uknown Uknown -0.25 7.77E-04
205.0739048 9.023701393 Indolelactate Amino Acid Metabolism Tryptophan metabolism -0.25 1.49E-03
294.1580464 4.968076467 Leu-Tyr Peptide(di-) Hydrophobic peptide -0.25 4.42E-04
169.085116 9.769249834 &alpha;-methylhistidine Uknown Uknown -0.25 3.67E-02
136.0384944 10.76548299 allopurinol Uknown Uknown -0.24 3.44E-02
195.0895847 9.939927534 alpha-Methyl-m-tyrosine Uknown Uknown -0.23 2.74E-03
294.1579915 7.813474072 Ile-Tyr Peptide(di-) Hydrophobic peptide -0.23 4.42E-03
245.1375452 8.234039343 Ile-Asn Peptide(di-) Hydrophobic peptide -0.23 3.03E-02
228.1110268 9.940139119 (S)-ATPA Uknown Uknown -0.23 3.64E-03
122.0479881 7.939025443 Nicotinamide Metabolism of Cofactors and Vitamins Nicotinate and nicotinamide metabolism -0.22 7.77E-04
358.2215796 7.739941614 Ala-Leu-Val-Gly Peptide(tetra-) Hydrophobic peptide -0.22 4.77E-02
159.0895673 5.168592922 Valerylglycine Uknown Uknown -0.22 1.45E-02
284.1987252 3.107790797 (10S)-Juvenile hormone III diol Biosynthesis of Secondary Metabolites Insect hormone biosynthesis -0.22 4.42E-03
257.1991104 6.472159347 N-Lauroylglycine Uknown Uknown -0.22 7.61E-05
300.1109767 7.723403758 5-Nitro-2-(3-phenylpropylamino)benzoic acid Uknown Uknown -0.21 2.22E-03
256.1059246 8.069962224 1-(beta-D-Ribofuranosyl)-1,4-dihydronicotinamide Uknown Uknown -0.21 1.45E-02
248.1697779 3.111472048 26-Hydroxy-24-epi-brassinolide Uknown Uknown -0.21 9.65E-03
183.0895824 11.34459057 L-Adrenaline Amino Acid Metabolism Tyrosine metabolism -0.21 4.77E-03
163.0666903 10.63807182 homomethionine Amino Acid Metabolism homomethionine biosynthesis __ glucosinolate biosynthesis from homomethionine-0.21 2.29E-02
313.2000565 9.939177102 Val-Val-Pro Peptide(tri-) Hydrophobic peptide -0.21 1.25E-02
177.0823518 9.101387147 dihomomethionine Uknown Uknown -0.20 3.24E-02
236.1412351 3.516586536 4-Heptyloxybenzoic acid Uknown Uknown -0.20 2.47E-03
238.1569127 3.423388918 7-oxo-11E,13-Tetradecadienoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.19 3.03E-03
297.1212497 7.971171234 Phenethylamineglucuronide Uknown Uknown -0.18 7.77E-04
185.1052103 10.96195238 Otonecine Uknown Uknown -0.18 6.20E-03
280.1423545 7.726177616 Val-Tyr Peptide(di-) Hydrophobic peptide -0.18 1.66E-03
183.0896326 7.771935261 L-Normetanephrine Amino Acid Metabolism Tyrosine metabolism -0.18 8.89E-05
153.0789166 11.35955738 1-(4-Hydroxyphenyl)-2-aminoethanol Uknown Uknown -0.17 1.57E-02
214.0953826 11.30658485 Pyrimidine nucleoside Uknown Uknown -0.17 4.68E-02
197.1052436 8.017803762 L-Metanephrine Amino Acid Metabolism Tyrosine metabolism -0.17 1.33E-03
167.0582701 7.954540292 Pyridoxal Metabolism of Cofactors and Vitamins Vitamin B6 metabolism -0.17 4.42E-04
292.142261 7.71761346 Phenylbutyrylglutamine Uknown Uknown -0.16 7.77E-04
491.3251912 3.666437905 [SP] N-(acyl)-sphing-4-enine-1-phosphocholine Lipids: Sphingolipids Ceramide phosphocholines (sphingomyelins) -0.16 1.25E-02
274.1780815 3.863178535 3-Hydroxytetradecanedioicacid Lipids: Fatty Acyls Uknown -0.16 1.66E-02
382.2719321 3.586894534 [FA oxo,hydroxy,dimethy] 9-oxo-11R,15S-dihydroxy-16,16-dimethyl-13E-prostaenoic acid Lipids: Fatty Acyls Eicosanoids -0.16 2.29E-02
193.1103353 13.23712195 3,4-Methylenedioxymethamphetamine Uknown Uknown -0.15 4.48E-02
95.03713494 7.546479848 2-Hydroxypyridine Uknown Uknown -0.15 3.03E-02
143.0946221 11.15830272 4-(Trimethylammonio)but-2-enoate Uknown Uknown -0.15 9.65E-03
240.147321 10.53145111 Slaframine Biosynthesis of Secondary Metabolites Alkaloid biosynthesis II -0.14 3.99E-04
217.1063259 8.553712894 Ala-Gln Peptide(di-) Polar peptide -0.13 3.03E-02
268.2036328 3.107690572 [FA oxo(5:2/5:0/6:0)] (1R,2R)-3-oxo-2-pentyl-cyclopentanehexanoic acid Lipids: Fatty Acyls Octadecanoids -0.13 2.83E-02
266.188201 3.437141531 [FA trimethyl(13:2)] 10,11-epoxy-3,7,11-trimethyl-2E,6E-tridecadienoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.13 4.48E-02
139.0632691 11.48735396 Gabaculine Uknown Uknown -0.13 6.79E-03
172.0484281 9.377414368 Hydantoin-5-propionate Amino Acid Metabolism Histidine metabolism -0.12 3.24E-02
265.1313785 7.993198062 N(alpha)-Benzyloxycarbonyl-L-leucine Uknown Uknown -0.12 1.41E-02
212.141254 3.750413557 [FA oxo(12:1)] 12-oxo-10E-dodecenoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.11 5.24E-03
264.1108877 7.707111607 alpha-N-Phenylacetyl-L-glutamine Amino Acid Metabolism Phenylalanine metabolism -0.10 3.44E-02
278.1266428 8.053787343 alpha-Ribazole Metabolism of Cofactors and Vitamins Riboflavin metabolism__Porphyrin and chlorophyll metabolism-0.10 4.77E-02
331.1420017 12.45192867 Ambelline Uknown Uknown -0.08 8.90E-03
229.1678152 4.379827321 N-Decanoylglycine Uknown Uknown 0.07 2.83E-02
312.1057302 14.9537125 Vicianose Uknown Uknown 0.09 2.83E-02
248.0894758 7.893238139 tetrahomocitrate Uknown Uknown 0.10 8.90E-03
188.0684904 7.848580139 2-oxosuberate Uknown Uknown 0.11 2.40E-02
252.1223848 10.48531531 Pro-His Peptide(di-) Basic peptide 0.12 3.87E-02
103.063339 12.81428074 L-3-Amino-isobutanoate Amino Acid Metabolism Valine, leucine and isoleucine degradation 0.12 4.48E-02
181.0600059 12.69572148 8-Hydroxy-7-methylguanine Uknown Uknown 0.12 3.44E-02
221.0899646 13.5764 N-Acetyl-D-mannosamine Carbohydrate Metabolism Aminosugars metabolism 0.14 4.48E-02
268.1674717 4.21803882 dihydroartemisinic acid hydroperoxide Biosynthesis of Secondary Metabolites artemisinin biosynthesis 0.14 2.05E-03
354.2556713 3.616548273 delta2-THA Lipids: Fatty Acyls Fatty Acids and Conjugates 0.14 1.25E-02
146.1054947 10.33770681 mildronate Uknown Uknown 0.14 4.20E-02
102.0317324 12.46554509 2-Methyl-3-oxopropanoate Amino Acid Metabolism Valine-LeucineandIsoleucineDegradation 0.14 3.03E-02
206.1670376 5.965188912 (+)-trans-alpha-Irone Uknown Uknown 0.15 1.69E-03












ACCEPTED MANUSCRIPT242.1882343 3.214797141 [FA oxo(14:0)] 3-oxo-tetradecanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.16 2.29E-02
98.03674202 7.957856073 [FA (5:2)] 2,4-pentadienoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.16 3.50E-03
95.03713617 16.03312885 pyridine-N-oxide Uknown Uknown 0.16 3.67E-02
478.3116465 3.263786752 [ST methy] 24-methylene-cholest-5-en-3beta-ol-3-sulfate Lipids: Sterol lipids Steroid conjugates 0.16 7.38E-03
270.2195351 3.473129391 [FA oxo(16:0)] 3-oxo-hexadecanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.16 6.20E-03
240.1220393 13.16729759 Homocarnosine Amino Acid Metabolism Arginine and proline metabolism 0.16 1.98E-02
328.2976339 3.510713702 L-2-Hydroxyphytanate Uknown Uknown 0.17 6.20E-03
654.5212333 3.317302322 [GL (17:2/22:4)] 1-(9Z,12Z-heptadecadienoyl)-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycerol Lipids: Glycerolipids Diradylglycerols 0.18 6.24E-04
757.5626059 4.19308879 PC(14:0/20:2(11Z,14Z)) Lipids: Glycerophospholipids Glycerophosphocholines 0.18 6.79E-03
113.0477753 16.40961675 (S)-1-Pyrroline-5-carboxylate Amino Acid Metabolism Glutamate metabolism__Arginine and proline metabolism 0.18 4.77E-03
96.99304995 16.92192441 Phosphoramidate Uknown Uknown 0.18 1.57E-02
195.053077 7.836772265 Dopaquinone Amino Acid Metabolism Tyrosine metabolism 0.18 8.90E-03
759.5784314 4.184466278 PC(14:0/20:1(11Z)) Lipids: Glycerophospholipids Glycerophosphocholines 0.18 1.45E-02
326.2818892 3.487377714 2-Oxophytanate Uknown Uknown 0.19 5.24E-03
115.063385 16.50789468 D-Proline Amino Acid Metabolism Arginine and proline metabolism 0.19 1.42E-04
474.3710466 4.292524765 Sapelin A Uknown Uknown 0.19 1.65E-03
175.0956425 16.4716143 L-Citrulline Amino Acid Metabolism Arginine and proline metabolism 0.19 9.68E-04
117.0789235 13.0436654 [FA amino(5:0)] 2S-amino-pentanoic acid Amino Acid Metabolism Amino Fatty Acids 0.20 2.05E-03
250.1317089 13.14158954 N-Caffeoylputrescine Uknown Uknown 0.20 3.44E-02
140.9828617 13.25642837 Carbamoyl phosphate Amino Acid Metabolism Arginine and proline metabolism__Purine metabolism__Pyrimidine metabolism__Glutamate metabolism__Nitrogen metabolism0.20 2.47E-02
310.2871272 3.498248076 [FA (20:0)] 11Z-eicosenoic acid Lipids: Fatty Acyls Biosynthesis of unsaturated fatty acids 0.20 1.57E-02
280.1422724 13.29062916 Val-Tyr Peptide(di-) Hydrophobic peptide 0.20 4.77E-02
157.1102367 14.26916189 Homostachydrine Uknown Uknown 0.21 1.42E-04
260.1987702 3.278987674 [FA hydroxy(14:0)] 3,11-dihydroxy-tetradecanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.21 3.67E-02
173.141676 13.94061205 Muscarine Uknown Uknown 0.21 4.42E-03
382.3446881 3.304524951 [FA hydroxy(24:0)] 2-hydroxy-15-tetracosenoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.21 2.29E-02
594.3415903 3.649497117 L-Urobilin Metabolism of Cofactors and Vitamins Porphyrin and chlorophyll metabolism 0.21 1.22E-03
203.1270499 25.73240106 Lys-Gly Peptide(di-) Basic peptide 0.21 3.95E-02
488.1743875 15.24554051 3-Fucosyllactose Uknown Uknown 0.21 4.77E-02
405.2880863 3.760052035 Cassaine Uknown Uknown 0.21 2.47E-02
325.1717455 3.90892414 Cycloxydim Uknown Uknown 0.22 1.09E-03
204.0899956 12.1889486 D-Tryptophan Amino Acid Metabolism Uknown 0.22 2.26E-03
75.03215089 16.18438897 Glycine Amino Acid Metabolism Bile acid biosynthesis__Purine metabolism__Glycine, serine and threonine metabolism__Lysine degradation__Cyanoamino acid metabolism__Glutathione metabolism__Methane metabolism__Thiamine metabolism__Porphyrin and chlorophyll metabolism__Nitrogen metabolism0.22 4.05E-03
165.0459637 13.66772856 L-Methionine S-oxide Amino Acid Metabolism Methionine metabolism 0.22 4.08E-03
422.3550155 4.140591037 Theonellasterol B Lipids: Sterol Lipids Sterols 0.22 6.24E-04
146.0691138 16.11058556 D-Glutamine Amino Acid Metabolism D-Glutamine and D-glutamate metabolism 0.23 3.99E-04
158.0578689 7.855403862 2-Isopropylmaleate Amino Acid Metabolism Valine, leucine and isoleucine biosynthesis 0.23 2.05E-03
119.0583012 14.92981154 L-Threonine Amino Acid Metabolism Glycine, serine and threonine metabolism__Valine, leucine and isoleucine biosynthesis__Porphyrin and chlorophyll metabolism0.23 2.15E-02
166.0490421 9.937251152 3-Methylxanthine Biosynthesis of Secondary Metabolites Caffeine metabolism 0.24 1.68E-04
303.1428742 14.56378259 Nicotianamine Metabolism of Cofactors and Vitamins nicotianamine biosynthesis __ 2&#039;-deoxymugineic acid phytosiderophore biosynthesis __ Fe(II)-NA phloem transport0.24 1.45E-02
105.042685 16.25309818 L-Serine Amino Acid Metabolism Glycine, serine and threonine metabolism__Methionine metabolism__Cysteine metabolism__Cyanoamino acid metabolism__Sphingolipid metabolism__Methane metabolism__Sulfur metabolism0.24 6.24E-04
553.5063024 4.03431435 4-hydroxysphing-8(E)-enine-16:0, ceramide Uknown Uknown 0.25 9.68E-04
288.1837102 4.429053048 4-DMA L-abrine Uknown Uknown 0.25 2.26E-03
565.5435741 4.047600946 [SP (18:0)] N-(octadecanoyl)-sphing-4-enine Lipids: Sphingolipids Ceramides 0.26 3.67E-02
525.5120652 4.082308443 Cer(d18:0/15:0) Lipids: Sphingolipids Ceramides 0.26 6.79E-03
260.1485286 24.34769485 Lys-Asn Peptide(di-) Basic peptide 0.26 2.65E-02
246.1214982 10.32113551 L-beta-aspartyl-L-leucine Peptide Uknown 0.26 5.50E-04
294.2193624 3.435242581 (9Z)-(13S)-12,13-Epoxyoctadeca-9,11-dienoic acid Uknown Uknown 0.26 1.16E-02
356.3289931 3.392818792 [FA hydroxy(22:0)] 13-hydroxy-docosanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.26 1.11E-03
159.0895222 12.26336867 5-Acetamidopentanoate Amino Acid Metabolism Lysine degradation 0.26 3.64E-03
181.0739123 13.48819778 3-Amino-3-(4-hydroxyphenyl)propanoate Amino Acid Metabolism Tyrosine metabolism 0.27 3.99E-04
86.03667005 8.693188589 Diacetyl Carbohydrate Metabolism Butanoate metabolism 0.27 4.96E-04
117.078943 12.40178021 L-Valine Amino Acid Metabolism Valine, leucine and isoleucine degradation__Valine, leucine and isoleucine biosynthesis__Penicillin and cephalosporin biosynthesis__Propanoate metabolism__Pantothenate and CoA biosynthesis0.27 3.35E-03
103.063331 14.33438239 N,N-Dimethylglycine Amino Acid Metabolism Glycine, serine and threonine metabolism 0.27 9.65E-03
490.3658687 3.39191278 Barringtogenol C Uknown Uknown 0.27 3.24E-02
187.1208011 14.32794973 (E)-2-Butenyl-4-methyl-threonine Uknown Uknown 0.27 1.24E-04
628.5064109 3.358150931 DG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0) Lipids: Glycerolipids Diradylglycerols 0.28 2.26E-03
357.1787839 4.782688005 Uplandicine Uknown Uknown 0.29 4.48E-02
273.1323944 13.44170927 Ala-Pro-Ser Peptide(tri-) Polar peptide 0.29 1.22E-03
165.0789978 10.7407401 D-Phenylalanine Amino Acid Metabolism Phenylalanine metabolism 0.30 3.99E-04
209.1052225 4.125643774 Tyr-OEt Uknown Uknown 0.31 1.25E-02
335.1330808 16.18085579 N4-(Acetyl-beta-D-glucosaminyl)asparagine Uknown Uknown 0.32 3.03E-03
194.0789858 9.488480045 3-O-Methyl-myo-inositol Carbohydrate Metabolism Inositol phosphate metabolism 0.32 3.64E-03
140.0585595 5.942508158 1-3-Dimethyluracil Uknown Uknown 0.33 6.20E-03
179.0582498 7.865741227 Hippurate Amino Acid Metabolism Phenylalanine metabolism 0.33 7.06E-04
163.0844782 12.29957892 DMDP Uknown Uknown 0.33 3.35E-03
188.1160892 14.36811875 N2-Acetyl-L-lysine Amino Acid Metabolism Lysine biosynthesis 0.33 2.65E-02
310.2145072 3.482546156 [FA (18:3)] 13S-hydroperoxy-9Z,11E,14Z-octadecatrienoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.36 8.90E-03
176.0684866 7.993435722 3-Propylmalate Carbohydrate Metabolism Glyoxylate and dicarboxylate metabolism 0.36 5.50E-04
161.0687439 15.13212616 L-2-Aminoadipate Amino Acid Metabolism Lysine biosynthesis__Lysine degradation__Penicillin and cephalosporin biosynthesis0.36 1.35E-02
268.1058595 13.34963981 Ser-Tyr Peptide(di-) Hydrophobic peptide 0.37 2.83E-02
292.2038259 3.664646603 12-OPDA Lipids: Fatty Acyls alpha-Linolenic acid metabolism 0.38 8.14E-03
329.2565177 3.627269701 4-8dimethylnonanoylcarnitine Lipid Metabolism OxidationofBranchedFattyAcids 0.38 3.24E-02
388.2614289 3.726266005 sarmentogenin Lipids: Sterol Lipids Sterols 0.38 3.35E-03
338.318562 3.457894703 [FA (22:1)] 13E-docosenoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.39 1.33E-03
366.3496648 3.433031779 [FA (24:0)] 15Z-tetracosenoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.43 7.61E-05
179.094619 13.70853002 (-)-Salsolinol Uknown Uknown 0.44 1.77E-05
176.0684394 8.408206657 (2S)-2-Isopropylmalate Amino Acid Metabolism Valine, leucine and isoleucine biosynthesis__Pyruvate metabolism0.44 1.09E-03
131.0694474 15.35157914 Creatine Amino Acid Metabolism Glycine, serine and threonine metabolism__Arginine and proline metabolism0.46 4.77E-03
298.1784937 3.178080995 L-Urobilinogen Metabolism of Cofactors and Vitamins Porphyrin and chlorophyll metabolism 0.48 1.95E-04
364.3342177 3.414302314 [FA (24:2)] 5,9-tetracosadienoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.53 1.77E-05
176.0586 13.3993983 Pemoline Xenobiotics Drugs etc Uknown 0.53 1.66E-03
126.0429134 8.303807152 Thymine Nucleotide Metabolism Pyrimidine metabolism 0.72 7.77E-04
336.3028501 3.462551887 [FA (22:2)] 13Z,16Z-docosadienoic acid Lipids: Fatty Acyls Biosynthesis of unsaturated fatty acids 0.73 6.76E-06
327.2410409 3.670374231 10-nitro-9E-octadecenoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.75 1.25E-02
370.147374 10.45871087 Amylose Carbohydrate Metabolism Starch and sucrose metabolism 1.12 5.31E-06
356.1320392 12.85523668 D-galactosylononitol Uknown galactosylcyclitol biosynthesis 1.12 6.76E-06
223.048083 5.638778211 4-(2-Amino-3-hydroxyphenyl)-2,4-dioxobutanoate Amino Acid Metabolism Tryptophan metabolism 1.14 5.15E-05
388.1773612 10.22876343 Ala-Met-Ala-Pro Peptide(tetra-) Hydrophobic peptide 1.15 5.31E-06
431.2008961 9.831247965 Ala-Leu-Asn-Asp Peptide(tetra-) Hydrophobic peptide 1.28 5.31E-06
549.2267222 12.7035796 Asp-Met-Trp-Val Peptide(tetra-) Hydrophobic peptide 1.39 5.31E-06
274.0454759 13.13670463 1-Deoxy-D-altro-heptulose 7-phosphate Uknown Uknown 1.53 1.35E-02
204.0999356 7.752623701 Diethyl (2R,3R)-2-methyl-3-hydroxysuccinate Uknown Uknown 1.53 5.31E-06












ACCEPTED MANUSCRIPTLog2 mean post/pre intervention ratio of metabolites significantly decreased (purple) or increased (green) only during EEN (p-value<0.05)
Mass RT Putative.metabolite Map Pathway logfold_EEN p_adj_EEN
173.0800885 13.35275391 5-Guanidino-2-oxopentanoate Amino Acid Metabolism D-Arginine and D-ornithine metabolism -1.20 9.00E-05
275.1116631 9.399423557 Gamma-Glutamylglutamine Peptide Uknown -1.12 1.23E-05
191.0252425 8.344430148 a Cysteine adduct Medium Contaminant Uknown -1.10 6.50E-06
275.1118278 15.16524756 Norophthalmicacid Uknown Uknown -1.09 8.08E-06
492.2433112 17.86183807 Ile-Met-Met-Val Peptide(tetra-) Hydrophobic peptide -1.08 1.63E-04
191.0582937 7.685091192 5-Hydroxyindoleacetate Amino Acid Metabolism Tryptophan metabolism -1.08 2.64E-05
228.1473571 13.66869286 L-isoleucyl-L-proline Uknown Uknown -1.07 4.22E-04
176.0320604 8.388115497 Ascorbate Carbohydrate Metabolism Ascorbate and aldarate metabolism__Glutathione metabolism-1.06 9.00E-05
228.1473903 10.57921017 Leu-Pro Peptide(di-) Hydrophobic peptide -1.06 3.75E-04
275.1117158 8.432314498 Glu-Ala-Gly Peptide(tri-) Acidic peptide -1.03 1.63E-04
249.0306703 8.138791257 Norepinephrinesulfate Uknown Uknown -1.00 2.70E-06
203.090685 16.78885755 Ala-Asn Peptide(di-) Polar peptide -0.96 8.95E-04
194.0425432 8.518792175 2-Dehydro-D-gluconate Carbohydrate Metabolism Pentose phosphate pathway -0.94 7.98E-04
261.132483 19.0674727 Aspartylysine Uknown Uknown -0.92 2.20E-05
130.0993774 3.839153783 Ethyl isovalerate Uknown Uknown -0.91 1.90E-04
217.1062687 15.35701268 Ala-Ala-Gly Peptide(tri-) Polar peptide -0.90 3.28E-04
803.4811099 4.851108103 Tacrolimus Biosynthesis of Polyketides and Nonribosomal Peptides Type I polyketide structures -0.88 9.05E-03
649.4690297 4.201984208 [PE (14:0/15:0)] 1-tetradecanoyl-2-pentadecanoyl-sn-glycero-3-phosphoethanolamine Lipids: Glycerophospholipids Glycerophosphoethanolamines -0.88 2.50E-04
579.5228265 3.704074537 N-(2-hydroxyoctadecanoyl)-4,8-sphingadienine Uknown Uknown -0.86 1.58E-03
88.01595536 8.277843016 Pyruvate Carbohydrate Metabolism Glycolysis / Gluconeogenesis__Citrate cycle (TCA cycle)__Pentose phosphate pathway__Ascorbate and aldarate metabolism__Biosynthesis of steroids__Alanine and aspartate metabolism__Glycine, serine and threonine metabolism-0.84 8.95E-04
302.1112634 8.609148824 Bicozamycin Uknown Uknown -0.81 1.80E-05
369.1647903 16.89102574 Val-Asp-His Peptide(tri-) Basic peptide -0.81 5.63E-05
204.0748378 10.19042375 L-beta-aspartyl-L-alanine Peptide Uknown -0.78 1.86E-06
117.0790071 11.89124834 L-Valine Amino Acid Metabolism Valine, leucine and isoleucine degradation__Valine, leucine and isoleucine biosynthesis__Penicillin and cephalosporin biosynthesis__Propanoate metabolism__Pantothenate and CoA biosynthesis-0.78 6.65E-05
541.0611299 9.627281722 Cyclic ADP-ribose Uknown Uknown -0.78 6.65E-05
298.1204385 4.590686426 Dibenzylsuccinate Uknown Uknown -0.77 9.00E-05
234.0851676 9.445771501 Glu-Ser Peptide(di-) Acidic peptide -0.77 5.02E-06
454.2426712 9.623593418 Glu-Ile-Pro-Pro Peptide(tetra-) Hydrophobic peptide -0.77 4.43E-03
187.1208248 10.24983857 8-Amino-7-oxononanoate Metabolism of Cofactors and Vitamins Biotin metabolism -0.76 1.03E-04
103.0633738 16.147361 L-3-Amino-isobutanoate Amino Acid Metabolism Valine, leucine and isoleucine degradation -0.76 1.23E-05
221.0358012 8.347953318 S-(3-oxo-3-carboxy-n-propyl)cysteine Uknown Uknown -0.75 2.50E-04
461.2122915 11.3089124 Asn-Glu-Ile-Ser Peptide(tetra-) Hydrophobic peptide -0.74 1.45E-05
115.0633488 8.272301369 nitrocyclopentane Uknown Uknown -0.74 1.80E-05
537.5120409 4.104777846 [SP (16:0)] N-(hexadecanoyl)-sphing-4-enine Lipids: Sphingolipids Ceramides -0.73 3.61E-02
175.0844355 10.81941877 N-Carboxyethyl-g-aminobutyricacid Uknown Uknown -0.69 6.50E-06
732.5310126 3.20950698 PG(O-16:0/18:2(9Z,12Z)) Lipids: Glycerophospholipids Glycerophosphoglycerols -0.68 1.20E-04
131.0581594 14.90669052 N-Acetyl-beta-alanine Amino Acid Metabolism beta-Alanine metabolism -0.67 8.08E-06
390.1753618 17.64038762 Ala-Val-Asp-Ser Peptide(tetra-) Hydrophobic peptide -0.66 1.40E-04
360.132035 13.98102772 Dityrosine Uknown Uknown -0.65 1.96E-03
797.5426868 3.573445843 N-(hexadecanoyl)-4R-hydroxysphinganine-1-phospho-(1'-myo-inositol) Sphingolipids [SP] Ceramide phosphoinositols (MIPC) -0.65 2.19E-04
106.0629973 9.247916048 Diethylene glycol Uknown Uknown -0.64 1.12E-03
334.0667128 10.62739496 2-(alpha-D-Galactosyl)-sn-glycerol 3-phosphate Uknown Uknown -0.62 1.07E-02
205.0950244 15.04304802 N-Acetyl-D-quinovosamine Uknown Uknown -0.62 1.03E-04
330.1106744 7.800748792 Samaderin A Uknown Uknown -0.61 3.15E-05
284.1119453 9.512681892 Coformycin Uknown Uknown -0.61 7.98E-04
173.0688742 8.109765948 N-Acetyl-L-glutamate 5-semialdehyde Amino Acid Metabolism Arginine and proline metabolism -0.60 6.23E-04
275.1481093 19.02814487 Val-Ala-Ser Peptide(tri-) Hydrophobic peptide -0.60 8.08E-06
663.483592 4.162949388 [PE (14:0/16:0)] 1-tetradecanoyl-2-hexadecanoyl-sn-glycero-3-phosphoethanolamine Lipids: Glycerophospholipids Glycerophosphoethanolamines -0.60 1.45E-05
275.1480685 14.98676259 Epsilon-(gamma-Glutamyl)-lysine Uknown Uknown -0.58 5.02E-06
145.0739279 13.61647374 4-Acetamidobutanoate Amino Acid Metabolism Arginine and proline metabolism -0.58 1.40E-04
241.0586517 7.9728618 N-(2,3-Dihydroxybenzoyl)-L-serine Uknown Uknown -0.58 3.87E-05
354.3497828 3.423154125 [FA (23:0)] tricosanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.57 1.01E-03
191.058424 5.096720641 5,6-Dihydroxy-3-methyl-2-oxo-1,2-dihydroquinoline Uknown 3-methylquinoline degradation -0.57 1.26E-02
122.057945 12.09088929 Erythritol Xenobiotics Drugs etc Uknown -0.57 9.88E-03
286.1202482 3.836203914 7,3'-Dihydroxy-4'-methoxy-8-methylflavan Uknown Uknown -0.57 3.28E-04
136.0734998 11.2623271 D-Apiitol Uknown Uknown -0.57 4.86E-03
234.1004798 7.709311433 5-Methoxytryptophan Uknown Uknown -0.57 9.00E-05
263.0463804 8.050003191 Epinephrinesulfate Uknown Uknown -0.56 8.08E-06
346.185111 13.82148984 Ala-Leu-Gly-Ser Peptide(tetra-) Hydrophobic peptide -0.56 5.02E-06
282.2558522 3.572405201 [FA (18:1)] 9Z-octadecenoic acid Lipids: Fatty Acyls Fatty acid biosynthesis__Biosynthesis of unsaturated fatty acids-0.55 3.28E-04
218.1266818 17.76043356 N2-(D-1-Carboxyethyl)-L-lysine Amino Acid Metabolism Lysine degradation -0.55 1.12E-03
373.2211457 7.779095706 Glu-Ile-Ile Peptide(tri-) Hydrophobic peptide -0.53 6.23E-04
134.0215291 8.27284443 3-Dehydro-L-threonate Carbohydrate Metabolism Ascorbate and aldarate metabolism -0.53 1.23E-05
748.5264612 3.212035937 [PG (16:0/18:1)] 1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-sn-glycerol Uknown Uknown -0.51 2.93E-02
216.1474033 13.24015888 Val-Val Peptide(di-) Hydrophobic peptide -0.50 2.38E-03
204.11101 14.78700171 &gamma;-glutamyl-L-alaninol Uknown Uknown -0.49 7.06E-04
132.0422771 8.112244505 2-Acetolactate Carbohydrate Metabolism Butanoate metabolism__Pantothenate and CoA biosynthesis-0.47 2.66E-03
346.1851386 15.33491733 Ala-Thr-Val-Gly Peptide(tetra-) Hydrophobic peptide -0.47 6.23E-04
481.353073 4.905946611 [PC (16:2)] 1-hexadecyl-sn-glycero-3-phosphocholine Lipids: Glycerophospholipids Glycerophosphocholines -0.47 1.48E-02
302.115831 7.75439477 Odoratol Lipids: Polyketides Flavonoids -0.46 9.82E-06
342.116317 16.09082748 Cellobiose Carbohydrate Metabolism Starch and sucrose metabolism -0.46 2.17E-03
218.0902183 8.647199704 L-Ala-L-Glu Peptide(di-) Acidic peptide -0.46 2.70E-06
190.0953172 18.84087095 LL-2,6-Diaminoheptanedioate Amino Acid Metabolism Lysine biosynthesis -0.45 2.96E-03
129.0790526 12.03427362 N4-Acetylaminobutanal Amino Acid Metabolism Arginine and proline metabolism -0.45 1.75E-03
182.0579569 7.799329221 3-(4-Hydroxyphenyl)lactate Amino Acid Metabolism Tyrosine metabolism -0.45 2.38E-03
177.1001319 15.55275197 validamine Uknown Uknown -0.45 1.86E-06
167.044262 13.49716848 2-8-Dihydroxyadenine Uknown Uknown -0.45 2.70E-06
186.0638967 9.43530201 (S)-AMPA Uknown Uknown -0.45 1.45E-05
199.0957633 8.743089429 gamma-Glutamyl-beta-aminopropiononitrile Amino Acid Metabolism Cyanoamino acid metabolism -0.44 7.98E-04
314.1156688 4.887905917 7,2'-Dihydroxy-6,8-dimethyl-4',5'-methylenedioxyflavan Lipids: Polyketides Flavonoids -0.44 4.84E-04
251.1004657 8.898754959 Muramic acid Uknown Uknown -0.44 1.29E-05
332.1263672 7.858365861 Catechin 5,7,3'-trimethyl ether Lipids: Polyketides Flavonoids -0.44 9.00E-05
340.3339747 3.397735896 Docosanoic acid Lipid Metabolism Biosynthesis of unsaturated fatty acids -0.42 3.29E-03
132.053479 15.58177066 L-Asparagine Amino Acid Metabolism Alanine and aspartate metabolism__Tetracycline biosynthesis__Cyanoamino acid metabolism__Nitrogen metabolism-0.42 2.36E-02
199.0956693 12.400764 gamma-Glutamyl-beta-aminopropiononitrile Amino Acid Metabolism Cyanoamino acid metabolism -0.42 9.82E-06
188.0321264 8.061065774 (E)-3-(Methoxycarbonyl)pent-2-enedioate Uknown Uknown -0.42 3.28E-04
150.0527411 13.71127575 L-Arabinose Carbohydrate Metabolism Pentose and glucuronate interconversions__Ascorbate and aldarate metabolism__Nucleotide sugars metabolism-0.42 4.65E-05
159.0895445 13.41568604 3-Dehydrocarnitine Uknown gamma-butyrobetaine degradation __ carnitine degradation II-0.42 1.58E-03
129.078967 11.61784069 L-Pipecolate Amino Acid Metabolism Lysine degradation__Alkaloid biosynthesis II -0.41 2.38E-03
291.0955273 8.111596236 2,7-Anhydro-alpha-N-acetylneuraminic acid Uknown Uknown -0.40 2.66E-03
276.0998358 7.788552257 Lactucin Uknown Uknown -0.40 1.12E-03
243.1218698 14.91711816 Ala-Gly-Pro Peptide(tri-) Polar peptide -0.40 3.37E-02
147.0531713 9.157668782 O-Acetyl-L-serine Amino Acid Metabolism Cysteine metabolism__Selenoamino acid metabolism__Zeatin biosynthesis__Sulfur metabolism-0.40 1.86E-06
146.0579415 7.965364184 (S)-2-Aceto-2-hydroxybutanoate Amino Acid Metabolism Valine, leucine and isoleucine biosynthesis -0.39 1.03E-04
678.4833513 3.234903866 PG(O-16:0/14:1(9Z)) Lipids: Glycerophospholipids Glycerophosphoglycerols -0.38 8.95E-04
231.0742718 7.949825353 N-Acetyl-L-2-amino-6-oxopimelate Amino Acid Metabolism Lysine biosynthesis -0.38 6.65E-05
230.1516563 3.833774909 Dodecanedioic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.38 1.12E-03
315.2774271 3.575048986 Dehydrophytosphingosine Lipids: Sphingolipids Sphingoid bases -0.37 6.41E-03
260.1372225 8.961251485 L-gamma-glutamyl-L-leucine Peptide Uknown -0.37 2.19E-04
173.1052034 10.66773278 N-Acetyl-L-leucine Uknown Uknown -0.37 3.61E-02
456.3604406 4.018263604 Betulinic acid Uknown Uknown -0.37 6.99E-03
236.0684984 7.760485163 5,6,7-Trimethoxycoumarin Uknown Uknown -0.36 5.86E-03
380.2927871 3.603530153 MG(0:0/20:3(11Z,14Z,17Z)/0:0) Lipids: Glycerolipids Monoradylglycerols -0.35 1.36E-02
161.1051598 12.45532762 (S)-Carnitine Uknown gamma-butyrobetaine degradation __ carnitine degradation II-0.35 1.36E-02
97.96741024 8.830982376 Sulfate Nucleotide Metabolism Purine metabolism__Cysteine metabolism__Sulfur metabolism-0.35 1.40E-04
266.1266128 14.3862534 Phe-Thr Peptide(di-) Hydrophobic peptide -0.35 2.19E-04
274.1276563 9.778341573 N2-Succinyl-L-arginine Amino Acid Metabolism Arginine and proline metabolism -0.35 6.23E-04
258.182924 3.605565383 [FA (14:0/2:0)] Tetradecanedioic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.35 2.17E-03
303.1430701 8.26642016 Glu-Gly-Val Peptide(tri-) Hydrophobic peptide -0.34 1.01E-03
261.0848593 7.976342553 Hymexazol  O-glucoside Uknown Uknown -0.34 1.20E-04
300.2662767 3.641702286 (R)-2-Hydroxystearate Uknown Uknown -0.34 2.17E-03
324.1057402 14.28618264 D-Fructofuranose 1,2':2,3'-dianhydride Uknown Uknown -0.34 4.43E-03
174.1004335 14.08230663 N5-Ethyl-L-glutamine Uknown Uknown -0.33 3.28E-04
133.0738036 16.06960996 N-hydroxyvaline Uknown superpathway of linamarin and lotaustralin biosynthesis __ linamarin biosynthesis-0.33 2.93E-02
279.2562844 4.351574474 Linoleamide Lipids: Fatty Acyls Fatty amides -0.33 9.05E-03
360.2011523 12.4753667 Ala-Leu-Ala-Ser Peptide(tetra-) Hydrophobic peptide -0.32 2.89E-04
360.1645997 8.270203808 Ala-Pro-Ser-Ser Peptide(tetra-) Polar peptide -0.32 9.00E-05
257.1375782 17.9409828 Ala-Ala-Pro Peptide(tri-) Nonpolar peptide -0.32 2.19E-02
194.1055526 14.63587922 6-Hydroxypseudooxynicotine Metabolism of Cofactors and Vitamins Nicotinate and nicotinamide metabolism -0.32 1.26E-02
240.0745559 7.957632449 Dinoseb Uknown Uknown -0.31 1.75E-03
148.0372442 8.086283237 D-Arabinono-1,4-lactone Carbohydrate Metabolism D-arabinose degradation III -0.31 1.43E-03
342.1163129 15.73603022 Maltose Carbohydrate Metabolism Starch and sucrose metabolism -0.30 6.41E-03
293.1111187 8.188055666 N-Acetylmuramate Uknown Uknown -0.30 6.41E-03
374.2166257 12.15337204 Ala-Leu-Thr-Ala Peptide(tetra-) Hydrophobic peptide -0.29 7.77E-05












ACCEPTED MANUSCRIPT261.1212547 8.387784052 Lotaustralin Uknown lotaustralin biosynthesis __ superpathway of linamarin and lotaustralin biosynthesis __ lotaustralin degradation-0.28 4.73E-02
111.0320041 7.952345782 Pyrrole-2-carboxylate Amino Acid Metabolism Arginine and proline metabolism -0.28 8.95E-04
308.1584048 17.17079729 psicoselysine Uknown fructoselysine and psicoselysine degradation -0.28 4.01E-03
216.1474743 7.773415919 Val-Val Peptide(di-) Hydrophobic peptide -0.28 3.29E-03
200.1048108 7.78799496 [FA (10:1/2:0)] 4Z-Decenedioic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.27 3.64E-03
211.0479875 7.951094291 5-(2'-Formylethyl)-4,6-dihydroxypicolinate Amino Acid Metabolism Tryptophan metabolism -0.27 5.86E-03
151.0493776 12.85126484 8-Hydroxyadenine Uknown Uknown -0.27 4.22E-04
359.2055214 7.81352008 Glu-Ile-Val Peptide(tri-) Hydrophobic peptide -0.27 2.38E-03
89.04759037 7.999083877 Urethane Uknown Uknown -0.27 2.50E-04
159.1007213 16.0721175 delta-Guanidinovaleric acid Uknown Uknown -0.27 9.05E-03
216.1222497 15.47780169 N-acetyl-(L)-arginine Uknown Uknown -0.27 6.99E-03
136.0735478 10.38994194 2-Methylerythritol Uknown Uknown -0.26 1.01E-03
88.05237367 8.328751636 (R)-Acetoin Carbohydrate Metabolism Butanoate metabolism__C5-Branched dibasic acid metabolism-0.26 1.68E-04
155.0695015 15.75079743 L-Histidine Amino Acid Metabolism Histidine metabolism__beta-Alanine metabolism-0.26 1.58E-03
246.121564 14.73969725 Glu-Val Peptide(di-) Hydrophobic peptide -0.26 7.69E-03
230.1630141 13.53553125 Leu-Val Peptide(di-) Hydrophobic peptide -0.26 2.93E-02
226.1065183 12.06265721 Carnosine Amino Acid Metabolism Alanine and aspartate metabolism__Histidine metabolism__beta-Alanine metabolism-0.26 1.96E-03
147.0894963 16.25045126 Fagomine Uknown Uknown -0.26 1.12E-03
155.0695044 15.19855339 3-(Pyrazol-1-yl)-L-alanine Uknown beta-pyrazole-1-ylalanine biosynthesis -0.25 4.01E-03
152.0684468 13.31958022 Xylitol Carbohydrate Metabolism Pentose and glucuronate interconversions -0.24 1.16E-02
317.1586603 8.098414682 Glu-Ala-Val Peptide(tri-) Hydrophobic peptide -0.24 3.29E-03
388.2323946 11.36285486 Ala-Leu-Val-Ser Peptide(tetra-) Hydrophobic peptide -0.24 7.06E-04
179.0793468 15.74052501 D-Glucosamine Carbohydrate Metabolism Aminosugars metabolism -0.24 4.43E-02
112.0272957 8.798241699 Uracil Nucleotide Metabolism Pyrimidine metabolism__beta-Alanine metabolism__Pantothenate and CoA biosynthesis-0.24 3.37E-02
226.1205745 3.936905813 3,7-Dimethyl-2E,6E-decadien-1,10-dioic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.24 2.54E-02
473.3505825 4.259841115 Docosa-4-7-10-13-16-pentaenoylcarnitine Uknown Uknown -0.23 1.01E-03
156.0535192 8.035138496 4-Imidazolone-5-propanoate Amino Acid Metabolism Histidine metabolism -0.22 1.26E-02
146.0691302 11.29072683 D-Glutamine Amino Acid Metabolism D-Glutamine and D-glutamate metabolism -0.22 7.69E-03
370.2358087 3.760096816 [FA oxo,trihydrox] 6-oxo-9S,11R,15S-trihydroxy-13E-prostenoic acid Lipids: Fatty Acyls Eicosanoids -0.21 1.07E-02
374.180172 8.074841143 Ala-Leu-Asp-Gly Peptide(tetra-) Hydrophobic peptide -0.21 8.33E-03
243.1834665 4.15342371 N-Undecanoylglycine Uknown Uknown -0.21 4.73E-02
213.0636958 7.94752015 N,N-Dihydroxy-L-tyrosine Amino Acid Metabolism Tyrosine metabolism -0.20 2.95E-03
438.3135201 4.21514787 [ST dimethyl(4:0/3:0)] (5Z,7E,17Z)-(1S,3R)-26,27-dimethyl-9,10-seco-5,7,10(19),17(20)-cholestatetraen-22-yne-1,3,25-triol Lipids: Sterol lipids Secosteroids -0.20 3.37E-02
213.1113568 13.80327597 Methyl 2-diazoacetamidohexanoate Uknown Uknown -0.19 8.33E-03
257.1376143 8.051360811 Ala-Ala-Pro Peptide(tri-) Nonpolar peptide -0.19 1.73E-02
148.0734341 9.04924546 (R)-2,3-Dihydroxy-3-methylpentanoate Amino Acid Metabolism Valine, leucine and isoleucine biosynthesis -0.19 1.75E-03
246.1215013 8.210256803 L-gamma-glutamyl-L-valine Peptide Uknown -0.19 6.99E-03
132.0533515 8.37339409 3-Ureidopropionate Nucleotide Metabolism Pyrimidine metabolism__beta-Alanine metabolism__Pantothenate and CoA biosynthesis-0.18 2.19E-02
187.0955794 11.29685 5-guanidino-3-methyl-2-oxo-pentanoate Uknown Uknown -0.18 3.16E-02
340.1005909 8.30218655 3-Ketosucrose Carbohydrate Metabolism Starch and sucrose metabolism -0.18 1.73E-02
298.2506239 3.572625457 2-Oxooctadecanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates -0.18 9.88E-03
372.2509367 3.762972014 [FA hydroxy(4:0)] 9S,11R,15S-19R-tetrahydroxy-13E-prostaenoic acid Lipids: Fatty Acyls Eicosanoids -0.17 1.16E-02
294.0951408 8.018738544 Tuliposide B Uknown Uknown -0.17 2.93E-02
176.0796717 11.24273094 Ala-Ser Peptide(di-) Polar peptide -0.16 1.36E-02
260.137263 8.139991679 L-gamma-glutamyl-L-isoleucine Peptide Uknown -0.16 8.33E-03
388.1955258 8.148241509 Ala-Glu-Gly-Ile Peptide(tetra-) Hydrophobic peptide -0.14 3.37E-02
186.0638939 8.850553961 (S)-AMPA Uknown Uknown -0.14 8.33E-03
147.0894786 14.73967474 Fagomine Uknown Uknown -0.13 5.29E-03
217.1062695 11.16034285 N-Acetyl-L-citrulline Amino Acid Metabolism arginine biosynthesis III -0.12 5.29E-03
132.053349 11.87979272 N-Carbamoylsarcosine Amino Acid Metabolism Arginine and proline metabolism -0.11 1.07E-02
472.3548856 4.030909667 Gratiogenin Uknown Uknown -0.04 6.99E-03
245.1627476 4.197337553 N-(octanoyl)-L-homoserine Uknown Uknown -0.04 3.88E-02
509.4814119 4.057721639 N-(Tetradecanoyl)-sphing-4-enine Lipids: Sphingolipids Ceramides 0.02 2.36E-02
131.0581523 9.495104048 N-Acetyl-beta-alanine Amino Acid Metabolism beta-Alanine metabolism 0.04 3.61E-02
179.0793671 11.70566446 D-Galactosamine Carbohydrate Metabolism Galactose metabolism 0.05 7.98E-04
212.1411898 4.184383127 Cucurbic acid Uknown Uknown 0.11 1.70E-02
140.9828882 21.63972914 Carbamoyl phosphate Amino Acid Metabolism Arginine and proline metabolism__Purine metabolism__Pyrimidine metabolism__Glutamate metabolism__Nitrogen metabolism0.11 3.88E-02
252.1109811 7.804390406 3-Hydroxyhexobarbital Uknown Uknown 0.11 3.83E-02
220.0849258 8.041840476 5-Hydroxy-L-tryptophan Amino Acid Metabolism Tryptophan metabolism 0.12 4.43E-03
439.4026475 4.27294663 Pentacosanoylglycine Uknown Uknown 0.13 1.87E-02
322.2869371 4.140858071 [FA methyl(20:2)] 19-methyl-5E,9E-eicosadienoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.13 2.38E-03
302.1732256 4.310149605 Tributyrin Uknown Uknown 0.14 3.16E-02
207.1106781 13.98058274 N-Ethylglycocyamine Uknown Uknown 0.14 3.61E-02
306.0951014 8.061897534 furaneol glucopyranoside Uknown furaneol biosynthesis 0.16 4.43E-02
239.0945073 9.036152486 N-Hydroxy-2-acetamidofluorene Uknown Uknown 0.16 1.07E-02
474.3349107 4.074973989 11-acetoxy-3beta,6alpha-dihydroxy-24-methyl-27-nor-9,11-seco-5alpha-cholesta-7,22E-dien-9-one. Lipids: Sterol Lipids Sterols 0.16 7.69E-03
245.1627048 8.208849986 2-Methylbutyroylcarnitine Uknown Uknown 0.17 1.26E-02
140.9828705 15.7865703 Carbamoyl phosphate Amino Acid Metabolism Arginine and proline metabolism__Purine metabolism__Pyrimidine metabolism__Glutamate metabolism__Nitrogen metabolism0.17 3.88E-02
187.0844301 5.040141281 6-Acetamido-2-oxohexanoate Amino Acid Metabolism Lysine degradation 0.18 1.35E-02
161.0476946 8.642423772 4,8-Dihydroxyquinoline Amino Acid Metabolism Tryptophan metabolism 0.18 1.12E-03
369.3244145 4.2348466 N-stearoyl GABA Lipids: Fatty Acyls Fatty amides 0.18 1.48E-02
464.3502687 4.143834119 Castasterone Biosynthesis of Secondary Metabolites Brassinosteroid biosynthesis 0.18 4.79E-02
271.1531519 8.414517443 Val-Gly-Pro Peptide(tri-) Hydrophobic peptide 0.19 4.73E-02
104.0473464 5.160223268 Methyl methoxyacetate Uknown Uknown 0.20 2.03E-02
271.1644069 24.66596012 Pro-Arg Peptide(di-) Basic peptide 0.20 1.43E-03
231.1107106 5.094519804 Suberylglycine Uknown Uknown 0.20 2.38E-03
235.0691256 8.168131029 N-Glycolyl-D-mannosaminolactone Uknown Uknown 0.20 4.17E-02
414.204467 4.272235024 Magnoshinin Uknown Uknown 0.20 1.73E-02
221.0899675 12.2169778 N-Acetyl-D-glucosamine Amino Acid Metabolism Glutamate metabolism__Aminosugars metabolism0.20 2.03E-02
397.2828531 3.612403664 [FA trihydroxy(2:0)] N-(9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine Lipids: Fatty Acyls Eicosanoids 0.21 4.86E-03
85.05280026 7.938205328 Acetone cyanohydrin Uknown linamarin degradation __ superpathway of linamarin and lotaustralin biosynthesis __ linamarin biosynthesis0.21 3.37E-02
576.4753322 3.458060175 DG(15:0/18:3(9Z,12Z,15Z)/0:0) Lipids: Glycerolipids Diradylglycerols 0.21 4.15E-02
304.2401407 3.526267316 [FA (20:4)] 5Z,8Z,11Z,14Z-eicosatetraenoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.21 4.15E-02
102.0681289 4.761823716 Methyl butyrate Lipids: Fatty Acyls Fatty esters 0.21 2.80E-02
153.042568 7.900455215 3-Hydroxyanthranilate Amino Acid Metabolism Tryptophan metabolism__Carbazole degradation0.22 3.37E-02
287.1956957 19.91842568 Ile-Arg Peptide(di-) Basic peptide 0.22 1.12E-03
193.1103175 12.13032089 Heliamine Uknown Uknown 0.22 2.50E-04
306.2560233 5.391883612 [FA (20:3)] 8Z,11Z,14Z-eicosatrienoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.23 1.27E-03
446.3396389 4.172477927 Stylisterol B Uknown Uknown 0.23 4.51E-05
116.0473342 4.89631021 Methylacetoacetic acid Uknown Uknown 0.23 1.27E-03
202.084151 4.899924064 Diethyl 2-methyl-3-oxosuccinate Uknown Uknown 0.23 4.86E-03
206.1670105 4.311002018 alpha-Irone Uknown Uknown 0.23 8.33E-03
307.1531486 8.257179717 Phe-Ala-Ala Peptide(tri-) Hydrophobic peptide 0.23 9.06E-03
117.0578527 10.74424586 Indole Amino Acid Metabolism Tryptophan metabolism__Phenylalanine, tyrosine and tryptophan biosynthesis__Benzoxazinone biosynthesis0.23 4.73E-02
482.4330873 3.571409141 [FA (2:0)] Triacontanedioic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.24 1.26E-02
446.1971535 3.693625496 Ptilosteroid A Lipids: Sterol Lipids Steroids 0.25 8.33E-03
204.1110821 8.092940685 Val-Ser Peptide(di-) Hydrophobic peptide 0.25 4.15E-02
250.1317393 10.43633772 N-Caffeoylputrescine Uknown Uknown 0.26 4.43E-02
369.2881688 4.932874069 cis-5-Tetradecenoylcarnitine Uknown Uknown 0.26 2.19E-02
424.2823108 3.812442268 [ST hydroxy(4:0)] 1beta,3alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholan-24-oic Acid Lipids: Sterol lipids Bile acids and derivatives 0.26 2.96E-03
393.2881928 4.911159328 PGH2-EA Lipids: Fatty Acyls Eicosanoids 0.27 1.16E-02
290.1267377 7.686539941 6-hydroxy-indole-3-acetyl-valine Uknown IAA degradation V 0.27 1.35E-04
285.168819 8.289699989 Leu-Gly-Pro Peptide(tri-) Hydrophobic peptide 0.29 1.73E-02
216.1722553 3.670006532 12-Hydroxydodecanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.29 1.96E-03
250.0953777 8.795734427 3-Oxohexobarbital Uknown Uknown 0.29 3.37E-02
285.2304714 4.963511753 Myristoylglycine Uknown Uknown 0.29 1.36E-02
139.0745422 8.860492882 L-Histidinal Amino Acid Metabolism Histidine metabolism 0.29 5.29E-03
427.3662229 4.632106257 Stearoylcarnitine Uknown Uknown 0.31 4.01E-03
313.2980376 4.263214959 Margaroyl-EA Lipids: Fatty Acyls Fatty amides 0.31 1.75E-03
145.0738552 14.81088848 Allysine Amino Acid Metabolism LysineBiosynthesis 0.31 4.22E-04
198.0752798 10.3603773 5-Acetylamino-6-amino-3-methyluracil Biosynthesis of Secondary Metabolites Caffeine metabolism 0.31 4.01E-03
136.0194359 7.932077762 S-Methyl-1-thio-D-glycerate Uknown Uknown 0.31 2.93E-02
117.0578764 6.185066479 Indole Amino Acid Metabolism Tryptophan metabolism__Phenylalanine, tyrosine and tryptophan biosynthesis__Benzoxazinone biosynthesis0.32 8.33E-03
228.0747658 8.374780911 Deoxyuridine Nucleotide Metabolism Pyrimidine metabolism 0.32 9.05E-03
132.0687012 7.416241754 Indoleamine Uknown Uknown 0.33 2.50E-04
132.0686946 6.963474997 Indoleamine Uknown Uknown 0.33 1.90E-04
228.1474231 8.15988563 Ile-Pro Peptide(di-) Hydrophobic peptide 0.33 4.22E-04
395.2674678 3.609741247 Prostaglandin E2 ethanolamide Uknown Uknown 0.33 1.58E-03
173.1052504 7.713416008 Isovalerylsarcosine Uknown Uknown 0.33 4.86E-03
592.326268 3.641851396 I-Urobilinogen Metabolism of Cofactors and Vitamins Porphyrin and chlorophyll metabolism 0.33 5.29E-03
202.0953455 12.90106853 2-(4-amino-4-carboxybutyl)aziridine-2-carboxylate Uknown Uknown 0.34 1.86E-06
306.0952134 5.366339615 furaneol glucopyranoside Uknown furaneol biosynthesis 0.34 1.75E-03
355.3086861 4.292015347 Pristanoylglycine Uknown Uknown 0.35 2.17E-03












ACCEPTED MANUSCRIPT422.2674151 3.860911984 [ST Trihydroxy,ox] 3alpha,7beta,12alpha-Trihydroxy-6-oxo-5alpha-cholan-24-oic Acid Lipids: Sterol lipids Bile acids and derivatives 0.35 2.64E-05
351.1795679 5.088673912 Ile-Gly-Tyr Peptide(tri-) Hydrophobic peptide 0.35 8.08E-06
430.3448162 4.117511472 3beta-Hydroxy-5alpha-cholest-7-ene-4alpha-carboxylate Uknown Uknown 0.37 2.70E-06
376.1382974 9.002931168 Riboflavin Metabolism of Cofactors and Vitamins Riboflavin metabolism 0.37 7.98E-04
132.0785704 4.754015382 Ethyl (R)-3-hydroxybutanoate Uknown Uknown 0.38 3.75E-04
198.0752493 8.606108474 5-Acetylamino-6-amino-3-methyluracil Biosynthesis of Secondary Metabolites Caffeine metabolism 0.40 1.75E-03
172.1001208 6.019058873 Deoxypeganine Uknown Uknown 0.41 1.86E-06
322.2141865 3.75860068 Rapanone Uknown Uknown 0.42 2.50E-04
432.3603362 4.144824547 Cathasterone Biosynthesis of Secondary Metabolites Brassinosteroid biosynthesis 0.42 9.00E-05
330.1901412 5.203190086 Ile-Ala-Gln Peptide(tri-) Hydrophobic peptide 0.42 1.40E-04
288.1545469 18.99912978 Asn-Arg Peptide(di-) Basic peptide 0.43 2.38E-03
467.3612797 4.945454078 [SP] sphinganine-1-phosphocholine Lipids: Sphingolipids Sphingoid bases 0.43 1.23E-05
267.0967271 11.48355903 Deoxyguanosine Nucleotide Metabolism Purine metabolism 0.43 1.36E-02
448.3553014 4.165436975 Teasterone Biosynthesis of Secondary Metabolites Brassinosteroid biosynthesis 0.44 9.82E-06
269.1375042 10.21546726 Gly-Pro-Pro Peptide(tri-) Polar peptide 0.44 5.02E-06
181.0600047 10.94683021 8-Hydroxy-7-methylguanine Uknown Uknown 0.44 3.28E-04
153.0425918 5.580912221 4-Nitroanisole Uknown Uknown 0.45 2.36E-02
237.1364151 13.03170342 (-)-Pellotine Uknown Uknown 0.45 2.89E-04
320.1986298 3.920712164 ubiquinol-2 Metabolism of Cofactors and Vitamins Oxidative phosphorylation 0.45 2.74E-02
480.3449566 4.205872495 [ST hydroxy(4:0)] 2alpha,3alpha,22R,23R-tetrahydroxy-6,7-seco-5-campestano-6,7-lactone Lipids: Sterol lipids Sterols 0.48 4.43E-03
158.0942517 7.673482891 Ethyl 3-oxohexanoate Uknown Uknown 0.48 5.08E-04
325.0304206 9.381239273 Urothion Uknown Uknown 0.49 5.52E-04
246.1004359 8.278723745 Mephobarbital Xenobiotics Drugs etc Uknown 0.49 4.22E-04
287.2461356 4.435818925 [SP hydroxy,hydroxy,methyl(10:2/2:0)] 6R-(8-hydroxydecyl)-2R-(hydroxymethyl)-piperidin-3R-ol Lipids: Sphingolipids Sphingoid bases 0.51 7.98E-04
436.3188976 5.071165181 Varanicacid Uknown Uknown 0.52 7.77E-05
423.3349735 4.701235482 Linoelaidylcarnitine Uknown Uknown 0.52 2.50E-04
306.2558111 3.531253207 Icosatrienoic acid Lipids: Fatty Acyls Biosynthesis of unsaturated fatty acids 0.53 4.22E-04
203.1157737 11.53513077 O-Acetylcarnitine Amino Acid Metabolism Alanine and aspartate metabolism 0.53 7.06E-04
341.2931198 4.321727663 [FA (18:0)] N-octadecanoyl-glycine Lipids: Fatty Acyls Fatty amides 0.54 5.29E-03
391.3085283 3.051347627 [FA hydroxy,ethyl(20:4)] N,N-(2,2-dihydroxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine Lipids: Fatty Acyls Fatty amides 0.54 2.19E-02
238.0952942 11.57835445 Gly-Tyr Peptide(di-) Hydrophobic peptide 0.54 1.80E-05
137.0840251 7.675085452 Tyramine Amino Acid Metabolism Tyrosine metabolism__Alkaloid biosynthesis I 0.55 7.06E-04
173.1053244 5.631074218 Hexanoylglycine Uknown Uknown 0.55 6.65E-05
312.2663132 3.483509441 [FA oxo(19:0)] 10-oxo-nonadecanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.58 1.45E-05
155.0582708 4.994145999 (3S,5R)-carbapenam Biosynthesis of Secondary Metabolites (5R)-carbapenem biosynthesis 0.59 1.86E-06
138.0429571 8.003617839 Urocanate Amino Acid Metabolism Histidine metabolism 0.60 3.75E-04
344.1319253 15.73813734 Melibiitol Carbohydrate Metabolism Galactose metabolism 0.62 2.66E-03
413.3506416 4.696005809 Heptadecanoylcarnitine Uknown Uknown 0.62 1.45E-05
450.3347081 4.720859267 [ST trihydrox] 3Alpha,7Alpha,12Alpha-trihydroxy-5Beta-cholestan-26-oic acid Lipids: Sterol lipids Bile acids and derivatives 0.64 1.03E-04
588.2945951 3.473030184 D-Urobilin Metabolism of Cofactors and Vitamins Porphyrin and chlorophyll metabolism 0.64 9.88E-03
229.1101285 8.093872861 thyronamine Uknown Uknown 0.65 2.70E-06
147.0352459 13.83634164 Thiomorpholine 3-carboxylate Uknown Uknown 0.68 1.12E-03
139.0633263 7.694058412 Trigonelline Uknown Uknown 0.69 1.20E-04
162.10034 15.23398461 N6-Hydroxy-L-lysine Amino Acid Metabolism Lysine degradation 0.70 1.27E-03
415.3296517 5.110298055 3-Hydroxyhexadecanoylcarnitine Uknown Uknown 0.74 2.36E-02
166.0841369 10.27178792 3-deoxy-D-galactose Uknown Uknown 0.75 1.29E-05
158.0942366 4.890063618 [FA oxo(8:0)] 3-oxo-octanoic acid Lipids: Fatty Acyls Fatty Acids and Conjugates 0.76 1.45E-05
275.1732981 7.854837749 Hydroxyhexanoycarnitine Uknown Uknown 0.84 1.86E-06
446.2528921 13.09084343 Ala-Leu-Phe-Pro Peptide(tetra-) Hydrophobic peptide 0.92 3.28E-04
355.3450209 4.192194082 [FA (20:0)] N-eicosanoyl-ethanolamine Lipids: Fatty Acyls Fatty amides 0.97 1.86E-06
411.4078827 4.131547365 Lignoceroyl-EA Lipids: Fatty Acyls Fatty amides 0.97 1.86E-06
456.2548236 3.261012171 Sulfolithocholicacid Uknown Uknown 0.99 1.01E-03
327.3137037 4.240678284 N,N-Dimethylsphing-4-enine Lipids: Sphingolipids Sphingoid bases 1.02 1.86E-06
212.1160906 12.15457309 Pro-Pro Peptide(di-) Nonpolar peptide 1.09 1.86E-06
375.2773471 7.787735115 N-arachidonoyl alanine Lipids: Fatty Acyls Fatty amides 1.17 1.86E-06
172.146409 5.574324867 p-Menthane-3,8-diol Uknown Uknown 1.18 1.86E-06
240.0569919 10.6062033 Bentazone Uknown Uknown 1.22 2.70E-06
383.3765514 4.164797219 Behenoyl-EA Lipids: Fatty Acyls Fatty amides 1.29 1.86E-06
254.1379169 8.382945197 Val-His Peptide(di-) Basic peptide 1.34 9.00E-05
331.2148615 10.14931198 Ipratropium Uknown Uknown 1.57 1.86E-06
366.194591 10.75199471 Aspidofractine Uknown Uknown 1.60 1.86E-06
172.1463101 3.716600735 Isoamyl isovalerate Uknown Uknown 1.64 2.70E-06
387.2774937 7.747677155 Myxalamid C Uknown Uknown 1.96 1.86E-06
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HLA-B27 CD-TREAT Rat i 
 















HLA-B27 CD-TREAT Rat iii 
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